ifosfamide has been researched along with Local Neoplasm Recurrence in 464 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase I/II study assessed the combination of brentuximab vedotin (BV) with ifosfamide-carboplatin-etoposide (ICE) as a second-line therapy in refractory/relapsed (R/R) classical Hodgkin lymphoma (cHL) patients." | 9.51 | Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study. ( André, M; Berriolo-Riedinger, A; Borel, C; Brice, P; Edeline, V; Feugier, P; Gac, AC; Gastinne, T; Ghesquières, H; Guidez, S; Le Bras, F; Morschhauser, F; Nicolas-Virelizier, E; Quittet, P; Ribrag, V; Stamatoullas, A; Vander Borght, T, 2022) |
| " We performed a phase I study to determine the safety and maximum tolerated dose (MTD) of selinexor when combined with high-dose dexamethasone, ifosfamide, carboplatin and etoposide (DICE) in relapsed/refractory (R/R) T-cell lymphoma (TCL) and natural-killer/T-cell lymphoma (NKTL)." | 9.41 | Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma ( Chan, JY; Farid, M; Lim, C; Lim, ST; Martin, P; Poon, E; Somasundaram, N; Tang, T; Tao, M; Toh, SQ; Yan, SX; Yunon, MJ, 2021) |
| "The objective of this study is to assess the effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma (STS) and provide a relative ranking of regimens for STS." | 9.12 | Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis. ( Hua, Q; Xu, G; Zhang, T; Zhao, L, 2021) |
| "Having determined in a phase I study the maximum tolerated dose of high-dose ifosfamide combined with high-dose doxorubicin, we now report the long-term results of a phase II trial in advanced soft-tissue sarcomas." | 9.12 | Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. ( Cerny, T; Christinat, A; Dietrich, D; Fey, MF; Guillou, L; Herrmann, R; Honegger, HP; Leyvraz, S; Pestalozzi, B; Sessa, C; Wernli, M, 2006) |
| "To determine progression-free survival (PFS) and overall survival (OS) in women with completely resected stage I or II carcinosarcoma of the uterus treated with adjuvant ifosfamide and cisplatin, and to assess the toxicity of this regimen." | 9.11 | Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. ( Carson, LF; Gallion, H; Kauderer, J; Lentz, SS; Sutton, G; Whitney, CW, 2005) |
| "To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 40 years of age with nonmetastatic osteosarcoma of the extremity." | 9.11 | Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. ( Alvegard, TA; Bacci, G; Bernini, G; Bertoni, F; Böhling, T; Brosjö, O; Capanna, R; Comandone, A; Del Prever, AB; Ferrari, S; Longhi, A; Mercuri, M; Müller, C; Picci, P; Ruggieri, P; Saeter, G; Smeland, S; Tienghi, A; Wiebe, T, 2005) |
| "This phase II study was designed to verify the activity and safety of an intensive epirubicin/ifosfamide schedule in untreated soft tissue sarcoma (STS) patients by using both the agents at the identified maximal tolerated doses." | 9.09 | Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. ( Bertero, G; Cosso, M; Neumaier, C; Palumbo, R; Pastorino, M; Raffo, P; Spadini, N; Toma, S; Valente, S; Villani, G, 1999) |
| "Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study." | 9.09 | Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001) |
| "The study was designed to assess the toxicity and activity of high-dose ifosfamide (HDI) administered by continuous infusion at a dose of 4 g/m2/d over 3 days every 4 weeks in adult patients with advanced soft tissue sarcomas (ASTS) pretreated with doxorubicin and/or a standard-dose ifosfamide (SDI)-containing regimen." | 9.08 | High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. ( Antoine, E; Brain, E; Fontaine, F; Genin, J; Janin, N; Kayitalire, L; Le Cesne, A; Le Chevalier, T; Spielmann, M; Toussaint, C, 1995) |
| "We conducted a phase I/II trial to investigate the activity of ifosfamide/carboplatin/etoposide given over 2 or 3 days (mini-ICE) to patients with anthracycline-refractory or recurrent metastatic breast cancer." | 9.08 | Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships. ( Elfenbein, GJ; Fields, KK; Perkins, JB, 1995) |
| "To determine the effectiveness and toxicity of ifosfamide chemotherapy in women with metastatic or recurrent endometrial stromal sarcomas unexposed to other chemotherapy." | 9.08 | Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. ( Blessing, JA; DiSaia, PJ; Park, R; Rosenshein, N; Sutton, G, 1996) |
| "Thirty-six patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea for malignant supratentorial gliomas received a combination of ifosfamide, carboplatin and etoposide (ICE) at tumour progression." | 9.08 | Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. ( Ameri, A; Delattre, JY; Monjour, A; Poisson, M; Ronchin, P; Sahmoud, T; Sanson, M, 1996) |
| "27 patients with recurrent high grade glioma following surgery and radiation therapy were treated with 100 mg/m2 cisplatin and 6 g/m2 ifosfamide per cycle, administered on days 1-3 in 4 week cycles, for a maximum of six cycles." | 9.08 | Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas. ( Jansen, RL; Kros, JM; Loosveld, OJ; Ma, J; Schellens, JH; Sillevis Smit, PA; Tijssen, CC; van den Bent, MJ; Vecht, CJ; Verweij, J, 1998) |
| "Fifty-two patients with advanced adenocarcinoma of the endometrium recurrent after surgery and/or radiation therapy and refractory to first-line chemotherapeutic agents were treated with ifosfamide, 1." | 9.07 | Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. ( Adcock, L; Blessing, JA; Homesley, HD; McGuire, WP; Sutton, GP, 1994) |
| "A total of 51 patients with large, primary, high-grade soft-tissue sarcomas of the extremities were treated at our institute with two preoperative and three postoperative cycles of doxorubicin plus ifosfamide/mesna." | 9.07 | Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities. ( Azzarelli, A; Casali, P; Fissi, S; Montalto, F; Quagliuolo, V; Santoro, A, 1993) |
| " A 49-year-old white male diagnosed with T3 N3 M0 Stage IIIB anal cancer was treated initially with surgical excision and adjuvant fluorouracil/cisplatin due unavailability of mitomycin." | 7.81 | Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. ( Baxley, A; Khawandanah, M; Pant, S, 2015) |
| "The aim of this retrospective study was to evaluate the feasibility and efficacy of response to continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for patients with recurrent or refractory osteosarcoma." | 7.81 | Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study. ( He, AN; Huang, YJ; Min, DL; Shen, Z; Sun, YJ; Yao, Y, 2015) |
| "This systemic analysis was conducted to evaluate the efficacy and safety of an ifosfamide- containing regimen in treating patients with osteosarcoma." | 7.80 | Ifosfamide-containing regimens for treating patients with osteosarcomas. ( Dong, YG; Jiang, XM; Li, YY; Ma, YB; Xu, G, 2014) |
| "To determine demographic data, prognostic factors and outcome of childhood osteosarcoma treated with a carboplatin-based chemotherapeutic protocol at Chiang Mai University." | 7.79 | Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( Charoenkwan, P; Choeyprasert, W; Natesirinilkul, R; Sittipreechacharn, S, 2013) |
| "To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management." | 7.76 | Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010) |
| "The efficacy of zoledronic acid (ZOL), with or without the anticancer drug ifosfamide (IFO), was tested on primary bone tumor growth using a rat-transplantable model of osteosarcoma." | 7.73 | Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. ( Blanchard, F; Charrier, C; Coipeau, P; Couillaud, S; Gouin, F; Heymann, D; Heymann, MF; Ory, B; Redini, F; Thiery, JP, 2005) |
| "To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas." | 7.73 | Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. ( Piura, B; Rabinovich, A, 2005) |
| "Recurrent and refractory neuroblastoma responds well to chemotherapy regimen of ifosphamide plus carboplatin." | 7.73 | [Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006) |
| "Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor." | 7.70 | [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998) |
| "To describe a patient with ifosfamide-induced nonconvulsive status epilepticus." | 7.69 | Ifosfamide-induced nonconvulsive status epilepticus. ( Badesha, PS; Bhardwaj, A, 1995) |
| "A Phase II study of VP-16 (etoposide), ifosfamide/mesna, and cisplatin (VIP) in advanced and recurrent carcinoma of the cervix was initiated March 1989." | 7.68 | Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. ( Kredentser, DC, 1991) |
| "Sixteen patients who developed CT or MRI scan evidence of recurrent diffuse astrocytoma after radiation therapy and nitrosourea-containing chemotherapy received ifosfamide (2500 mg/m2/day for 3 consecutive days) and mesna (500 mg/m2/dose, 5 doses/day for 3 consecutive days)." | 7.68 | Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma. ( Buckner, JC; Cascino, TL; Elliott, TE; Levitt, R; O'Fallon, JR; Scheithauer, BW, 1991) |
| "One hundred twenty-four children and young adults with recurrent tumors, predominantly sarcomas, were treated with the combination of ifosfamide, etoposide, and the uroprotector, mesna (2-mercaptoethane sulphonate), in a phase II trial." | 7.67 | Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. ( Forquer, R; Jarosinski, P; Kinsella, TJ; Magrath, I; Miser, JS; Triche, TJ; Tsokos, M; Wesley, R, 1987) |
| "We have evaluated the activity of ifosfamide in 75 patients with recurrent sarcomas and pediatric solid tumors." | 7.67 | A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. ( Arasi, V; Magrath, I; Miser, J; Raynor, A; Rosenberg, S; Sandlund, J, 1986) |
| "Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation." | 6.69 | Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. ( Bejkos, D; Bischof-Delaloye, A; Chassot, PG; Chiolero, R; Genton, A; Guillou, L; Landry, M; Lejeune, FJ; Leyvraz, PF; Leyvraz, S; Liénard, D; Mirimanoff, RO; Mosimann, F; Pujol, N; Raffoul, W, 2000) |
| " Dosing was modified for elderly patients." | 5.72 | Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma. ( Borawska, A; Chełstowska, M; Dąbrowska-Iwanicka, A; Domańska-Czyż, K; Druzd-Sitek, A; Giebel, S; Knopińska-Posłuszny, W; Konecki, R; Kumiega, B; Lange, A; Malenda, A; Michalski, W; Mordak-Domagała, M; Najda, J; Osowiecki, M; Ostrowska, B; Paszkiewicz-Kozik, E; Pluta, A; Popławska, L; Romejko-Jarosińska, J; Rymkiewicz, G; Świerkowska, M; Szpila, T; Szymański, M; Targoński, Ł; Taszner, M; Walewski, J; Zaucha, JM, 2022) |
| "This phase I/II study assessed the combination of brentuximab vedotin (BV) with ifosfamide-carboplatin-etoposide (ICE) as a second-line therapy in refractory/relapsed (R/R) classical Hodgkin lymphoma (cHL) patients." | 5.51 | Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study. ( André, M; Berriolo-Riedinger, A; Borel, C; Brice, P; Edeline, V; Feugier, P; Gac, AC; Gastinne, T; Ghesquières, H; Guidez, S; Le Bras, F; Morschhauser, F; Nicolas-Virelizier, E; Quittet, P; Ribrag, V; Stamatoullas, A; Vander Borght, T, 2022) |
| " We performed a phase I study to determine the safety and maximum tolerated dose (MTD) of selinexor when combined with high-dose dexamethasone, ifosfamide, carboplatin and etoposide (DICE) in relapsed/refractory (R/R) T-cell lymphoma (TCL) and natural-killer/T-cell lymphoma (NKTL)." | 5.41 | Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma ( Chan, JY; Farid, M; Lim, C; Lim, ST; Martin, P; Poon, E; Somasundaram, N; Tang, T; Tao, M; Toh, SQ; Yan, SX; Yunon, MJ, 2021) |
| " In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment." | 5.39 | Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. ( Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC, 2013) |
| "Despite the fact that Ewing sarcoma family of tumors (ET) is chemosensitive, long-term survival is extremely rare for patients with primary refractory or recurrent disease." | 5.32 | VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors. ( Allam, A; Bazarbashi, S; El Foudeh, M; El Hassan, I; El Weshi, A; Ezzat, A; Memon, M; Pai, C; Rahal, M; Raja, M, 2004) |
| "Ifosfamide is a chemotherapeutic agent used for treatment of pediatric solid tumors." | 5.28 | Rickets--a complication of ifosfamide chemotherapy for Wilms tumor. ( Boal, DK; Relf, M, 1992) |
| "The aim of this phase II study was to investigate the efficacy and toxicity of combined ifosfamide and cisplatin chemotherapy in patients with recurrent epithelial ovarian cancer (EOC)." | 5.17 | Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer. ( Bae, DS; Choi, CH; Kim, BG; Kim, MK; Kim, TJ; Lee, JW; Lee, YY; Song, T, 2013) |
| "To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the treatment of osteosarcoma." | 5.13 | Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. ( Bernstein, ML; Betcher, D; Ferguson, WS; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, M; Healey, JH; Kleinerman, E; Krailo, MD; Link, MP; Meyers, PA; Nadel, H; Nieder, M; Schwartz, CL; Siegal, GP; Weiner, MA; Wells, RJ; Womer, RB, 2008) |
| "The objective of this study is to assess the effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma (STS) and provide a relative ranking of regimens for STS." | 5.12 | Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis. ( Hua, Q; Xu, G; Zhang, T; Zhao, L, 2021) |
| "Patients < or = 30 years with Ewing sarcoma, primitive neuroectodermal tumor or primitive sarcoma of bone were randomly assigned to receive chemotherapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin, (VACA) or with these four drugs alternating with ifosfamide and etoposide (VACA-IE)." | 5.12 | Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group. ( Bernstein, M; Chen, Z; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, M; Laurie, F; Miser, JS; Tarbell, NJ; Yock, TI, 2006) |
| "Having determined in a phase I study the maximum tolerated dose of high-dose ifosfamide combined with high-dose doxorubicin, we now report the long-term results of a phase II trial in advanced soft-tissue sarcomas." | 5.12 | Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. ( Cerny, T; Christinat, A; Dietrich, D; Fey, MF; Guillou, L; Herrmann, R; Honegger, HP; Leyvraz, S; Pestalozzi, B; Sessa, C; Wernli, M, 2006) |
| "To determine progression-free survival (PFS) and overall survival (OS) in women with completely resected stage I or II carcinosarcoma of the uterus treated with adjuvant ifosfamide and cisplatin, and to assess the toxicity of this regimen." | 5.11 | Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. ( Carson, LF; Gallion, H; Kauderer, J; Lentz, SS; Sutton, G; Whitney, CW, 2005) |
| "To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 40 years of age with nonmetastatic osteosarcoma of the extremity." | 5.11 | Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. ( Alvegard, TA; Bacci, G; Bernini, G; Bertoni, F; Böhling, T; Brosjö, O; Capanna, R; Comandone, A; Del Prever, AB; Ferrari, S; Longhi, A; Mercuri, M; Müller, C; Picci, P; Ruggieri, P; Saeter, G; Smeland, S; Tienghi, A; Wiebe, T, 2005) |
| "This phase II study was designed to verify the activity and safety of an intensive epirubicin/ifosfamide schedule in untreated soft tissue sarcoma (STS) patients by using both the agents at the identified maximal tolerated doses." | 5.09 | Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. ( Bertero, G; Cosso, M; Neumaier, C; Palumbo, R; Pastorino, M; Raffo, P; Spadini, N; Toma, S; Valente, S; Villani, G, 1999) |
| "Six cases with recurrent or refractory primary central nervous system lymphoma were treated with a new chemotherapeutic regimen "DeVIC (dexamethasone, VP16, ifosfamide, carboplatin)"." | 5.09 | [Effectiveness of DeVIC chemotherapy for recurrent primary central nervous system lymphoma]. ( Hatano, H; Hatano, N; Kajita, Y; Kinoshita, T; Takasu, S; Usui, T; Wakabayashi, T; Yoshida, J, 2000) |
| "Patients with nonmetastatic osteosarcoma of the extremity were preoperatively treated with high-dose methotrexate, cisplatin, and doxorubicin (ADM)." | 5.09 | Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. ( Bacci, G; Bertoni, F; Campanacci, M; Casadei, R; Fabbri, N; Ferrari, S; Forni, C; Longhi, A; Picci, P; Ruggieri, P; Versari, M, 2000) |
| "The aim of this study was to examine the strategy, feasibility and outcome of neo-adjuvant chemotherapy, with doxorubicin and ifosfamide, in adult patients with 'high-risk' soft-tissue sarcomas." | 5.09 | A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. ( Azzarelli, A; Bramwell, VH; Buesa, J; Ezzat, A; Gortzak, E; Kirkpatrick, A; Oosterhuis, JW; Santoro, A; van Coevorden, F; van Geel, AN; van Glabbeke, M; Verweij, J, 2001) |
| "Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study." | 5.09 | Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001) |
| "The study was designed to assess the toxicity and activity of high-dose ifosfamide (HDI) administered by continuous infusion at a dose of 4 g/m2/d over 3 days every 4 weeks in adult patients with advanced soft tissue sarcomas (ASTS) pretreated with doxorubicin and/or a standard-dose ifosfamide (SDI)-containing regimen." | 5.08 | High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. ( Antoine, E; Brain, E; Fontaine, F; Genin, J; Janin, N; Kayitalire, L; Le Cesne, A; Le Chevalier, T; Spielmann, M; Toussaint, C, 1995) |
| "We conducted a phase I/II trial to investigate the activity of ifosfamide/carboplatin/etoposide given over 2 or 3 days (mini-ICE) to patients with anthracycline-refractory or recurrent metastatic breast cancer." | 5.08 | Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships. ( Elfenbein, GJ; Fields, KK; Perkins, JB, 1995) |
| " Based on the limited clinical impact and the high incidence of rhGM-CSF-related toxicity that required growth factor discontinuation, the routine administration of rhGM-CSF to prevent neutropenia and infection after ifosfamide-based chemotherapy for GCT patients is not recommended." | 5.08 | Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. ( Bajorin, DF; Bokemeyer, C; Bosl, GJ; Demetri, GD; Einhorn, LH; Kantoff, PW; Nichols, CR; Schmoll, HJ, 1995) |
| "To determine the effectiveness and toxicity of ifosfamide chemotherapy in women with metastatic or recurrent endometrial stromal sarcomas unexposed to other chemotherapy." | 5.08 | Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. ( Blessing, JA; DiSaia, PJ; Park, R; Rosenshein, N; Sutton, G, 1996) |
| "Thirty-six patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea for malignant supratentorial gliomas received a combination of ifosfamide, carboplatin and etoposide (ICE) at tumour progression." | 5.08 | Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. ( Ameri, A; Delattre, JY; Monjour, A; Poisson, M; Ronchin, P; Sahmoud, T; Sanson, M, 1996) |
| "27 patients with recurrent high grade glioma following surgery and radiation therapy were treated with 100 mg/m2 cisplatin and 6 g/m2 ifosfamide per cycle, administered on days 1-3 in 4 week cycles, for a maximum of six cycles." | 5.08 | Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas. ( Jansen, RL; Kros, JM; Loosveld, OJ; Ma, J; Schellens, JH; Sillevis Smit, PA; Tijssen, CC; van den Bent, MJ; Vecht, CJ; Verweij, J, 1998) |
| "Fifty-two patients with advanced adenocarcinoma of the endometrium recurrent after surgery and/or radiation therapy and refractory to first-line chemotherapeutic agents were treated with ifosfamide, 1." | 5.07 | Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. ( Adcock, L; Blessing, JA; Homesley, HD; McGuire, WP; Sutton, GP, 1994) |
| "A total of 51 patients with large, primary, high-grade soft-tissue sarcomas of the extremities were treated at our institute with two preoperative and three postoperative cycles of doxorubicin plus ifosfamide/mesna." | 5.07 | Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities. ( Azzarelli, A; Casali, P; Fissi, S; Montalto, F; Quagliuolo, V; Santoro, A, 1993) |
| "Thirty-six patients with recurrent carcinoma of the head and neck and no prior exposure to chemotherapy were treated with Ifosfamide." | 5.07 | Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. ( Barón, FJ; Buesa, JM; Esteban, E; Estrada, E; Fernández, R; Gracia, M; Lacave, AJ; Palacio, I, 1991) |
| "Adjuvant chemotherapy of ovarian angiosarcoma with a combination of doxorubicin and ifosfamide appears effective and should be considered in women at risk of relapse who wish to conserve fertility." | 4.82 | Pregnancy following recurrent angiosarcoma of the ovary--a case report and review of literature. ( Chan, KK; Jha, S; Poole, CJ; Rollason, TP, 2005) |
| "The purpose of the German HB99 trial (1999-2008) for hepatoblastoma (HB), was primarily to analyse the effect of high dose (HD) chemotherapy with carboplatin/etoposide (CE) in high risk (HR) patients with extended tumors, vessel involvement, extrahepatic tumor or distant metastases." | 3.91 | High Dose Chemotherapy with Autologous Stem Cell Transplantation in Hepatoblastoma does not Improve Outcome. Results of the GPOH Study HB99. ( Häberle, B; Maxwell, R; Schmid, I; Schweinitz, DV, 2019) |
| "This study was designed to assess patterns of recurrence and long-term outcomes of patients undergoing surgery for localized retroperitoneal sarcoma (RPS) after neoadjuvant high dose long-infusion ifosfamide (HLI) and radiotherapy (RT)." | 3.85 | Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303. ( Basso, S; Bertola, G; Bertuzzi, A; Buonadonna, A; Casali, PG; Colombo, C; De Paoli, A; De Sanctis, R; Fiore, M; Giordano, L; Gronchi, A; Marrari, A; Navarria, F; Navarria, P; Quagliuolo, V; Sanfilippo, R; Sangalli, C; Santoro, A, 2017) |
| " A 49-year-old white male diagnosed with T3 N3 M0 Stage IIIB anal cancer was treated initially with surgical excision and adjuvant fluorouracil/cisplatin due unavailability of mitomycin." | 3.81 | Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. ( Baxley, A; Khawandanah, M; Pant, S, 2015) |
| "The aim of this retrospective study was to evaluate the feasibility and efficacy of response to continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for patients with recurrent or refractory osteosarcoma." | 3.81 | Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study. ( He, AN; Huang, YJ; Min, DL; Shen, Z; Sun, YJ; Yao, Y, 2015) |
| "We reviewed the records of 50 patients with osteosarcoma who underwent marginal resection following effective preoperative chemotherapy; 18 were treated with the MMIA (high-dose methotrexate (HD-MTX), adriamycin (ADR), ifosfamide (IFO)) and cisplatin (DDP), and 32 patients were treated with the DIA (DDP, ADR and IFO)." | 3.80 | Marginal resection for osteosarcoma with effective neoadjuvant chemotherapy: long-term outcomes. ( Xu, M; Xu, S; Yu, X, 2014) |
| "This systemic analysis was conducted to evaluate the efficacy and safety of an ifosfamide- containing regimen in treating patients with osteosarcoma." | 3.80 | Ifosfamide-containing regimens for treating patients with osteosarcomas. ( Dong, YG; Jiang, XM; Li, YY; Ma, YB; Xu, G, 2014) |
| "Patients with localized germinoma received either CSI or 2 courses of carboplatin and etoposide alternating with etoposide and ifosfamide, followed by local radiotherapy." | 3.79 | SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for pat ( Alapetite, C; Calaminus, G; Frappaz, D; Garrè, ML; Kortmann, R; Nicholson, JC; Patte, C; Ricardi, U; Saran, F; Worch, J, 2013) |
| "To determine demographic data, prognostic factors and outcome of childhood osteosarcoma treated with a carboplatin-based chemotherapeutic protocol at Chiang Mai University." | 3.79 | Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( Charoenkwan, P; Choeyprasert, W; Natesirinilkul, R; Sittipreechacharn, S, 2013) |
| "To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management." | 3.76 | Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010) |
| "Our study corroborates GOG 150 results, and shows that paclitaxel-carboplatin appears to be an efficacious adjuvant chemotherapy regimen for completely resected uterine carcinosarcoma." | 3.74 | A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. ( Abu-Rustum, NR; Aghajanian, CA; Alektiar, KM; Hensley, ML; Iasonos, A; Makker, V; Zhou, Q, 2008) |
| "The efficacy of zoledronic acid (ZOL), with or without the anticancer drug ifosfamide (IFO), was tested on primary bone tumor growth using a rat-transplantable model of osteosarcoma." | 3.73 | Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. ( Blanchard, F; Charrier, C; Coipeau, P; Couillaud, S; Gouin, F; Heymann, D; Heymann, MF; Ory, B; Redini, F; Thiery, JP, 2005) |
| "To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas." | 3.73 | Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. ( Piura, B; Rabinovich, A, 2005) |
| "We report a case of postoperative recurrence of liposarcoma of the mesenterium successfully treated by chemotherapy using ifosfamide (IFM) and cisplatin (CDDP)." | 3.73 | [A case of liposarcoma of the sigmoid colon mesenterium successfully treated with chemotherapy]. ( Aoki, T; Kondo, M; Mizumura, Y; Moritani, M; Sasaki, Y; Tsuchida, A; Wada, T; Yamamoto, K, 2006) |
| "Recurrent and refractory neuroblastoma responds well to chemotherapy regimen of ifosphamide plus carboplatin." | 3.73 | [Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006) |
| "Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor." | 3.70 | [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998) |
| "A neoadjuvant chemotherapy protocol (1/93-1/95) for extremity osteosarcoma preoperatively using high-dose methotrexate (HDMTX) as single agent per cycle and three different combinations of other drugs (CDP/IFO,CDP/ADM,IFO/ADM) is reported." | 3.70 | Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study. ( Bacci, G; Bernini, G; Brach del Prever, A; Capanna, R; Cesari, M; Comandone, A; Ferrari, S; Longhi, A; Mercuri, M; Picci, P; Tienghi, A, 1998) |
| "To describe a patient with ifosfamide-induced nonconvulsive status epilepticus." | 3.69 | Ifosfamide-induced nonconvulsive status epilepticus. ( Badesha, PS; Bhardwaj, A, 1995) |
| "Eighteen patients with high grade malignant fibrous histiocytoma (MFH) of bone and 112 patients with high grade osteosarcoma (OS) of the extremity were treated with neoadjuvant chemotherapy comprised of methotrexate, cisplatinum, doxorubicin and ifosfamide." | 3.69 | Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen. ( Bacci, G; Bertoni, F; Campanacci, M; Cesari, M; Ferrari, S; Forni, C; Gasbarrini, A; Mercuri, M; Sottili, S; Tienghi, A, 1997) |
| "A Phase II study of VP-16 (etoposide), ifosfamide/mesna, and cisplatin (VIP) in advanced and recurrent carcinoma of the cervix was initiated March 1989." | 3.68 | Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. ( Kredentser, DC, 1991) |
| "Sixteen patients who developed CT or MRI scan evidence of recurrent diffuse astrocytoma after radiation therapy and nitrosourea-containing chemotherapy received ifosfamide (2500 mg/m2/day for 3 consecutive days) and mesna (500 mg/m2/dose, 5 doses/day for 3 consecutive days)." | 3.68 | Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma. ( Buckner, JC; Cascino, TL; Elliott, TE; Levitt, R; O'Fallon, JR; Scheithauer, BW, 1991) |
| "One hundred twenty-four children and young adults with recurrent tumors, predominantly sarcomas, were treated with the combination of ifosfamide, etoposide, and the uroprotector, mesna (2-mercaptoethane sulphonate), in a phase II trial." | 3.67 | Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. ( Forquer, R; Jarosinski, P; Kinsella, TJ; Magrath, I; Miser, JS; Triche, TJ; Tsokos, M; Wesley, R, 1987) |
| "We have evaluated the activity of ifosfamide in 75 patients with recurrent sarcomas and pediatric solid tumors." | 3.67 | A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. ( Arasi, V; Magrath, I; Miser, J; Raynor, A; Rosenberg, S; Sandlund, J, 1986) |
| " Carfilzomib, an irreversible proteasome inhibitor, can overcome acquired rituximab-chemotherapy resistance and, when combined with R-ICE, improves outcomes in patients with R/R DLBCL." | 3.30 | Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. ( Burke, SM; Ghasemi, M; Goey, AKL; Hernandez-Ilizaliturri, FJ; Lin, LH; Mager, DE; Mavis, CK; Nichols, JR; Torka, P, 2023) |
| " We conducted a phase 1 trial to evaluate the safety of olaratumab and determine a recommended dose in combination with three different chemotherapy regimens in children." | 3.01 | Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. ( Bishop, MW; Borinstein, SC; DuBois, SG; Hingorani, P; Krystal, J; Laetsch, TW; Levy, DE; Mascarenhas, L; Mo, G; Muscal, JA; Ogawa, C; Shahir, A; Slotkin, EK; Weigel, BJ; Wright, J, 2021) |
| "This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma." | 2.87 | Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. ( Claret, L; Copeland, AR; Fanale, MA; Fayad, LE; Feng, L; Fowler, N; Hagemeister, FB; Hu, B; Nastoupil, LJ; Neelapu, S; Nieto, Y; Oki, Y; Rodriguez, MA; Romaguera, J; Samaniego, F; Turturro, F; Westin, JR; Younes, A, 2018) |
| " This phase II study evaluated the efficacy and safety of IFM combination with recommended current supportive therapy for recurrent SCLC in second-line and heavily treated setting." | 2.87 | A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting. ( Fukatsu, A; Hase, T; Hasegawa, Y; Hayashi, H; Kawada, K; Kondo, M; Morise, M; Nomura, F; Sokai, A; Tanaka, I, 2018) |
| "Patients with soft tissue sarcoma are at risk for local recurrence and distant metastases despite optimal local treatment." | 2.87 | Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. ( Abdel-Rahman, S; Angele, M; Belka, C; Daugaard, S; Dürr, HR; Ghadjar, P; Gronchi, A; Hiddemann, W; Hohenberger, P; Issels, RD; Jauch, KW; Knösel, T; Lindner, LH; Mansmann, U; Mella, O; Reichardt, P; Salat, C; Schmidt, M; Verweij, J; Vujaskovic, Z; Wessalowski, R; Wust, P, 2018) |
| "Metastatic germ cell tumors remain potentially curable when treated with salvage chemotherapy at first relapse." | 2.87 | Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer. ( Bowers, M; Cozens, K; Cross, N; Hennig, IM; Huddart, R; McKenzie, HS; Mead, G; Rustin, GJS; Wheater, MJ; White, JD, 2018) |
| "To select suitable chemotherapy for cervical cancer patients by ATP-tumor chemosensitivity assay." | 2.78 | [ATP-tumor chemosensitivity assay directed chemotherapy in patients with cervical cancer]. ( Jiang, Y; Yang, L; Yuan, Z; Zhang, Y; Zhao, Q, 2013) |
| "Neuroblastoma is the most common extracranial and deadly solid tumor in children." | 2.76 | Did salvage ICE chemotherapy improve the outcome in primary resistant/relapsing stage III/IV neuroblastoma? ( Abdel Rahman, H; El Debawy, E; Ezzat, S; Mostafa, NE; Moussa, EA; Rayan, Ael R; Yones, A; Zekri, WZ, 2011) |
| "The role of chemotherapy in high-risk soft tissue sarcoma is controversial." | 2.76 | A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma. ( Bischof, M; Dietrich, S; Dimitrakopoulou-Strauss, A; Egerer, G; Ho, AD; Kasper, B; Lehner, B; Mechtersheimer, G; Roeder, F; Schmitt, T; Strauss, LG; Wuchter, P, 2011) |
| "Cervical cancer is a disease of middle-aged and elderly but still there are young women diagnosed with advanced disease that is incurable with local treatment and is treated with platinum-based combination chemotherapy." | 2.73 | The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy. ( Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Papadimitriou, C; Rodolakis, A; Vlahos, G; Voulgaris, Z, 2007) |
| "Grade 3/4 neutropenia was observed in 21 % of patients and grade 3/4 febrile neutropenia was seen in only one patient." | 2.73 | Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. ( Ahn, JS; Ahn, MJ; Hwang, IG; Im, YH; Kang, WK; Lee, SC; Lim, HY; Park, BB; Park, K, 2008) |
| "Primary laryngeal synovial sarcoma is an extremely rare tumor predominantly affecting young adults." | 2.72 | Laryngeal Synovial Sarcoma: A Systematic Review of the Last 40 Years of Reported Cases. ( Anazodo, A; Jacobson, I; Loo, C; Potter, A; Sandhu, G; Shein, G, 2021) |
| "Uterine sarcomas are rare tumors." | 2.72 | Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus. ( Fietkau, R; Gerber, B; Klautke, G; Kortmann, B; Reimer, T, 2006) |
| "Twelve patients in stage IIIB cervical cancer were submitted to NAC and 12 (control group)--received standart pelvic radiation to whole pelvis--52 Gy." | 2.71 | [Effect of neoadjuvant chemotherapy in the treatment of patients with stage IIIB cervical cancer]. ( Gorchev, G; Kornovski, Ia, 2003) |
| "Ifosfamide was given intravenously (IV) at a dose of 1." | 2.71 | Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: a Hoosier Oncology Group (HOG) study. ( Einhorn, LH; Look, KY; McClean, JW; Shaheen, M; Stender, MJ, 2004) |
| " Hence, we decided to explore the option of neoadjuvant chemotherapy using effective agents like ifosfamide and paclitaxel in combination with cisplatin in these patients." | 2.71 | Two- vs three-drug combination chemotherapy in advanced or recurrent head and neck cancer: a single institution experience of 361 patients. ( Bakshi, AV; D'Cruz, AK; Deshmukh, CD; Mazumdar, AT; Mistry, RC; Pai, VR; Parikh, DM; Parikh, PM; Pathak, KA, 2004) |
| " The results however, did not show expected treatment efficacy and we raise the idea of paclitaxel dosage relevance in TIP." | 2.71 | Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study. ( Hlavatá, Z; Koza, I; Mardiak, J; Mego, M; Obertová, J; Recková, M; Sálek, T; Sycová-Milá, Z, 2005) |
| " was applied in combination with high-dose methotrexate (HDMTX) and adriamycin (ADM) within a three-drug regimen." | 2.70 | A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. ( Bacchini, P; Bacci, G; Bertoni, F; De Giorgi, U; Ferrari, S; Fiorentini, G; Forni, C; Longhi, A; Mercuri, M; Picci, P; Rimondini, S; Tienghi, A, 2001) |
| "In patients with recurrent breast cancer, triple-modality therapy is feasible with acceptable toxicity." | 2.70 | Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease. ( Feyerabend, T; Jäger, B; Mahlmann, B; Richter, E; Vesely, H; Wiedemann, GJ, 2001) |
| "In this phase II study, activity and safety of neoadjuvant regional hyperthermia (RHT) combined with chemotherapy was investigated in 59 patients with primary advanced or recurrent high-risk soft-tissue sarcoma (STS)." | 2.70 | Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. ( Abdel-Rahman, S; Aydemir, U; Falk, MH; Hiddemann, W; Issels, RD; Kurze, V; Sauer, H; Wendtner, C, 2001) |
| " 54 patients were prospectively treated with four cycles of etoposide, ifosfamide and doxorubicin (EIA) combined with regional hyperthermia (RHT) followed by surgery, another four cycles of EIA without RHT and external beam radiation." | 2.70 | Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. ( Abdel-Rahman, S; Baumert, J; Falk, MH; Hiddemann, W; Issels, RD; Krych, M; Santl, M; Wendtner, C, 2001) |
| "Paclitaxel was given at a dose of 175 mg/m2, ifosfamide at a dose of 5 g/m2, and cisplatin at a dose of 75 mg/m2 (50 mg/m2 in irradiated patients) at three-week intervals." | 2.69 | Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer. ( Balestrino, M; Fei, F; Gabriele, A; Lissoni, A; Mangioni, C; Parma, G; Zanetta, G, 1999) |
| "The first Scandinavian protocol for Ewing's sarcoma, SSG IV, resulted in a local control rate of 74% and 5-year metastasis-free survival (MFS) of 43%." | 2.69 | Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. ( Akerman, M; Alvegård, TA; Björk, O; Blomqvist, CP; Elomaa, I; Saeter, G; Stenwig, E; Wiebe, T, 2000) |
| "Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation." | 2.69 | Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. ( Bejkos, D; Bischof-Delaloye, A; Chassot, PG; Chiolero, R; Genton, A; Guillou, L; Landry, M; Lejeune, FJ; Leyvraz, PF; Leyvraz, S; Liénard, D; Mirimanoff, RO; Mosimann, F; Pujol, N; Raffoul, W, 2000) |
| " At the same time the carboplatin dosing calculation was changed and an area under the curve (AUC) formula rather than by mg/m2 was used to calculate this." | 2.69 | Should high-dose chemotherapy be used to consolidate second or third line treatment in relapsing germ cell tumours? ( Gallagher, CJ; Gupta, RK; Kelsey, S; Lister, TA; Newland, AC; O'Doherty, CA; Oliver, RT; Shamash, J, 2000) |
| "Granulocytopenia was the dose-limiting toxicity." | 2.68 | Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck. ( Benner, SE; Hong, WK; Huber, MH; Lippman, SM, 1995) |
| "Ifosfamide is an active agent in recurrent squamous cell carcinoma of the head and neck." | 2.68 | A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. ( Benner, SE; Dimery, IW; Dunnington, JS; Hong, WK; Huber, MH; Lippman, SM; Shirinian, M, 1996) |
| "The prognosis of advanced ovarian cancer is very poor, with about 15% of patients surviving at five years." | 2.68 | Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer. ( Beuzeboc, P; Dorval, T; Garcia-Giralt, E; Jouve, M; Livartowski, A; Mosseri, V; Palangié, T; Pouillart, P; Sastre, X; Scholl, S; Soussain, C, 1996) |
| "Ifosfamide was infused at the dose of 2 g/m2 over a 4-hour bolus infusion, followed by 2-g/m2 24-hour continuous infusions of ifosfamide, for a total of 14 or 18 g/m2 (6-8 days)." | 2.67 | Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. ( Eckardt, J; Eilber, F; Forscher, C; Fu, YS; Holmes, C; Lowenbraun, S; Rosen, G, 1994) |
| "The ifosfamide was escalated in 20% increments to the maximum tolerated dosage in cohorts of three patients." | 2.67 | Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study. ( Bell, B; Bernstein, ML; Buchanan, GR; Devine, S; Dreyer, Z; Grier, H; Krischer, J; Kung, F; Land, V; Whitehead, VM, 1993) |
| "A total of 37 men with epidermoid head and neck cancer whose disease had recurred following primary treatment (surgery and/or radiotherapy) received first-line chemotherapy with ifosfamide at i." | 2.67 | Ifosfamide in advanced epidermoid head and neck cancer. ( Almenarez, J; Casado, A; Diaz-Rubio, E; Dominguez, S; González Larriba, JL; López-Vega, JM; Martín, M; Sastre, J, 1993) |
| "Ifosfamide/VP-16 is an active combination in children with recurrent malignant solid tumors." | 2.67 | Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. ( Golembe, B; Holbrook, CT; Homans, AC; Jaffe, N; Kung, FH; Nitschke, R; Pratt, CB; Schwenn, M; Strother, D; Vega, RA, 1993) |
| "Patients with localized high-risk soft tissue sarcoma are at high risk for both local recurrence and distant metastases despite optimal surgical treatment." | 2.61 | [Multimodal treatment of sarcomas: standards and new aspects in pharmacological and radio-oncological treatment]. ( Lindner, LH, 2019) |
| "Localized soft tissue sarcoma may be cured with complete tumor excision, but overall, outcomes are sub-optimal." | 2.58 | Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy. ( Charlson, J, 2018) |
| "Primary malignant cardiac tumors are very rare." | 2.50 | Recurrent primary cardiac osteosarcoma: a case report and literature review. ( Asadi, N; Bini, A; Caroli, G; Dell'Amore, A; Dolci, G; Stella, F, 2014) |
| "The present case, a CNS PNET, is suspected as a secondary brain tumor induced by radiation therapy previously used to treat a medulloblastoma, and it represents a rare late-onset complication of radiation therapy." | 2.50 | [CNS primitive neuroectodermal tumor suspected as a secondary recurrence after radiation therapy for medulloblastoma:a case report]. ( Endo, S; Kato, S; Koizumi, T; Sato, H; Shibuya, K, 2014) |
| "Patients with relapsed germ cell tumors (GCT) are potentially curable despite the failure of initial cisplatin based therapy." | 2.48 | Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy. ( Lim, L; Powles, T; Rashid, S, 2012) |
| "The occurrence of primary extraskeletal Ewing's sarcoma (EES) of the spinal epidural space has been rarely reported in the literature." | 2.47 | Extraskeletal Ewing's sarcoma of the thoracic epidural space: case report and review of the literature. ( Bridge, JA; Hori, T; Huang, D; Kanamori, M; Kimura, T; Suzuki, K; Yasuda, T, 2011) |
| "Myxoid liposarcoma has a relatively good prognosis but tends to recur locally." | 2.43 | Myxoid liposarcoma metastatic to the thyroid gland: a case report and literature review. ( Clarke, PM; Sandison, A; Tysome, JR, 2006) |
| "Ifosfamide (IFO) is a widely used antitumor agent, requiring activation to isophosphoramide mustard (IPM) for DNA alkylation." | 2.43 | Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. ( Lokiec, F, 2006) |
| "Ifosfamide has been studied as a single agent or in combination with other drugs in different studies." | 2.42 | Role of ifosfamide in cervical cancer: an overview. ( Buda, A; Dell'Anna, T; Mangioni, C; Signorelli, M, 2003) |
| "Soft tissue sarcomas are a heterogeneous group of malignancies arising from mesenchymal tissues." | 2.42 | Emerging treatments for soft tissue sarcoma of adults. ( Fahn, W; Issels, RD, 2004) |
| "Paclitaxel has been tested with interesting results in cervical cancer." | 2.41 | Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza. ( Fei, F; Mangioni, C; Zanetta, G, 2000) |
| "Patients with advanced squamous cell head and neck cancer have a dismal long-term survival rate not only because of metastatic disease, but also primarily because of failure in local disease control." | 2.41 | Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. ( Glisson, BS; Hong, WK; Khuri, FR; Lippman, SM; Shin, DM, 2000) |
| "Brain metastases are rare in the natural history of Wilms tumor." | 2.41 | Brain metastases in Wilms' tumor: case report and literature review. ( Grimard, L; Halton, JM; Hsu, E; MacRae, R; Nizalik, E, 2002) |
| "Epithelial ovarian cancer is the most lethal of all gynecologic malignancies." | 2.41 | Epithelial ovarian cancer. ( Hensley, ML, 2002) |
| "Ifosfamide has been used extensively for the treatment of patients with non-Hodgkin's lymphoma (NHL)." | 2.39 | Ifosfamide in the treatment of non-Hodgkin's lymphoma. ( Pohlman, B, 1996) |
| "Patients with testicular cancer who relapse after primary chemotherapy are still curable and should be treated aggressively with this goal in mind." | 2.38 | Salvage therapy in recurrent testicular cancer. ( Saxman, S, 1992) |
| " The purpose of this study was to explore the efficacy and safety of programmed cell death 1 (PD-1) blockade combined with ICE regimen (P-ICE) in the treatment of R/R DLBCL patients." | 1.91 | PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma. ( Bai, B; Gao, Y; He, Y; Huang, C; Huang, H; Ping, L; Shi, L; Wang, X, 2023) |
| " Romidepsin (Ro) and brentuximab vedotin (Bv), combined with ifosfamide, carboplatin, and etoposide (ICE) has not been significantly studied in PTCL." | 1.72 | Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma. ( Gentille, C; Joshi, J; Pingali, SR; Randhawa, J; Sarfraz, H; Shah, S, 2022) |
| " Dosing was modified for elderly patients." | 1.72 | Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma. ( Borawska, A; Chełstowska, M; Dąbrowska-Iwanicka, A; Domańska-Czyż, K; Druzd-Sitek, A; Giebel, S; Knopińska-Posłuszny, W; Konecki, R; Kumiega, B; Lange, A; Malenda, A; Michalski, W; Mordak-Domagała, M; Najda, J; Osowiecki, M; Ostrowska, B; Paszkiewicz-Kozik, E; Pluta, A; Popławska, L; Romejko-Jarosińska, J; Rymkiewicz, G; Świerkowska, M; Szpila, T; Szymański, M; Targoński, Ł; Taszner, M; Walewski, J; Zaucha, JM, 2022) |
| "Most aspects of osteosarcoma have been addressed in detail, but there is no comprehensive analysis of deceased patients and causes of death." | 1.72 | Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS). ( Bielack, SS; Blattmann, C; Borkhardt, A; Csóka, M; Hassenpflug, W; Hecker-Nolting, S; Kabíčková, E; Kager, L; Kessler, T; Kevric, M; Kratz, C; Kühne, T; Lehrnbecher, T; Mayer-Steinacker, R; Mettmann, V; Metzler, M; Reichardt, P; Rossig, C; Sorg, B; von Luettichau, I; Windhager, R, 2022) |
| "Relapsed Hodgkin lymphoma with central nervous system involvement is relatively rare with just over two dozen cases reported to date and is observed infrequently in developing nations." | 1.62 | Atypical involvement of central nervous system in classic Hodgkin lymphoma: a case report. ( Ahmed, S; Haider, G; Irfan, B; Raza, M, 2021) |
| "Malignant germ cell tumors (GCTs) are a heterogeneous group of rare neoplasms in children." | 1.56 | Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience. ( Biasoni, D; Bisogno, G; Boldrini, R; Conte, M; Crocoli, A; D'Angelo, P; Dall'Igna, P; De Pasquale, MD; Inserra, A; Miele, E; Siracusa, F; Spreafico, F; Terenziani, M, 2020) |
| "Soft tissue sarcomas are a group of tumors derived from the mesenchymal origin." | 1.56 | Epithelioid Hyalinizing Sarcoma With MGA-NUTM1 Fusion. ( Al-Rohil, RN; Bentley, RC; Cardona, DM; Feng, X; Jour, G; Shen, G; Underwood, CIM, 2020) |
| "Hepatic angiosarcoma is an extremely rare diagnosis in children, with fewer than 50 pediatric cases reported in the literature worldwide." | 1.51 | Success of chemotherapy and a liver transplant in a pediatric patient with hepatic angiosarcoma: A case report. ( Chinnakotla, S; Eidenschink, B; Luquette, M; Neglia, J; Pilbeam, K; Sulciner, M, 2019) |
| "Ameloblastoma is generally characterized as a benign tumor originating in odontogenic epithelium." | 1.51 | MAID chemotherapy regimen as a treatment strategy for metastatic malignant ameloblastoma: A case report. ( Li, D; Liu, Y; Qiao, L; Sun, M; Wang, L; Xu, S, 2019) |
| " In this study, we adjusted the dosage of the triplet regimen and introduced carboplatin in cisplatin-intolerable patients." | 1.48 | Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis. ( Bae, DS; Choi, CH; Choi, HJ; Kim, BG; Kim, TJ; Lee, JW; Lee, YY; Paik, ES, 2018) |
| "On multivariate analysis, positive surgical margins negatively impacted LRC, DFS, and OS (hazard ratio [HR]=10." | 1.43 | The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome. ( Benedetto, P; Conway, S; Dosch, A; Fernandez, G; Kwon, D; Mahmoud, O; Pitcher, JD; Temple, HT; Trent, J; Wolfson, AH, 2016) |
| "Both the International Germ Cell Cancer Collaborative Group and the International Prognostic Factors Study Group risk groups were significantly associated with progression-free survival (log-rank P = ." | 1.43 | Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors. ( Gunnarsson, O; Hwang, WT; Narayan, V; Nathanson, KL; Squillante, CM; Stadtmauer, EA; Vaughn, DJ, 2016) |
| "Relapsed/refractory Hodgkin's lymphoma (HL) is treated with salvage chemotherapy and autologous stem cell transplantation (ASCT)." | 1.43 | High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma. ( Aurer, I; Bašić-Kinda, S; Dotlić, S; Dujmović, D; Kralik, M; Labar, B; Mazić, S; Mitrović, Z; Nemet, D; Radman, I; Šantek, F; Sertić, D, 2016) |
| "The ifosfamide dosage was reduced to two-thirds of the original protocol." | 1.43 | Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. ( Arima, N; Fukunaga, A; Hyuga, M; Iwasaki, M; Kishimoto, W; Maesako, Y; Nakae, Y, 2016) |
| "We report a case of HIV-negative Burkitt lymphoma (BL) that relapsed 9 years after complete remission." | 1.42 | A case of clonally distinct relapse of Burkitt lymphoma 9 years after complete remission. ( Ando, K; Kikuchi, T; Kikuti, YY; Kojima, M; Moriuchi, M; Murayama, H; Nakamura, N; Ogawa, Y; Tokunaka, M; Tsuboi, K; Yabe, M, 2015) |
| "Extraosseous osteosarcoma is rare, and the most appropriate therapy is unclear because there are few studies regarding its treatment." | 1.42 | Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas? ( Fan, Z; Guadagnolo, BA; Lewis, VO; Lin, PP; Patel, S, 2015) |
| "Some children with extracranial germ cell tumors (GCT) relapse after or do not respond to first-line treatment combining chemotherapy and surgery, of whom very few experience long-term survival despite multimodal salvage treatment." | 1.40 | Salvage therapy for refractory or recurrent pediatric germ cell tumors: the French SFCE experience. ( Baranzelli, MC; Corradini, N; Cropet, C; Fasola, S; Faure-Conter, C; Frappaz, D; Kalfa, N; Martelli, H; Orbach, D; Patte, C; Rocourt, N; Rome, A; Thebaud, E; Vérité, C, 2014) |
| "Plerixafor has shown a potential to mobilize adequate CD34+HSCs numbers in this context." | 1.40 | Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumo ( Athanasopoulos, A; Daladimos, T; Dimitriadis, G; Gekas, C; Kosmas, C; Lydakis, D; Magiorkinis, E; Miltiadous, C; Mylonakis, N; Zilakos, M; Ziras, N, 2014) |
| "Head and neck myxofibrosarcoma is rare." | 1.40 | Myxofibrosarcoma of the thyroid gland. ( Attifi, H; Benariba, F; Darouassi, Y; Rharrassi, I; Zalagh, M, 2014) |
| "In adolescents aged 10-15 years germ cell tumors of the testis (TGCT) are rare and information for a risk adapted therapy limited." | 1.40 | Testicular germ cell tumors in adolescents - results of the protocol MAHO 98 and the identification of good risk patients. ( Calaminus, G; Göbel, U; Haas, R; Harms, D; Leuschner, I; Schneider, DT; Schönberger, S; Teske, C, 2014) |
| " The aim of this retrospective study was to evaluate the activity and toxicity of bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer." | 1.40 | Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases. ( Li, Y; Shang, YM; Yang, Y; Zheng, H, 2014) |
| "No significant dose-response effect of adjuvant RT was demonstrated." | 1.39 | Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall. ( Bauer, HC; Bruland, OS; Eide, GE; Engellau, J; Engström, K; Jebsen, NL; Monge, OR; Muren, LP; Trovik, CS, 2013) |
| " In the present analysis, we retrospectively investigated the feasibility and effectiveness of bevacizumab combined with ICE in patients with glioblastoma at second relapse during ICE treatment." | 1.39 | Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma. ( Arakawa, Y; Fujimoto, K; Kikuchi, T; Kunieda, T; Miyamoto, S; Mizowaki, T; Murata, D; Takagi, Y; Takahashi, JC, 2013) |
| "Late relapses following stage I germ cell tumors were associated with seminoma, older age, and worse outcome after induction chemotherapy." | 1.39 | Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival. ( Bulanov, A; Burova, A; Fainshtein, I; Fedyanin, M; Figurin, K; Garin, A; Kanagavel, D; Sergeev, U; Tjulandin, S; Tryakin, A; Zakharova, T, 2013) |
| "We report a case of CD20 Burkitt leukemia with inverted duplication (1q) mutation, who had an early relapse during NHL-BFM 95 treatment." | 1.38 | Successful treatment of ICE-rituximab chemotherapy and subsequent bone marrow transplantation in a patient with early-relapse Burkitt leukemia and inverted duplication of 1q. ( Avci, Z; Gursel, O; Kurekci, E; Malbora, B; Olgac, A; Ozbek, N, 2012) |
| "Data of patients with extraskeletal Ewing's sarcoma followed up at our center between 1997 and 2010 were retrospectively analyzed." | 1.38 | Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome. ( Colpan Oksuz, D; Dervisoglu, S; Hiz, M; Kantarci, F; Koca, S; Molinas Mandel, N; Oner Dincbas, F; Selcukbiricik, F; Tural, D; Turna, H, 2012) |
| "Alveolar soft part sarcomas are rarely seen and highly malignant tumors, and the prognosis of stage IV ASPS is poor." | 1.38 | [Treatment and prognosis of stage IV alveolar soft part sarcoma]. ( Yang, Y; Zhao, J, 2012) |
| "Malignant peripheral nerve sheath tumors (MPNST) are rare soft-tissue sarcomas with a tendency for recurrence and metastasis." | 1.37 | Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy. ( Crawford, EA; Lackman, RD; Moretti, VM; Ogilvie, CM; Staddon, AP, 2011) |
| "High-risk soft tissue sarcoma was defined as high-grade malignancy and at least two of the following criteria: size≥8 cm, vascular invasion, or necrosis." | 1.37 | Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall. ( Bruland, ØS; Engellau, J; Eriksson, M; Folin, A; Hall, KS; Jebsen, NL; Trovik, CS; Turesson, I, 2011) |
| "We evaluated whether Korean Ewing sarcoma family of tumors patients have poorer outcomes than Euro-American patients." | 1.37 | Treatment outcome of Korean patients with localized Ewing sarcoma family of tumors: a single institution experience. ( Cho, J; Cho, WH; Jeon, DG; Kim, DH; Kim, MS; Koh, JS; Kong, CB; Lee, JA; Lee, SY; Lim, JS; Song, WS; Yoo, JY, 2011) |
| "In relapsed germ cell tumors, salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) is a well-established regimen for patients with favorable features such as a primary testicular tumor and prior complete remission (CR) after the initial chemotherapy." | 1.37 | Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors. ( Kang, WK; Lee, J; Lee, S; Lim, HY; Park, JO; Park, S; Park, SH; Park, YS, 2011) |
| "Uterine mullerian adenosarcoma is a rare tumor without specific clinical symptoms and signs." | 1.36 | [Mullerian adenosarcoma of the uterus: A clinicopathologic analysis of 9 cases]. ( Guo, LN; Han, XY; Huang, HF; Pan, LY; Sheng, K; Wan, XR; Xiang, Y, 2010) |
| "Medulloblastoma is a common paediatric brain tumor." | 1.35 | [Frontal relapse of medulloblastoma. Causes and consequences (a case report)]. ( Besbes, M; Chaari, N; Ghorbel, I; Kochbati, L; Maalej, M, 2008) |
| "We present a case of pleomorphic malignant fibrous histiocytoma arising from the left forearm in a 45-year-old man who had undergone resection and radiotherapy for a tumor 3 years previously." | 1.35 | Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy. ( Hoshi, M; Ieguchi, M; Takami, M, 2008) |
| "After disease progression despite the administration of CAV in clinically appropriate patients, alpha-interferon (alpha-IFN) (9 patients) was administered." | 1.35 | Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. ( Chamberlain, MC; Glantz, MJ, 2008) |
| "The outcome of Ewing's sarcoma depends on the anatomical site of the tumor." | 1.35 | Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone. ( Arpaci, F; Ataergin, S; Beyzadeoglu, M; Komurcu, S; Oysul, K; Ozet, A; Ozturk, M; Solchaga, L; Surenkok, S; Turan, M, 2009) |
| "Cystosarcoma phyllodes is an important but relatively uncommon fibroepithelial breast neoplasm that accounts for 0." | 1.35 | Metastatic phyllodes tumor causing small-bowel obstruction. ( Barrett, C; Kelly, RJ; McDermott, R; Swan, N, 2009) |
| "Recurrent or metastatic cervical cancer represents an aggressive malignancy with a high rate of locoregional and distant failure." | 1.35 | Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer. ( Akrivos, T; Daladimos, T; Kalinoglou, N; Karabelis, A; Karvounis, N; Kosmas, C; Malamos, N; Mylonakis, N; Tsakonas, G; Tsavaris, N; Vorgias, G, 2009) |
| "Soft tissue sarcoma is a malignant connective tissue tumor that may arise anywhere in the body and from diverse mesenchymal elements." | 1.35 | Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy? ( Patel, S; Schuetze, SM, 2009) |
| "Advances in the treatment of Ewing sarcoma family of tumors (ESFT) are the result of improvements in systemic and local therapies." | 1.35 | Prognostic factors for local and distant control in Ewing sarcoma family of tumors. ( Billups, CA; Krasin, MJ; Liu, T; Navid, F; Rao, BN; Rodríguez-Galindo, C, 2008) |
| "Osteosarcomas are highly malignant tumours of bone, and are rare in the craniofacial area." | 1.35 | Interdisciplinary combined treatment of craniofacial osteosarcoma with neoadjuvant and adjuvant chemotherapy and excision of the tumour: a retrospective study. ( Bacon, C; Egerer, G; Freier, K; Hofele, CM; Thiele, OC, 2008) |
| "The prognosis of recurrent metastatic cervical cancer is extremely poor." | 1.34 | Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series. ( Abu-Rustum, NR; Aghajanian, C; Bowes, RJ; Jhamb, N; Khoury-Collado, F, 2007) |
| "Except for a temporal exacerbation of bronchiolitis obliterans organizing pneumonia, she has been free from disease for more than a year without other treatments against lymphoma." | 1.34 | Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation. ( Chiba, S; Izutsu, K; Kako, S; Kanda, Y; Kurokawa, M; Motokura, T; Oshima, K; Sato, H, 2007) |
| "Suprasellar germinomas are rare intracranial neoplasms, which mainly occur in children and adolescents and manifest with endocrine symptoms and/or compression syndromes." | 1.34 | [Long-term follow-up of patients with suprasellar germinomas]. ( Bauditz, J; Lochs, H; Ventz, M, 2007) |
| "The local management of Ewing sarcoma family of tumors (ESFT) often centers on the surgical resectability of the primary lesion and physician biases regarding differences in the morbidity between primary surgical and radiotherapeutic management." | 1.33 | Definitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors: local outcome and prognostic factors. ( Billups, CA; Davidoff, AM; Fuller, CE; Krasin, MJ; Merchant, TE; Neel, MD; Rodriguez-Galindo, C, 2005) |
| "Spinal chondrosarcoma are extremely rare and slowly growing tumors." | 1.33 | [Upper cervical chondrosarcoma]. ( Domínguez, CJ; Joly, C; Martín-Ferrer, S; Rimbau, J, 2005) |
| "Medulloblastomas are highly lethal tumors when they recur." | 1.33 | Stereotactic radiation therapy with chemotherapy in the management of recurrent medulloblastomas. ( Abe, M; Imamura, J; Kida, Y; Tabuchi, K; Takagi, M; Tokumaru, S, 2006) |
| "Although rapid disease progression had resolved transiently, after the start of high-dose chemotherapy, re-progression was apparently observed from day 14." | 1.32 | Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation. ( Hosoi, H; Iehara, T; Misawa, A; Sawada, T; Sugimoto, T; Tsuchiya, K, 2003) |
| "Numerous studies on extremity soft tissue sarcomas have consistently shown that presentation with locally recurrent disease is associated with the development of subsequent local recurrences and that large tumor size and high histologic grade are significant factors associated with decreased survival." | 1.32 | High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. ( Dorey, F; Eckardt, J; Eilber, FC; Eilber, FR; Nelson, SD; Rosen, G; Selch, M, 2003) |
| "Synovial sarcoma is an extremely rare primary pulmonary tumor whose description is based on a limited number of cases." | 1.32 | [Primary pulmonary synovial sarcoma: a report and diagnosis of 2 cases]. ( Baldo Padró, X; Bernadó Turmo, L; Haro Estarriol, M; Rubio Goday, M; Sebastián Quetglas, F; Viñas Villaró, G, 2003) |
| "Febrile neutropenia was observed in 5 patients (41." | 1.32 | [Paclitaxel, ifosfamide, nedaplatin (TIN) for patients with metastatic urothelial cancer]. ( Demura, T; Harabayashi, T; Ishikawa, R; Koyanagi, T; Mitsuhashi, K; Murakumo, M; Seki, H; Shinohara, N; Suzuki, S; Toyota, H, 2004) |
| " As cytostatics for hyperthermic peritoneal perfusion, we have used Mitomycin in a dosage of 18 mg/m2 plus Melphalan in a dosage of 25 mg/m2." | 1.32 | Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)--report of six cases. ( Müller, H; Nakchbandi, V, 2004) |
| "Spinal cord compression has also been rarely reported in all age groups." | 1.32 | Spinal cord compression and lung metastasis of Wilms' tumor in a pregnant adolescent. ( Akansel, G; Arisoy, AE; Calişkan, M; Corapcioglu, F; Dillioğlugil, O; Sarper, N, 2004) |
| "Despite the fact that Ewing sarcoma family of tumors (ET) is chemosensitive, long-term survival is extremely rare for patients with primary refractory or recurrent disease." | 1.32 | VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors. ( Allam, A; Bazarbashi, S; El Foudeh, M; El Hassan, I; El Weshi, A; Ezzat, A; Memon, M; Pai, C; Rahal, M; Raja, M, 2004) |
| "Data on 359 patients with nonmetastatic Ewing's sarcoma of bone treated at a single institution between January 1979 and April 1995 were retrospectively considered." | 1.31 | Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. ( Bacchini, P; Bacci, G; Bertoni, F; Donati, D; Ferrari, S; Forni, C; Longhi, A; Manfrini, M; Picci, P; Rimondini, S, 2000) |
| "Thirty patients with recurrent ovarian cancer who underwent salvage surgical cytoreduction were retrospectively reviewed." | 1.31 | Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. ( Cosio, S; Cristofani, R; Fanucchi, A; Gadducci, A; Iacconi, P; Riccardo Genazzani, A, 2000) |
| "A diagnosis of bilateral Wilms tumor was made following percutaneous biopsy of both kidneys; histologic examination confirmed that the tumor was predominantly rhabdomyomatous." | 1.31 | Serum creatine kinase levels parallel the clinical course for rhabdomyomatous Wilms tumor. ( Crooke, MJ; Delahunt, B; Lewis, ME; Pringle, KC; Wiltshire, EJ, 2001) |
| "We report a case of relapsed testicular tumor complicated by neutropenic enterocolitis during high dose chemotherapy with PBSCT." | 1.30 | [A case of neutropenic enterocolitis in high dose chemotherapy with peripheral blood stem cell transplantation for relapsed testicular tumor]. ( Haga, N; Honda, K; Itoh, M; Muraki, O; Ohto, H; Tsuruya, Y; Yamaguchi, O, 1998) |
| "11 months later brain metastases were diagnosed." | 1.29 | Undifferentiated (embryonal) sarcoma of the liver in an adult patient with metastasis of the heart and brain. ( Fehske, W; Fischer, HP; Hartlapp, JH; Reichel, C, 1994) |
| "Ifosfamide is a chemotherapeutic agent used for treatment of pediatric solid tumors." | 1.28 | Rickets--a complication of ifosfamide chemotherapy for Wilms tumor. ( Boal, DK; Relf, M, 1992) |
| "For the recurrent ovarian cancer patients at present there are no definite strategy to treat the recurrent cases." | 1.28 | [Treatment of recurrent ovarian cancer]. ( Kudo, R; Sagae, S, 1992) |
| "Chemorefractory metastatic germ cell tumors and elevated tumor markers generally indicate inoperable disease." | 1.28 | Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. ( Bosl, GJ; Herr, HW; Morse, MJ; Motzer, RJ; Reuter, V; Sogani, PC; Wood, DP, 1992) |
| "Twelve patients with localized Ewing's sarcoma were treated between 1980-1990 at the Istanbul School of Medicine, Department of Pediatric Oncology-Hematology, Oncology Research and Treatment Center and Our Children Leukemia Foundation." | 1.28 | Ewing's sarcoma: experience with 12 cases. ( Gedikoğlu, G; Zülfikar, B, 1992) |
| "Cerebral metastases occurred in 20% of all patients and was the apparent sole site of relapse in 11% of the CR patients." | 1.28 | Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy. ( Burt, P; Prendiville, J; Radford, J; Ranson, M; Steward, W; Stout, R; Thatcher, N, 1991) |
| "Two cases of Ewing's sarcoma originating from the adult rib were reported." | 1.28 | [Two cases of Ewing's sarcoma originating from the adult rib]. ( Akiba, Y; Fujita, Y; Ikushima, Y; Ishida, S; Ohosaki, Y; Onodera, S; Sakai, E; Saotome, K; Shimizu, T; Tagaki, S, 1991) |
| "The tumors included 5 squamous cell carcinomas (non keratinizing: 2, keratinizing: 3), two adenosquamous (including one glassy cell carcinoma), one adenocarcinoma (endometrioid type) and one argyrophil cell carcinoma." | 1.28 | Ifosfamide, adriamycin and cisplatin (IAP) plus bleomycin (B) combination chemotherapy in patients with recurrent cancer of the uterine cervix. ( Arimatsu, T; Izumi, S; Matsumura, T; Nagano, H; Nagasue, N; Nishida, T; Okura, N; Yakushiji, M, 1989) |
| " No significant dose-response relationship was demonstrated in this heterogeneous group of patients." | 1.28 | A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer. ( Coleman, RE; Gallagher, CJ; Harper, PG; Wiltshaw, E, 1989) |
| "Treatment with ifosfamide or combination chemotherapy with vincristine, ifosfamide and peplomycin was performed in some of the 65 cases above mentioned." | 1.27 | [Reactivation of prostatic cancer and chemotherapy in reactivated prostatic cancer]. ( Ando, K; Fuse, H; Hara, S; Shimazaki, J; Zama, S, 1985) |
| "Ten patients with reactivated stage D prostatic cancer were treated with the combination therapy of vincristine, ifosfamide and peplomycin (VIP therapy)." | 1.27 | [Combination chemotherapy of vincristine, ifosfamide and peplomycin in patients with reactivated prostatic cancer]. ( Akiya, T; Katayama, T; Kazama, T; Nakada, T; Umeda, K, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (5.60) | 18.7374 |
| 1990's | 119 (25.65) | 18.2507 |
| 2000's | 156 (33.62) | 29.6817 |
| 2010's | 131 (28.23) | 24.3611 |
| 2020's | 32 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, S | 1 |
| Irfan, B | 1 |
| Raza, M | 1 |
| Haider, G | 1 |
| Aykan, MB | 1 |
| Erturk, I | 1 |
| Acar, R | 1 |
| Yildiran, GS | 1 |
| Yildiz, B | 1 |
| Karadurmus, N | 1 |
| Groenendijk, A | 1 |
| van Tinteren, H | 1 |
| Jiang, Y | 3 |
| de Krijger, RR | 1 |
| Vujanic, GM | 1 |
| Godzinski, J | 2 |
| Rübe, C | 1 |
| Schenk, JP | 1 |
| Morosi, C | 1 |
| Pritchard-Jones, K | 1 |
| Al-Saadi, R | 1 |
| Vaidya, SJ | 1 |
| Verschuur, AC | 1 |
| Ramírez-Villar, GL | 1 |
| Graf, N | 2 |
| de Camargo, B | 1 |
| Drost, J | 1 |
| Perotti, D | 1 |
| van den Heuvel-Eibrink, MM | 1 |
| Brok, J | 1 |
| Spreafico, F | 2 |
| Mavinkurve-Groothuis, AMC | 1 |
| Miyazaki, K | 1 |
| Suzuki, R | 1 |
| Oguchi, M | 1 |
| Taguchi, S | 1 |
| Amaki, J | 1 |
| Maeda, T | 2 |
| Kubota, N | 1 |
| Maruyama, D | 1 |
| Terui, Y | 1 |
| Sekiguchi, N | 1 |
| Takizawa, J | 1 |
| Tsukamoto, H | 1 |
| Murayama, T | 1 |
| Ando, T | 1 |
| Matsuoka, H | 1 |
| Hasegawa, M | 1 |
| Wada, H | 1 |
| Sakai, R | 1 |
| Kameoka, Y | 1 |
| Tsukamoto, N | 1 |
| Choi, I | 1 |
| Masaki, Y | 1 |
| Shimada, K | 1 |
| Fukuhara, N | 1 |
| Utsumi, T | 1 |
| Uoshima, N | 1 |
| Kagami, Y | 1 |
| Asano, N | 1 |
| Ejima, Y | 1 |
| Katayama, N | 1 |
| Yamaguchi, M | 1 |
| Gentille, C | 1 |
| Sarfraz, H | 1 |
| Joshi, J | 1 |
| Randhawa, J | 1 |
| Shah, S | 1 |
| Pingali, SR | 1 |
| Paszkiewicz-Kozik, E | 1 |
| Michalski, W | 1 |
| Taszner, M | 1 |
| Mordak-Domagała, M | 1 |
| Romejko-Jarosińska, J | 1 |
| Knopińska-Posłuszny, W | 1 |
| Najda, J | 1 |
| Borawska, A | 1 |
| Chełstowska, M | 1 |
| Świerkowska, M | 1 |
| Dąbrowska-Iwanicka, A | 1 |
| Malenda, A | 1 |
| Druzd-Sitek, A | 1 |
| Konecki, R | 1 |
| Kumiega, B | 1 |
| Osowiecki, M | 1 |
| Ostrowska, B | 1 |
| Szpila, T | 1 |
| Szymański, M | 1 |
| Targoński, Ł | 1 |
| Domańska-Czyż, K | 1 |
| Popławska, L | 1 |
| Giebel, S | 1 |
| Lange, A | 1 |
| Pluta, A | 1 |
| Zaucha, JM | 1 |
| Rymkiewicz, G | 1 |
| Walewski, J | 1 |
| Dittus, C | 1 |
| Miller, JA | 1 |
| Wehbie, R | 1 |
| Castillo, JJ | 1 |
| Shafagati, N | 1 |
| Koh, MJ | 1 |
| Boussi, L | 1 |
| Park, HJ | 1 |
| Stuver, R | 1 |
| Bain, P | 1 |
| Foss, FM | 1 |
| Shen, C | 1 |
| Jain, S | 2 |
| Stamatoullas, A | 2 |
| Ghesquières, H | 1 |
| Feugier, P | 1 |
| André, M | 1 |
| Le Bras, F | 1 |
| Gac, AC | 1 |
| Borel, C | 1 |
| Gastinne, T | 1 |
| Quittet, P | 1 |
| Morschhauser, F | 1 |
| Ribrag, V | 1 |
| Guidez, S | 1 |
| Nicolas-Virelizier, E | 1 |
| Berriolo-Riedinger, A | 1 |
| Vander Borght, T | 1 |
| Edeline, V | 1 |
| Brice, P | 2 |
| Bielack, SS | 1 |
| Blattmann, C | 1 |
| Borkhardt, A | 1 |
| Csóka, M | 1 |
| Hassenpflug, W | 1 |
| Kabíčková, E | 1 |
| Kager, L | 1 |
| Kessler, T | 1 |
| Kratz, C | 1 |
| Kühne, T | 1 |
| Kevric, M | 1 |
| Lehrnbecher, T | 1 |
| Mayer-Steinacker, R | 1 |
| Mettmann, V | 1 |
| Metzler, M | 1 |
| Reichardt, P | 3 |
| Rossig, C | 1 |
| Sorg, B | 1 |
| von Luettichau, I | 1 |
| Windhager, R | 1 |
| Hecker-Nolting, S | 1 |
| Corvest, V | 1 |
| Marec-Bérard, P | 1 |
| Lervat, C | 1 |
| Pacquement, H | 1 |
| Toulmonde, M | 1 |
| Gentet, JC | 2 |
| Laurence, V | 1 |
| Cleirec, M | 1 |
| Mansuy, L | 1 |
| Bompas, E | 1 |
| Castex, MP | 1 |
| Taque, S | 1 |
| Filhon, B | 1 |
| Tabone, MD | 2 |
| Verité, C | 2 |
| Entz-Werle, N | 1 |
| Saumet, L | 1 |
| Guimard, G | 1 |
| Pondrom, M | 1 |
| Chevreau, C | 3 |
| Flandrin, J | 1 |
| Duranteau, L | 1 |
| Rousset-Jablonski, C | 1 |
| Brugières, L | 1 |
| Jimenez, M | 1 |
| Le Deley, MC | 1 |
| Gaspar, N | 1 |
| Fresneau, B | 1 |
| Ramanathan, S | 1 |
| Prasad, M | 1 |
| Vora, T | 1 |
| Badira, CP | 1 |
| Kembhavi, S | 1 |
| Ramadwar, M | 1 |
| Khanna, N | 1 |
| Laskar, S | 1 |
| Muckaden, MA | 1 |
| Qureshi, S | 1 |
| Banavali, S | 1 |
| Chinnaswamy, G | 1 |
| Merjaneh, N | 1 |
| Kim, H | 1 |
| Escoto, H | 1 |
| Metts, J | 1 |
| Ray, A | 1 |
| Bukowinski, A | 1 |
| LeBlanc, Z | 1 |
| Fair, D | 1 |
| Watanbe, M | 1 |
| Alva, E | 1 |
| Todd, K | 1 |
| Daley, J | 1 |
| Hartt, D | 1 |
| Cramer, SL | 1 |
| Szabo, S | 1 |
| Pressey, JG | 1 |
| Ping, L | 1 |
| Gao, Y | 1 |
| He, Y | 1 |
| Bai, B | 1 |
| Huang, C | 1 |
| Shi, L | 1 |
| Wang, X | 2 |
| Huang, H | 1 |
| Lin, LH | 1 |
| Ghasemi, M | 1 |
| Burke, SM | 1 |
| Mavis, CK | 1 |
| Nichols, JR | 1 |
| Torka, P | 1 |
| Mager, DE | 1 |
| Hernandez-Ilizaliturri, FJ | 1 |
| Goey, AKL | 1 |
| Salah, S | 1 |
| Abuhijla, F | 1 |
| Ismail, T | 1 |
| Yaser, S | 1 |
| Sultan, I | 1 |
| Halalsheh, H | 1 |
| Shehadeh, A | 1 |
| Abdelal, S | 1 |
| Almousa, A | 1 |
| Jaber, O | 1 |
| Abu-Hijlih, R | 1 |
| Häberle, B | 1 |
| Maxwell, R | 1 |
| Schweinitz, DV | 1 |
| Schmid, I | 1 |
| De Pasquale, MD | 1 |
| D'Angelo, P | 1 |
| Crocoli, A | 1 |
| Boldrini, R | 1 |
| Conte, M | 1 |
| Bisogno, G | 4 |
| Inserra, A | 2 |
| Biasoni, D | 1 |
| Dall'Igna, P | 2 |
| Siracusa, F | 1 |
| Miele, E | 1 |
| Terenziani, M | 1 |
| Choi, HJ | 2 |
| Lee, YY | 3 |
| Choi, CH | 4 |
| Kim, TJ | 4 |
| Lee, JW | 4 |
| Bae, JH | 1 |
| Bae, DS | 4 |
| Kim, BG | 4 |
| Dangien, A | 1 |
| Ram-Wolff, C | 1 |
| Battistella, M | 1 |
| Roelens, M | 1 |
| Moins-Teisserenc, H | 1 |
| Peffault de Latour, R | 1 |
| Mourah, S | 1 |
| Bouaziz, JD | 1 |
| Lebbé, C | 1 |
| Bagot, M | 1 |
| de Masson, A | 1 |
| Kajita, N | 1 |
| Saito, Y | 1 |
| Makimoto, A | 1 |
| Miyahara, S | 1 |
| Yuza, Y | 1 |
| Nobre, L | 1 |
| Zapotocky, M | 1 |
| Khan, S | 1 |
| Fukuoka, K | 2 |
| Fonseca, A | 1 |
| McKeown, T | 1 |
| Sumerauer, D | 1 |
| Vicha, A | 1 |
| Grajkowska, WA | 1 |
| Trubicka, J | 1 |
| Li, KKW | 1 |
| Ng, HK | 1 |
| Massimi, L | 1 |
| Lee, JY | 1 |
| Kim, SK | 1 |
| Zelcer, S | 1 |
| Vasiljevic, A | 2 |
| Faure-Conter, C | 2 |
| Hauser, P | 1 |
| Lach, B | 1 |
| van Veelen-Vincent, ML | 1 |
| French, PJ | 1 |
| Van Meir, EG | 1 |
| Weiss, WA | 1 |
| Gupta, N | 1 |
| Pollack, IF | 1 |
| Hamilton, RL | 1 |
| Nageswara Rao, AA | 1 |
| Giannini, C | 1 |
| Rubin, JB | 1 |
| Moore, AS | 1 |
| Chambless, LB | 1 |
| Vibhakar, R | 1 |
| Ra, YS | 1 |
| Massimino, M | 1 |
| McLendon, RE | 1 |
| Wheeler, H | 1 |
| Zollo, M | 1 |
| Ferruci, V | 1 |
| Kumabe, T | 1 |
| Faria, CC | 1 |
| Sterba, J | 1 |
| Jung, S | 1 |
| López-Aguilar, E | 1 |
| Mora, J | 1 |
| Carlotti, CG | 1 |
| Olson, JM | 1 |
| Leary, S | 1 |
| Cain, J | 1 |
| Krskova, L | 1 |
| Zamecnik, J | 1 |
| Hawkins, CE | 1 |
| Tabori, U | 1 |
| Huang, A | 1 |
| Bartels, U | 1 |
| Northcott, PA | 1 |
| Taylor, MD | 1 |
| Yip, S | 1 |
| Hansford, JR | 1 |
| Bouffet, E | 3 |
| Ramaswamy, V | 1 |
| Han, J | 1 |
| Yu, Y | 1 |
| Wu, S | 1 |
| Wang, Z | 2 |
| Zhang, W | 1 |
| Zhao, M | 1 |
| Yao, Y | 2 |
| Hu, Y | 1 |
| Wang, W | 2 |
| Liu, X | 1 |
| Yu, W | 1 |
| Cheng, J | 1 |
| Yu, L | 1 |
| Bao, Q | 1 |
| Zhang, G | 1 |
| Yu, X | 3 |
| Song, R | 1 |
| Underwood, CIM | 1 |
| Cardona, DM | 1 |
| Bentley, RC | 1 |
| Shen, G | 1 |
| Feng, X | 1 |
| Jour, G | 1 |
| Al-Rohil, RN | 1 |
| Imai, K | 1 |
| Yamasaki, T | 1 |
| Sakamoto, H | 1 |
| Nakamura, K | 1 |
| Mizowaki, T | 2 |
| Ogawa, O | 1 |
| Aoyama, T | 1 |
| Tang, T | 2 |
| Martin, P | 1 |
| Somasundaram, N | 1 |
| Lim, C | 1 |
| Tao, M | 1 |
| Poon, E | 1 |
| Yunon, MJ | 1 |
| Toh, SQ | 1 |
| Yan, SX | 1 |
| Farid, M | 1 |
| Chan, JY | 1 |
| Lim, ST | 2 |
| Yahiro, K | 1 |
| Matsumoto, Y | 1 |
| Mascarenhas, L | 1 |
| Ogawa, C | 1 |
| Laetsch, TW | 1 |
| Weigel, BJ | 1 |
| Bishop, MW | 1 |
| Krystal, J | 1 |
| Borinstein, SC | 1 |
| Slotkin, EK | 1 |
| Muscal, JA | 1 |
| Hingorani, P | 1 |
| Levy, DE | 1 |
| Mo, G | 1 |
| Shahir, A | 1 |
| Wright, J | 1 |
| DuBois, SG | 2 |
| Hua, Q | 1 |
| Xu, G | 2 |
| Zhao, L | 1 |
| Zhang, T | 1 |
| Massard, C | 2 |
| Flechon, A | 2 |
| Delva, R | 3 |
| Gravis, G | 3 |
| Lotz, JP | 2 |
| Bay, JO | 1 |
| Gross-Goupil, M | 1 |
| Fizazi, K | 4 |
| Mourey, L | 1 |
| Paci, A | 1 |
| Guitton, J | 1 |
| Thomas, F | 1 |
| Lelièvre, B | 1 |
| Ciccolini, J | 1 |
| Moeung, S | 1 |
| Gallois, Y | 1 |
| Olivier, P | 1 |
| Culine, S | 4 |
| Filleron, T | 1 |
| Chatelut, E | 1 |
| Li, ZK | 1 |
| Liu, J | 2 |
| Chen, C | 1 |
| Yang, KY | 1 |
| Deng, YT | 1 |
| Karageorgopoulou, S | 1 |
| Kostakis, ID | 1 |
| Gazouli, M | 1 |
| Markaki, S | 1 |
| Papadimitriou, M | 1 |
| Bournakis, E | 1 |
| Dimopoulos, MA | 3 |
| Papadimitriou, CA | 2 |
| Hu, B | 1 |
| Younes, A | 2 |
| Westin, JR | 1 |
| Turturro, F | 1 |
| Claret, L | 1 |
| Feng, L | 1 |
| Fowler, N | 1 |
| Neelapu, S | 1 |
| Romaguera, J | 1 |
| Hagemeister, FB | 1 |
| Rodriguez, MA | 2 |
| Samaniego, F | 1 |
| Fayad, LE | 1 |
| Copeland, AR | 1 |
| Nastoupil, LJ | 1 |
| Nieto, Y | 2 |
| Fanale, MA | 1 |
| Oki, Y | 1 |
| Ahmed, SK | 1 |
| Randall, RL | 2 |
| Harmsen, WS | 1 |
| Krailo, M | 2 |
| Marcus, KJ | 1 |
| Janeway, KA | 1 |
| Geller, DS | 1 |
| Sorger, JI | 1 |
| Womer, RB | 2 |
| Granowetter, L | 1 |
| Grier, HE | 3 |
| Gorlick, RG | 1 |
| Laack, NNI | 1 |
| De Sanctis, R | 2 |
| Giordano, L | 1 |
| Colombo, C | 1 |
| De Paoli, A | 3 |
| Navarria, P | 1 |
| Sangalli, C | 2 |
| Buonadonna, A | 1 |
| Sanfilippo, R | 1 |
| Bertola, G | 1 |
| Fiore, M | 2 |
| Marrari, A | 1 |
| Navarria, F | 1 |
| Bertuzzi, A | 1 |
| Casali, PG | 3 |
| Basso, S | 1 |
| Santoro, A | 3 |
| Quagliuolo, V | 4 |
| Gronchi, A | 4 |
| Calaminus, G | 4 |
| Frappaz, D | 4 |
| Kortmann, RD | 2 |
| Krefeld, B | 1 |
| Saran, F | 2 |
| Pietsch, T | 2 |
| Garre, ML | 2 |
| Ricardi, U | 2 |
| Mann, JR | 1 |
| Göbel, U | 4 |
| Alapetite, C | 3 |
| Murray, MJ | 1 |
| Nicholson, JC | 2 |
| Tanaka, I | 1 |
| Kawada, K | 1 |
| Morise, M | 1 |
| Hase, T | 1 |
| Hayashi, H | 1 |
| Sokai, A | 1 |
| Fukatsu, A | 1 |
| Kondo, M | 2 |
| Nomura, F | 1 |
| Hasegawa, Y | 1 |
| Issels, RD | 6 |
| Lindner, LH | 3 |
| Verweij, J | 4 |
| Wessalowski, R | 3 |
| Wust, P | 2 |
| Ghadjar, P | 1 |
| Hohenberger, P | 2 |
| Angele, M | 1 |
| Salat, C | 2 |
| Vujaskovic, Z | 2 |
| Daugaard, S | 2 |
| Mella, O | 1 |
| Mansmann, U | 2 |
| Dürr, HR | 2 |
| Knösel, T | 1 |
| Abdel-Rahman, S | 5 |
| Schmidt, M | 1 |
| Hiddemann, W | 5 |
| Jauch, KW | 3 |
| Belka, C | 1 |
| Fagerstedt, KW | 1 |
| Salonen, T | 1 |
| Zhao, F | 1 |
| Kytölä, S | 1 |
| Böhling, T | 2 |
| Andersson, LC | 1 |
| Elsebaie, MAT | 1 |
| Amgad, M | 1 |
| Elkashash, A | 1 |
| Elgebaly, AS | 1 |
| Ashal, GGEL | 1 |
| Shash, E | 1 |
| Elsayed, Z | 1 |
| Albany, C | 1 |
| Paik, ES | 1 |
| Turki, AT | 1 |
| Lamm, W | 1 |
| Liebregts, T | 1 |
| Dührsen, U | 1 |
| McKenzie, HS | 1 |
| Mead, G | 2 |
| Huddart, R | 1 |
| White, JD | 1 |
| Rustin, GJS | 1 |
| Hennig, IM | 1 |
| Cozens, K | 1 |
| Cross, N | 1 |
| Bowers, M | 1 |
| Wheater, MJ | 1 |
| Kurita, D | 1 |
| Mokuno, Y | 1 |
| Matsubara, H | 1 |
| Kaneko, H | 1 |
| Shamoto, M | 1 |
| Satou, A | 1 |
| Iyomasa, S | 1 |
| Charlson, J | 1 |
| Tatenuma, T | 1 |
| Mizuno, N | 1 |
| Jikuya, R | 1 |
| Hashizume, A | 1 |
| Yasui, M | 1 |
| Umemoto, S | 1 |
| Kawai, M | 1 |
| Hiruma, T | 1 |
| Kishida, T | 1 |
| Spunt, SL | 1 |
| Francotte, N | 1 |
| De Salvo, GL | 2 |
| Chi, YY | 1 |
| Zanetti, I | 1 |
| Hayes-Jordan, A | 1 |
| Kao, SC | 1 |
| Orbach, D | 5 |
| Brennan, B | 2 |
| Weiss, AR | 1 |
| van Noesel, MM | 1 |
| Million, L | 1 |
| Alaggio, R | 1 |
| Parham, DM | 1 |
| Kelsey, A | 1 |
| McCarville, MB | 1 |
| Hawkins, DS | 1 |
| Ferrari, A | 3 |
| Pilbeam, K | 1 |
| Eidenschink, B | 1 |
| Sulciner, M | 1 |
| Luquette, M | 1 |
| Neglia, J | 1 |
| Chinnakotla, S | 1 |
| Li, D | 1 |
| Xu, S | 3 |
| Sun, M | 1 |
| Qiao, L | 1 |
| Wang, L | 1 |
| Liu, Y | 1 |
| Natarajan, E | 1 |
| Auerbach, C | 1 |
| Cheron, R | 1 |
| Pashankar, F | 1 |
| Shein, G | 1 |
| Sandhu, G | 1 |
| Potter, A | 1 |
| Loo, C | 1 |
| Jacobson, I | 1 |
| Anazodo, A | 1 |
| Kortmann, R | 1 |
| Worch, J | 1 |
| Patte, C | 3 |
| Dell'Amore, A | 1 |
| Asadi, N | 1 |
| Caroli, G | 1 |
| Dolci, G | 1 |
| Bini, A | 1 |
| Stella, F | 1 |
| Eroglu, C | 1 |
| Kaynar, L | 1 |
| Orhan, O | 1 |
| Keklik, M | 1 |
| Sahin, C | 1 |
| Yildiz, OG | 1 |
| Mentes, S | 1 |
| Kurnaz, F | 1 |
| Aslan, D | 1 |
| Sivgin, S | 1 |
| Soyuer, S | 1 |
| Eser, B | 1 |
| Cetin, M | 1 |
| Unal, A | 1 |
| Choeyprasert, W | 1 |
| Natesirinilkul, R | 1 |
| Charoenkwan, P | 1 |
| Sittipreechacharn, S | 1 |
| Johnson, K | 1 |
| Notrica, DM | 1 |
| Carpentieri, D | 1 |
| Jaroszewski, D | 1 |
| Henry, MM | 1 |
| Jebsen, NL | 2 |
| Engellau, J | 2 |
| Engström, K | 1 |
| Bauer, HC | 1 |
| Monge, OR | 1 |
| Muren, LP | 1 |
| Eide, GE | 1 |
| Trovik, CS | 2 |
| Bruland, OS | 1 |
| Schneider, DT | 2 |
| Mils, O | 1 |
| Friemann, V | 1 |
| Kyrillopoulou, O | 1 |
| Schaper, J | 1 |
| Matuschek, C | 1 |
| Rothe, K | 1 |
| Leuschner, I | 2 |
| Willers, R | 1 |
| Schönberger, S | 2 |
| Choi, MK | 1 |
| Kang, ES | 1 |
| Kim, DW | 1 |
| Ko, YH | 3 |
| Seok, H | 1 |
| Park, JH | 1 |
| Pyo, DH | 1 |
| Hoon Lim, D | 1 |
| Kim, SJ | 4 |
| Kim, WS | 4 |
| Song, T | 1 |
| Kim, MK | 1 |
| Cropet, C | 1 |
| Baranzelli, MC | 2 |
| Martelli, H | 4 |
| Thebaud, E | 2 |
| Rome, A | 1 |
| Fasola, S | 2 |
| Corradini, N | 1 |
| Rocourt, N | 1 |
| Kalfa, N | 1 |
| Ozdemir, O | 1 |
| Ozdemir, P | 1 |
| Veral, A | 1 |
| Uluer, H | 1 |
| Ozhan, MH | 1 |
| Arakawa, Y | 1 |
| Murata, D | 1 |
| Fujimoto, K | 1 |
| Kikuchi, T | 2 |
| Kunieda, T | 1 |
| Takahashi, JC | 1 |
| Takagi, Y | 1 |
| Miyamoto, S | 1 |
| Chang, WJ | 1 |
| Ma, K | 1 |
| Yang, YH | 1 |
| Yang, X | 1 |
| Feng, ZY | 1 |
| Liu, TY | 1 |
| Wen, HW | 1 |
| Liao, QP | 1 |
| Zhang, Y | 1 |
| Zhao, Q | 1 |
| Yuan, Z | 1 |
| Yang, L | 1 |
| Cao, J | 1 |
| Huang, XE | 1 |
| Wu, XY | 1 |
| Lu, YY | 1 |
| Cardellicchio, S | 1 |
| Farina, S | 1 |
| Buccoliero, AM | 1 |
| Agresti, B | 1 |
| Genitori, L | 1 |
| de Martino, M | 1 |
| Fangusaro, J | 1 |
| Sardi, I | 1 |
| Geoffrois, L | 2 |
| Laguerre, B | 1 |
| Eymard, JC | 1 |
| Rolland, F | 1 |
| Houede, N | 1 |
| Laplanche, A | 1 |
| Burcoveanu, D | 1 |
| Kosmas, C | 4 |
| Athanasopoulos, A | 1 |
| Dimitriadis, G | 1 |
| Miltiadous, C | 1 |
| Zilakos, M | 1 |
| Lydakis, D | 1 |
| Magiorkinis, E | 1 |
| Gekas, C | 1 |
| Daladimos, T | 3 |
| Mylonakis, N | 3 |
| Ziras, N | 1 |
| Khawandanah, M | 1 |
| Baxley, A | 1 |
| Pant, S | 1 |
| Mancari, R | 1 |
| Signorelli, M | 2 |
| Gadducci, A | 2 |
| Carinelli, S | 1 |
| De Ponti, E | 1 |
| Sesana, S | 1 |
| Corso, S | 1 |
| Chiappa, V | 1 |
| Colombo, N | 1 |
| Lissoni, AA | 1 |
| Ji, J | 1 |
| Liu, T | 2 |
| Xiang, B | 1 |
| Liu, W | 1 |
| He, C | 1 |
| Chen, X | 1 |
| Li, J | 1 |
| Chang, H | 1 |
| Dai, Y | 1 |
| Dong, T | 1 |
| Darouassi, Y | 1 |
| Attifi, H | 1 |
| Zalagh, M | 1 |
| Rharrassi, I | 1 |
| Benariba, F | 1 |
| Kushnir, I | 1 |
| Kolander, Y | 1 |
| Bickels, J | 2 |
| Gortzak, Y | 1 |
| Flusser, G | 1 |
| Issakov, J | 1 |
| Merimsky, O | 2 |
| Mahmoud, O | 1 |
| Dosch, A | 1 |
| Kwon, D | 1 |
| Pitcher, JD | 1 |
| Conway, S | 1 |
| Benedetto, P | 1 |
| Fernandez, G | 1 |
| Trent, J | 1 |
| Temple, HT | 1 |
| Wolfson, AH | 2 |
| Sagara, K | 1 |
| Takayoshi, K | 1 |
| Kusumoto, E | 1 |
| Uchino, K | 1 |
| Matsumura, T | 2 |
| Kusaba, H | 1 |
| Momosaki, S | 1 |
| Ikejiri, K | 1 |
| Baba, E | 1 |
| Sato, H | 2 |
| Shibuya, K | 1 |
| Koizumi, T | 1 |
| Kato, S | 1 |
| Endo, S | 1 |
| Kurobe, M | 1 |
| Kawai, K | 1 |
| Oikawa, T | 1 |
| Ichioka, D | 1 |
| Kandori, S | 1 |
| Takaoka, E | 1 |
| Kojima, T | 1 |
| Joraku, A | 1 |
| Suetomi, T | 1 |
| Miyazaki, J | 1 |
| Nishiyama, H | 1 |
| Chakiba, C | 1 |
| Lagarde, P | 1 |
| Pissaloux, D | 1 |
| Neuville, A | 1 |
| Brulard, C | 1 |
| Pérot, G | 1 |
| Coindre, JM | 1 |
| Terrier, P | 1 |
| Ranchere-Vince, D | 1 |
| Collini, P | 1 |
| Suurmeijer, AJH | 1 |
| Blay, JY | 2 |
| Terrisse, SA | 1 |
| Piperno-Neumann, S | 1 |
| Averous, G | 1 |
| Bui, B | 2 |
| Italiano, A | 1 |
| Chibon, F | 1 |
| Trippett, TM | 1 |
| Schwartz, CL | 3 |
| Guillerman, RP | 2 |
| Gamis, AS | 1 |
| Gardner, S | 1 |
| Hogan, S | 1 |
| London, WB | 1 |
| Chen, L | 2 |
| de Alarcon, P | 1 |
| Hung, GY | 1 |
| Yen, HJ | 1 |
| Yen, CC | 1 |
| Chen, WM | 1 |
| Chen, PC | 1 |
| Wu, HT | 1 |
| Chiou, HJ | 1 |
| Chang, WH | 1 |
| Hsu, HE | 1 |
| Lee, M | 1 |
| Kim, SW | 1 |
| Nam, EJ | 1 |
| Cho, H | 1 |
| Kim, JH | 1 |
| Kim, YT | 1 |
| Kim, S | 1 |
| Sueoka, K | 1 |
| Umayahara, K | 1 |
| Abe, A | 1 |
| Usami, T | 1 |
| Yamamoto, A | 1 |
| Nomura, H | 1 |
| Matoda, M | 1 |
| Okamoto, S | 1 |
| Omatsu, K | 1 |
| Kondo, E | 1 |
| Kato, K | 1 |
| Takeshima, N | 1 |
| Xu, M | 2 |
| Xiao, X | 1 |
| Nakamura, T | 1 |
| Ueda, T | 1 |
| Oishi, M | 1 |
| Nakanishi, H | 1 |
| Fujihara, A | 1 |
| Naya, Y | 1 |
| Hongo, F | 1 |
| Kamoi, K | 1 |
| Okihara, K | 1 |
| Miki, T | 1 |
| Haas, R | 1 |
| Teske, C | 1 |
| Harms, D | 1 |
| Joly, C | 2 |
| Deblock, M | 1 |
| Desandes, E | 1 |
| Li, YY | 1 |
| Jiang, XM | 1 |
| Dong, YG | 1 |
| Ma, YB | 1 |
| Kojima, M | 1 |
| Nakamura, N | 1 |
| Yabe, M | 1 |
| Tokunaka, M | 1 |
| Kikuti, YY | 1 |
| Murayama, H | 1 |
| Moriuchi, M | 1 |
| Tsuboi, K | 1 |
| Ogawa, Y | 1 |
| Ando, K | 2 |
| Fayad, L | 1 |
| Ansell, SM | 1 |
| Advani, R | 1 |
| Coiffier, B | 1 |
| Stuart, R | 1 |
| Bartlett, NL | 1 |
| Forero-Torres, A | 1 |
| Kuliczkowski, K | 1 |
| Belada, D | 1 |
| Ng, E | 1 |
| Drachman, JG | 1 |
| Li, Y | 2 |
| Yang, Y | 3 |
| Shang, YM | 1 |
| Zheng, H | 1 |
| Huang, YJ | 1 |
| He, AN | 1 |
| Sun, YJ | 1 |
| Shen, Z | 1 |
| Min, DL | 1 |
| Horton, TM | 1 |
| Drachtman, RA | 1 |
| Cole, PD | 1 |
| McCarten, K | 1 |
| Voss, S | 1 |
| Buxton, A | 1 |
| Howard, SC | 1 |
| Hogan, SM | 1 |
| Sheehan, AM | 1 |
| López-Terrada, D | 1 |
| Mrazek, MD | 1 |
| Agrawal, N | 1 |
| Wu, MF | 1 |
| Liu, H | 1 |
| De Alarcon, PA | 1 |
| Trippet, TM | 1 |
| Jelavić, TB | 1 |
| Miše, BP | 1 |
| Strikic, A | 1 |
| Ban, M | 1 |
| Vrdoljak, E | 1 |
| Yanagisawa, T | 1 |
| Watanabe, Y | 1 |
| Suzuki, T | 1 |
| Matsutani, M | 2 |
| Kuji, I | 1 |
| Nishikawa, R | 1 |
| Winter, S | 1 |
| Brisse, H | 2 |
| Mosseri, V | 2 |
| Fan, Z | 1 |
| Patel, S | 2 |
| Lewis, VO | 1 |
| Guadagnolo, BA | 1 |
| Lin, PP | 1 |
| Tu, SM | 1 |
| Bassett, R | 1 |
| Jones, RB | 1 |
| Gulbis, AM | 1 |
| Tannir, N | 1 |
| Kingham, A | 1 |
| Ledesma, C | 1 |
| Margolin, K | 1 |
| Holmberg, L | 1 |
| Champlin, R | 1 |
| Pagliaro, L | 1 |
| Sugitani, A | 1 |
| Asai, K | 1 |
| Kojima, K | 1 |
| Eguchi, Y | 1 |
| Kawaguchi, T | 1 |
| Ohsawa, M | 1 |
| Hirata, K | 1 |
| Palassini, E | 2 |
| Ferrari, S | 14 |
| Verderio, P | 2 |
| Martin Broto, J | 1 |
| Comandone, A | 4 |
| Palmerini, E | 2 |
| Lopez-Pousa, A | 1 |
| Bottelli, S | 1 |
| Libertini, M | 1 |
| Picci, P | 9 |
| Sun, X | 1 |
| Xu, B | 1 |
| Du, J | 1 |
| Dong, L | 2 |
| Gao, X | 1 |
| Li, G | 1 |
| Wei, X | 1 |
| Song, Y | 1 |
| Noujaim, J | 1 |
| Thway, K | 1 |
| Jones, RL | 1 |
| Miah, A | 1 |
| Khabra, K | 1 |
| Langer, R | 1 |
| Kasper, B | 2 |
| Judson, I | 1 |
| Benson, C | 1 |
| Kollàr, A | 1 |
| Wang, B | 1 |
| O'Kane, G | 1 |
| Bracken-Clarke, D | 1 |
| Gardiner, N | 1 |
| Lee, G | 1 |
| Ni Chonghaile, M | 1 |
| Power, D | 1 |
| Daly, PA | 1 |
| McCaffrey, J | 1 |
| Bacon, CL | 1 |
| Conneally, E | 1 |
| Flynn, C | 1 |
| Vandenberghe, E | 1 |
| Kennedy, MJ | 1 |
| Browne, PV | 1 |
| O'Donnell, DM | 1 |
| Hayden, PJ | 1 |
| Li, X | 1 |
| Cui, Y | 1 |
| Sun, Z | 1 |
| Zhang, L | 1 |
| Li, L | 1 |
| Wu, J | 1 |
| Fu, X | 1 |
| Ma, W | 1 |
| Zhang, X | 1 |
| Chang, Y | 1 |
| Nan, F | 1 |
| Li, W | 2 |
| Su, L | 1 |
| Wang, J | 1 |
| Xue, H | 1 |
| Zhang, M | 1 |
| Narayan, V | 1 |
| Gunnarsson, O | 1 |
| Hwang, WT | 1 |
| Squillante, CM | 1 |
| Nathanson, KL | 1 |
| Stadtmauer, EA | 1 |
| Vaughn, DJ | 1 |
| Schorb, E | 1 |
| Finke, J | 1 |
| Ferreri, AJ | 1 |
| Ihorst, G | 1 |
| Mikesch, K | 1 |
| Kasenda, B | 1 |
| Fritsch, K | 1 |
| Fricker, H | 1 |
| Burger, E | 1 |
| Grishina, O | 1 |
| Valk, E | 1 |
| Zucca, E | 1 |
| Illerhaus, G | 1 |
| Aurer, I | 2 |
| Nemet, D | 2 |
| Mitrović, Z | 2 |
| Dujmović, D | 1 |
| Bašić-Kinda, S | 1 |
| Radman, I | 2 |
| Sertić, D | 2 |
| Šantek, F | 2 |
| Kralik, M | 1 |
| Dotlić, S | 1 |
| Mazić, S | 1 |
| Labar, B | 2 |
| Deme, D | 1 |
| Abdulfatah, B | 1 |
| Telekes, A | 1 |
| Fukunaga, A | 1 |
| Hyuga, M | 1 |
| Iwasaki, M | 1 |
| Nakae, Y | 1 |
| Kishimoto, W | 1 |
| Maesako, Y | 1 |
| Arima, N | 1 |
| Lorch, A | 2 |
| Beyer, J | 4 |
| Ogden, S | 1 |
| Harave, S | 1 |
| McPartland, J | 1 |
| Jeys, L | 1 |
| Losty, P | 1 |
| Pizer, B | 1 |
| Zschäbitz, S | 1 |
| Lasitschka, F | 1 |
| Hadaschik, B | 1 |
| Hofheinz, RD | 1 |
| Jentsch-Ullrich, K | 1 |
| Grüner, M | 1 |
| Jäger, D | 1 |
| Grüllich, C | 1 |
| Hancock, SB | 1 |
| Krempl, GA | 1 |
| Canfield, V | 1 |
| Bogardus, C | 1 |
| Kojouri, K | 1 |
| Kaneaster, SK | 1 |
| Medina, JE | 1 |
| Kochbati, L | 1 |
| Ghorbel, I | 1 |
| Chaari, N | 1 |
| Besbes, M | 1 |
| Maalej, M | 1 |
| Neven, J | 1 |
| Hulsbergen-van der Kaa, C | 1 |
| Groot-Loonen, J | 1 |
| de Wilde, PC | 1 |
| Merkx, MA | 1 |
| Rivera, F | 1 |
| Eugenia Vega-Villegas, M | 1 |
| López, C | 1 |
| Francisca López-Brea, M | 1 |
| Rubio, A | 1 |
| Del Valle, A | 1 |
| García-Reija, F | 1 |
| García-Montesinos, B | 1 |
| Rodríguez-Iglesias, J | 1 |
| Hinojo, C | 1 |
| Márquez, R | 1 |
| Angel Alonso-Bermejo, M | 1 |
| Salcedo, M | 1 |
| Blanco, Y | 1 |
| Vega, N | 1 |
| López-Tarruella, S | 1 |
| Sanz-Ortiz, J | 1 |
| Kollmannsberger, C | 2 |
| Bokemeyer, C | 4 |
| Ford, ME | 1 |
| Stevens, R | 1 |
| Rosado-de-Christenson, ML | 1 |
| Hall, NC | 1 |
| Suster, S | 1 |
| Makker, V | 1 |
| Abu-Rustum, NR | 2 |
| Alektiar, KM | 1 |
| Aghajanian, CA | 1 |
| Zhou, Q | 1 |
| Iasonos, A | 1 |
| Hensley, ML | 2 |
| Hoshi, M | 1 |
| Takami, M | 1 |
| Ieguchi, M | 1 |
| Chamberlain, MC | 1 |
| Glantz, MJ | 1 |
| Ataergin, S | 1 |
| Ozet, A | 1 |
| Solchaga, L | 1 |
| Turan, M | 1 |
| Beyzadeoglu, M | 1 |
| Oysul, K | 1 |
| Arpaci, F | 1 |
| Komurcu, S | 1 |
| Surenkok, S | 1 |
| Ozturk, M | 1 |
| Serventi-Seiwerth, R | 1 |
| Stern-Padovan, R | 1 |
| Nola, M | 1 |
| Mrsić, M | 1 |
| Li, XP | 1 |
| Cui, H | 1 |
| Zhou, JW | 1 |
| Wei, LH | 1 |
| Wang, JL | 1 |
| Zhao, Y | 1 |
| Wang, Y | 1 |
| Wang, SJ | 1 |
| Zhu, HL | 1 |
| Zhang, H | 1 |
| Liu, XM | 1 |
| Wang, HQ | 1 |
| Zhang, HL | 1 |
| Qiu, LH | 1 |
| Li, LF | 1 |
| Cui, XZ | 1 |
| Liu, PF | 1 |
| Hao, XS | 1 |
| Di Benedetto, G | 1 |
| Sperti, V | 1 |
| Grassetti, L | 1 |
| Forlini, W | 1 |
| Scalise, A | 1 |
| Bertani, A | 1 |
| Lazar, AD | 1 |
| Shpilberg, O | 1 |
| Shaklai, M | 1 |
| Bairey, O | 1 |
| Aoki, T | 2 |
| Mizutani, T | 1 |
| Nojima, K | 1 |
| Takagi, T | 1 |
| Okumura, R | 1 |
| Yuba, Y | 1 |
| Ueba, T | 1 |
| Takahashi, JA | 1 |
| Miyatake, S | 1 |
| Nozaki, K | 1 |
| Taki, W | 1 |
| Briccoli, A | 4 |
| Rocca, M | 2 |
| Salone, M | 1 |
| Balladelli, A | 1 |
| Ferrari, C | 1 |
| Di Fiore, M | 1 |
| Bacci, G | 13 |
| Kelly, RJ | 1 |
| Barrett, C | 1 |
| Swan, N | 1 |
| McDermott, R | 1 |
| Lashkari, A | 1 |
| Chow, WA | 1 |
| Valdes, F | 1 |
| Leong, L | 1 |
| Phan, V | 1 |
| Twardowski, P | 1 |
| Kapoor, N | 1 |
| Molina, A | 1 |
| Al-Kadhimi, Z | 1 |
| Frankel, P | 1 |
| Somlo, G | 1 |
| Tsakonas, G | 2 |
| Vorgias, G | 2 |
| Karvounis, N | 1 |
| Tsavaris, N | 3 |
| Kalinoglou, N | 2 |
| Malamos, N | 2 |
| Akrivos, T | 1 |
| Karabelis, A | 2 |
| Kang, H | 1 |
| Lee, JH | 1 |
| Schuetze, SM | 1 |
| Kim, K | 1 |
| Kim, BS | 1 |
| Kim, CY | 1 |
| Suh, C | 1 |
| Huh, J | 1 |
| Lee, SW | 1 |
| Kim, JS | 1 |
| Cho, J | 2 |
| Lee, GW | 1 |
| Kang, KM | 1 |
| Eom, HS | 1 |
| Pyo, HR | 1 |
| Ahn, YC | 1 |
| Joly, F | 1 |
| Sevin, E | 1 |
| Lortholary, A | 1 |
| Priou, F | 1 |
| Paitel, JF | 1 |
| Fabbro, M | 1 |
| Henry-Amar, M | 1 |
| Hamond, K | 1 |
| Bourgeois, H | 1 |
| Han, XY | 1 |
| Xiang, Y | 1 |
| Guo, LN | 1 |
| Sheng, K | 1 |
| Wan, XR | 1 |
| Huang, HF | 1 |
| Pan, LY | 1 |
| Xing, PY | 1 |
| Shi, YK | 2 |
| Feng, FY | 2 |
| Qin, Y | 1 |
| Liu, P | 2 |
| Schem, BC | 1 |
| Wendtner, CM | 1 |
| Ploner, F | 1 |
| Baur-Melnyk, A | 1 |
| Liu, YL | 1 |
| Tsai, SH | 1 |
| Chang, FW | 1 |
| Yu, MH | 1 |
| Machak, GN | 1 |
| Polotskiĭ, BE | 1 |
| Meluzova, OM | 1 |
| Chernov, IS | 1 |
| Aliev, MD | 1 |
| Buchbinder, D | 1 |
| Steinberg, G | 1 |
| Linetsky, M | 1 |
| Casillas, J | 1 |
| Lindet, C | 1 |
| Vanhuyse, M | 1 |
| Robin, YM | 1 |
| Penel, N | 1 |
| Raquin, MA | 1 |
| Gaboriaud, G | 1 |
| Carrie, C | 1 |
| Habrand, JL | 3 |
| Thiesse, P | 1 |
| Cuilliere, JC | 1 |
| Bernier, V | 1 |
| Ben-Hassel, M | 1 |
| Indelicato, DJ | 1 |
| Keole, SR | 1 |
| Lagmay, JP | 1 |
| Morris, CG | 1 |
| Gibbs, CP | 1 |
| Scarborough, MT | 1 |
| Islam, S | 1 |
| Marcus, RB | 1 |
| Moskowitz, AJ | 1 |
| Yahalom, J | 1 |
| Kewalramani, T | 1 |
| Maragulia, JC | 1 |
| Vanak, JM | 1 |
| Zelenetz, AD | 2 |
| Moskowitz, CH | 2 |
| Moretti, VM | 1 |
| Crawford, EA | 1 |
| Staddon, AP | 1 |
| Lackman, RD | 1 |
| Ogilvie, CM | 1 |
| Bruland, ØS | 1 |
| Eriksson, M | 1 |
| Turesson, I | 1 |
| Folin, A | 1 |
| Hall, KS | 1 |
| Downs, LS | 2 |
| Chura, JC | 1 |
| Argenta, PA | 2 |
| Judson, PL | 2 |
| Ghebre, R | 1 |
| Geller, MA | 1 |
| Carson, LF | 3 |
| Chu, P | 1 |
| Lu, CH | 1 |
| Sheng, XG | 1 |
| Zhou, CX | 1 |
| Li, DP | 1 |
| DU, XL | 1 |
| Liu, NF | 1 |
| Minobe, S | 1 |
| Todo, Y | 1 |
| Suzuki, Y | 1 |
| Aoyagi, Y | 1 |
| Umazume, T | 1 |
| Okamoto, K | 1 |
| Kato, H | 1 |
| Lee, JA | 1 |
| Kim, DH | 1 |
| Lim, JS | 1 |
| Koh, JS | 1 |
| Yoo, JY | 1 |
| Kim, MS | 1 |
| Kong, CB | 1 |
| Song, WS | 1 |
| Cho, WH | 1 |
| Lee, SY | 1 |
| Jeon, DG | 1 |
| Zheng, M | 1 |
| Huang, L | 1 |
| Liu, JH | 1 |
| Xiong, Y | 1 |
| Li, JD | 1 |
| Huang, X | 1 |
| He, L | 1 |
| Ren, YF | 1 |
| Wang, HY | 1 |
| Yasuda, T | 1 |
| Suzuki, K | 1 |
| Kanamori, M | 1 |
| Hori, T | 1 |
| Huang, D | 1 |
| Bridge, JA | 1 |
| Kimura, T | 1 |
| Hong, S | 1 |
| Shin, SJ | 1 |
| Jung, M | 1 |
| Jeong, J | 1 |
| Lee, YJ | 1 |
| Shin, KH | 1 |
| Roh, JK | 1 |
| Rha, SY | 1 |
| Patrij, K | 1 |
| Reiser, M | 1 |
| Wätzel, L | 1 |
| Pels, H | 1 |
| Kowoll, A | 1 |
| Herrlinger, U | 1 |
| Engert, A | 1 |
| Linnebank, M | 1 |
| Schackert, G | 1 |
| Vogt-Schaden, M | 1 |
| Egerer, G | 3 |
| Lamprecht, M | 1 |
| Batchelor, TT | 1 |
| Schlegel, U | 1 |
| Schmidt-Wolf, IG | 1 |
| Fedyanin, M | 1 |
| Tryakin, A | 1 |
| Kanagavel, D | 1 |
| Bulanov, A | 1 |
| Burova, A | 1 |
| Figurin, K | 1 |
| Fainshtein, I | 1 |
| Sergeev, U | 1 |
| Zakharova, T | 1 |
| Garin, A | 1 |
| Tjulandin, S | 1 |
| Jacot, W | 1 |
| Pujol, JL | 2 |
| Chakra, M | 1 |
| Molinier, O | 1 |
| Bozonnat, MC | 1 |
| Gervais, R | 1 |
| Quantin, X | 1 |
| Politis, P | 1 |
| Panagiotidi, E | 1 |
| Papachrysanthou, T | 1 |
| Moschovis, D | 1 |
| Park, S | 1 |
| Lee, S | 1 |
| Lee, J | 1 |
| Park, SH | 1 |
| Park, JO | 1 |
| Kang, WK | 2 |
| Park, YS | 1 |
| Lim, HY | 2 |
| Brandts, CH | 1 |
| Schulz, C | 1 |
| Willich, N | 1 |
| Steffen, B | 1 |
| Hardes, J | 1 |
| Gosheger, G | 1 |
| Winkelmann, W | 1 |
| Serve, H | 1 |
| Heinecke, A | 1 |
| Berdel, WE | 1 |
| Thomas, M | 2 |
| Xu, Y | 1 |
| Wang, K | 1 |
| Geng, Y | 1 |
| Shao, Y | 1 |
| Yin, Y | 1 |
| Sugito, K | 1 |
| Furuya, T | 1 |
| Kaneda, H | 1 |
| Masuko, T | 1 |
| Ohashi, K | 1 |
| Inoue, M | 1 |
| Ikeda, T | 1 |
| Koshinaga, T | 1 |
| Yagasaki, H | 1 |
| Mugishima, H | 1 |
| Maebayashi, T | 1 |
| Abdel Rahman, H | 1 |
| Moussa, EA | 1 |
| Zekri, WZ | 1 |
| El Debawy, E | 1 |
| Mostafa, NE | 1 |
| Yones, A | 1 |
| Ezzat, S | 1 |
| Rayan, Ael R | 1 |
| Schmitt, T | 1 |
| Lehner, B | 1 |
| Bischof, M | 1 |
| Roeder, F | 1 |
| Dietrich, S | 1 |
| Dimitrakopoulou-Strauss, A | 1 |
| Strauss, LG | 1 |
| Mechtersheimer, G | 1 |
| Wuchter, P | 1 |
| Ho, AD | 1 |
| Malbora, B | 1 |
| Avci, Z | 1 |
| Olgac, A | 1 |
| Gursel, O | 1 |
| Kurekci, E | 1 |
| Ozbek, N | 1 |
| Chen, Y | 1 |
| Wang, C | 1 |
| Shi, Y | 1 |
| Tural, D | 1 |
| Molinas Mandel, N | 1 |
| Dervisoglu, S | 1 |
| Oner Dincbas, F | 1 |
| Koca, S | 1 |
| Colpan Oksuz, D | 1 |
| Kantarci, F | 1 |
| Turna, H | 1 |
| Selcukbiricik, F | 1 |
| Hiz, M | 1 |
| Rashid, S | 1 |
| Lim, L | 1 |
| Powles, T | 1 |
| Vercellino, GF | 1 |
| Piek, JM | 1 |
| Schneider, A | 1 |
| Köhler, C | 1 |
| Mangler, M | 1 |
| Speiser, D | 1 |
| Chiantera, V | 1 |
| Meazza, C | 1 |
| De Leonardis, F | 1 |
| Manzitti, C | 1 |
| De Ioris, MA | 1 |
| Casanova, M | 1 |
| Carli, M | 2 |
| Dede, DS | 1 |
| Aksoy, S | 2 |
| Cengiz, M | 2 |
| Gullu, I | 2 |
| Altundag, K | 2 |
| Kwong, YL | 1 |
| Tse, E | 1 |
| Leung, AY | 1 |
| Chim, CS | 1 |
| Burnside, N | 1 |
| MacGowan, SW | 1 |
| Look Hong, NJ | 1 |
| Hornicek, FJ | 1 |
| Harmon, DC | 1 |
| Choy, E | 1 |
| Chen, YL | 1 |
| Yoon, SS | 1 |
| Nielsen, GP | 1 |
| Szymonifka, J | 1 |
| Yeap, BY | 1 |
| DeLaney, TF | 1 |
| Mullen, JT | 1 |
| Kramar, A | 1 |
| Hartmann, JT | 2 |
| Pico, JL | 1 |
| Rosti, G | 1 |
| Droz, JP | 3 |
| Ferraro, A | 1 |
| Tendero, O | 1 |
| Majò, J | 1 |
| Martin, J | 1 |
| Grignani, G | 1 |
| Pizzamiglio, S | 1 |
| Frustaci, S | 1 |
| Dei Tos, AP | 1 |
| Stacchiotti, S | 1 |
| Birnbaum, T | 1 |
| Bochmann, K | 1 |
| von Baumgarten, L | 1 |
| Straube, A | 1 |
| Zhao, J | 1 |
| Serrone, L | 1 |
| Nardoni, C | 1 |
| Gelibter, A | 1 |
| Felici, A | 1 |
| Cognetti, F | 2 |
| Porcaro, AB | 1 |
| Antoniolli, SZ | 1 |
| Maffei, N | 1 |
| Beltrami, P | 1 |
| Bassetto, MA | 1 |
| Curti, P | 1 |
| Tanaka, N | 1 |
| Matsui, H | 1 |
| Nagai, Y | 1 |
| Suzuka, K | 1 |
| Seki, K | 1 |
| Sekiya, S | 1 |
| Rozan, O | 1 |
| Janot, F | 1 |
| Oberlin, O | 5 |
| Schwaab, G | 1 |
| Quintana, E | 4 |
| Tran Ba Huy, P | 1 |
| Georges, B | 1 |
| Luboinski, B | 1 |
| Crinò, L | 1 |
| Misawa, A | 2 |
| Hosoi, H | 2 |
| Tsuchiya, K | 2 |
| Iehara, T | 2 |
| Sawada, T | 1 |
| Sugimoto, T | 2 |
| Serra, M | 1 |
| Scotlandi, K | 1 |
| Reverter-Branchat, G | 1 |
| Manara, MC | 1 |
| Benini, S | 1 |
| Incaprera, M | 1 |
| Bertoni, F | 8 |
| Mercuri, M | 8 |
| Eilber, FC | 4 |
| Rosen, G | 4 |
| Nelson, SD | 2 |
| Selch, M | 2 |
| Dorey, F | 2 |
| Eckardt, J | 4 |
| Eilber, FR | 4 |
| Stewart, RJ | 1 |
| Rey, A | 4 |
| Bouvet, N | 2 |
| Spicer, RD | 2 |
| Stevens, MC | 3 |
| Haro Estarriol, M | 1 |
| Baldo Padró, X | 1 |
| Rubio Goday, M | 1 |
| Sebastián Quetglas, F | 1 |
| Viñas Villaró, G | 1 |
| Bernadó Turmo, L | 1 |
| Arellano-Rodrigo, E | 1 |
| López-Guillermo, A | 1 |
| Bessell, EM | 1 |
| Nomdedeu, B | 1 |
| Montserrat, E | 1 |
| Graus, F | 1 |
| Schleucher, N | 1 |
| Metzner, B | 1 |
| Rick, O | 3 |
| Schmoll, HJ | 2 |
| Boehlke, I | 1 |
| Kanz, L | 1 |
| Anand, AK | 1 |
| Khanna, A | 1 |
| Sinha, SK | 1 |
| Mukherjee, U | 1 |
| Walia, JS | 1 |
| Singh, AN | 1 |
| Donati, D | 2 |
| Longhi, A | 6 |
| Bacchini, P | 3 |
| Giacomini, S | 1 |
| Forni, C | 8 |
| Manfrini, M | 2 |
| Galletti, S | 1 |
| Fahn, W | 2 |
| Schlemmer, M | 1 |
| Issels, R | 1 |
| Uberfuhr, P | 1 |
| Reichart, B | 1 |
| Darnton, SJ | 2 |
| Archer, VR | 2 |
| Stocken, DD | 2 |
| Mulholland, PJ | 2 |
| Casson, AG | 1 |
| Ferry, DR | 2 |
| Buda, A | 1 |
| Dell'Anna, T | 1 |
| Mangioni, C | 3 |
| Kollender, Y | 1 |
| Inbar, M | 1 |
| Meller, I | 1 |
| Loss, JF | 1 |
| Santos, PP | 1 |
| Leone, LD | 1 |
| Brunetto, AL | 1 |
| Gorchev, G | 1 |
| Kornovski, Ia | 1 |
| Sharif, K | 1 |
| English, M | 1 |
| Ramani, P | 1 |
| Alberti, D | 1 |
| Otte, JB | 1 |
| McKiernan, P | 1 |
| Gosseye, S | 1 |
| Jenney, M | 1 |
| de Ville de Goyet, J | 1 |
| Suzuki, S | 2 |
| Shinohara, N | 2 |
| Harabayashi, T | 2 |
| Seki, H | 2 |
| Murakumo, M | 2 |
| Ishikawa, R | 1 |
| Demura, T | 2 |
| Mitsuhashi, K | 2 |
| Toyota, H | 1 |
| Koyanagi, T | 1 |
| Müller, H | 1 |
| Nakchbandi, V | 1 |
| Shaheen, M | 1 |
| Stender, MJ | 1 |
| McClean, JW | 1 |
| Look, KY | 1 |
| Einhorn, LH | 7 |
| Zylberberg, B | 1 |
| Dormont, D | 1 |
| Madelenat, P | 1 |
| Daraï, E | 1 |
| Donfrancesco, A | 2 |
| Jenkner, A | 1 |
| Castellano, A | 1 |
| Ilari, I | 1 |
| Milano, GM | 1 |
| De Sio, L | 1 |
| Cozza, R | 1 |
| Fidani, P | 1 |
| Deb, G | 1 |
| De Laurentis, C | 1 |
| Dominici, C | 1 |
| Hemmings, C | 1 |
| Fisher, C | 1 |
| Van der Mieren, G | 1 |
| Willems, S | 1 |
| Sciot, R | 1 |
| Dumez, H | 1 |
| Van Oosterom, A | 1 |
| Flameng, W | 1 |
| Herijgers, P | 1 |
| Riedel, E | 2 |
| Maki, RG | 2 |
| Brennan, MF | 2 |
| Singer, S | 2 |
| Altundag, O | 1 |
| Ozyar, E | 1 |
| Yalcin, S | 2 |
| Akyol, F | 1 |
| Krasin, MJ | 3 |
| Rodriguez-Galindo, C | 3 |
| Billups, CA | 3 |
| Davidoff, AM | 2 |
| Neel, MD | 2 |
| Merchant, TE | 2 |
| Kun, LE | 1 |
| Corapcioglu, F | 1 |
| Dillioğlugil, O | 1 |
| Sarper, N | 1 |
| Akansel, G | 1 |
| Calişkan, M | 1 |
| Arisoy, AE | 1 |
| Boente, MP | 1 |
| Rawlins, JM | 1 |
| Batchelor, AG | 1 |
| Liddington, MI | 1 |
| Towns, G | 1 |
| Pai, VR | 1 |
| Mazumdar, AT | 1 |
| Deshmukh, CD | 1 |
| Bakshi, AV | 1 |
| Parikh, DM | 1 |
| Parikh, PM | 1 |
| Mistry, RC | 1 |
| Pathak, KA | 1 |
| D'Cruz, AK | 1 |
| El Weshi, A | 1 |
| Memon, M | 1 |
| Raja, M | 2 |
| Bazarbashi, S | 1 |
| Rahal, M | 1 |
| El Foudeh, M | 1 |
| Pai, C | 1 |
| Allam, A | 1 |
| El Hassan, I | 1 |
| Ezzat, A | 2 |
| Cadron, I | 1 |
| Jakobsen, A | 2 |
| Vergote, I | 1 |
| de Bree, E | 1 |
| Romanos, J | 1 |
| Relakis, K | 1 |
| Tsiftsis, DD | 1 |
| Gomez, F | 1 |
| Théodore, C | 2 |
| Caty, A | 1 |
| Peny, J | 1 |
| Viens, P | 1 |
| Duclos, B | 1 |
| De Revel, T | 1 |
| Curé, H | 1 |
| Gligorov, J | 1 |
| Guillemaut, S | 1 |
| Ségura, C | 1 |
| Provent, S | 1 |
| Biron, P | 2 |
| Sutton, G | 2 |
| Kauderer, J | 1 |
| Lentz, SS | 1 |
| Whitney, CW | 1 |
| Gallion, H | 1 |
| Ellershaw, C | 1 |
| Flamant, F | 3 |
| Marsden, HB | 1 |
| Sanchez de Toledo, J | 2 |
| Spooner, D | 6 |
| Terrier-Lacombe, MJ | 3 |
| van Unnik, A | 2 |
| Musolino, A | 1 |
| Perrone, MA | 1 |
| Michiara, M | 1 |
| Delnevo, D | 1 |
| Franciosi, V | 1 |
| Di Blasio, B | 1 |
| Ceci, G | 1 |
| Camisa, R | 1 |
| Ardizzoni, A | 1 |
| Cocconi, G | 1 |
| Zhou, SY | 1 |
| He, XH | 1 |
| Zhang, P | 1 |
| Dong, M | 1 |
| Huang, DZ | 1 |
| Yang, JL | 1 |
| Zhang, CG | 1 |
| Yang, S | 1 |
| Heymann, D | 1 |
| Ory, B | 1 |
| Blanchard, F | 1 |
| Heymann, MF | 1 |
| Coipeau, P | 1 |
| Charrier, C | 1 |
| Couillaud, S | 1 |
| Thiery, JP | 1 |
| Gouin, F | 1 |
| Redini, F | 1 |
| Razak, AR | 1 |
| Nasser, Q | 1 |
| Morris, P | 1 |
| Alcutt, D | 1 |
| Grogan, L | 1 |
| Jha, S | 1 |
| Chan, KK | 1 |
| Poole, CJ | 1 |
| Rollason, TP | 1 |
| Fuller, CE | 1 |
| Olivier Pascual, N | 1 |
| Calvo, JM | 1 |
| Abelairas Gómez, JM | 1 |
| Piura, B | 1 |
| Rabinovich, A | 1 |
| Domínguez, CJ | 1 |
| Martín-Ferrer, S | 1 |
| Rimbau, J | 1 |
| Nath, SV | 1 |
| Seymour, JF | 1 |
| Kondagunta, GV | 1 |
| Bacik, J | 2 |
| Donadio, A | 1 |
| Bajorin, D | 2 |
| Marion, S | 1 |
| Sheinfeld, J | 2 |
| Bosl, GJ | 4 |
| Motzer, RJ | 4 |
| Jahnke, K | 1 |
| Korfel, A | 1 |
| Komm, J | 1 |
| Bechrakis, NE | 1 |
| Stein, H | 1 |
| Thiel, E | 1 |
| Coupland, SE | 1 |
| Smeland, S | 1 |
| Ruggieri, P | 3 |
| Alvegard, TA | 2 |
| Capanna, R | 2 |
| Bernini, G | 2 |
| Müller, C | 1 |
| Tienghi, A | 5 |
| Wiebe, T | 2 |
| Del Prever, AB | 1 |
| Brosjö, O | 1 |
| Saeter, G | 2 |
| Mardiak, J | 1 |
| Sálek, T | 1 |
| Sycová-Milá, Z | 1 |
| Obertová, J | 1 |
| Hlavatá, Z | 1 |
| Mego, M | 1 |
| Recková, M | 1 |
| Koza, I | 1 |
| Nagao, K | 1 |
| Nagamori, S | 1 |
| Matsuyama, H | 1 |
| Naito, K | 1 |
| Nonomura, K | 1 |
| Abe, M | 1 |
| Tokumaru, S | 1 |
| Tabuchi, K | 1 |
| Kida, Y | 1 |
| Takagi, M | 1 |
| Imamura, J | 1 |
| Markman, M | 1 |
| Tysome, JR | 1 |
| Sandison, A | 1 |
| Clarke, PM | 1 |
| Sasaki, Y | 1 |
| Moritani, M | 1 |
| Wada, T | 1 |
| Mizumura, Y | 1 |
| Yamamoto, K | 1 |
| Tsuchida, A | 1 |
| Corazzelli, G | 1 |
| Russo, F | 1 |
| Capobianco, G | 1 |
| Marcacci, G | 1 |
| Della Cioppa, P | 1 |
| Pinto, A | 1 |
| Hertzberg, MS | 1 |
| Crombie, C | 1 |
| Benson, W | 1 |
| Taper, J | 1 |
| Gottlieb, D | 1 |
| Bradstock, KF | 1 |
| Hagberg, H | 1 |
| Gisselbrecht, C | 1 |
| Lokiec, F | 1 |
| Kortmann, B | 1 |
| Reimer, T | 1 |
| Gerber, B | 1 |
| Klautke, G | 1 |
| Fietkau, R | 1 |
| Bedano, PM | 1 |
| Bonnin, J | 1 |
| Bendell, JC | 1 |
| Lauwers, GY | 1 |
| Willett, C | 1 |
| Clark, JW | 1 |
| Warshaw, AL | 1 |
| Wain, JC | 1 |
| Ryan, DP | 1 |
| Hiraki, A | 1 |
| Murakami, T | 1 |
| Aoe, K | 1 |
| Matsuda, E | 1 |
| Uemori, Y | 1 |
| Ueoka, H | 1 |
| Yock, TI | 1 |
| Fryer, CJ | 1 |
| Donaldson, SS | 2 |
| Miser, JS | 2 |
| Chen, Z | 1 |
| Bernstein, M | 1 |
| Laurie, F | 1 |
| Gebhardt, MC | 2 |
| Tarbell, NJ | 1 |
| Kastritis, E | 1 |
| Bamias, A | 1 |
| Bozas, G | 1 |
| Koutsoukou, V | 1 |
| Voulgaris, Z | 1 |
| Vlahos, G | 1 |
| Rodolakis, A | 1 |
| Gika, D | 2 |
| Papadimitriou, C | 1 |
| Leyvraz, S | 2 |
| Herrmann, R | 1 |
| Guillou, L | 2 |
| Honegger, HP | 1 |
| Christinat, A | 1 |
| Fey, MF | 1 |
| Sessa, C | 1 |
| Wernli, M | 1 |
| Cerny, T | 1 |
| Dietrich, D | 1 |
| Pestalozzi, B | 1 |
| Zhen, ZJ | 1 |
| Sun, XF | 1 |
| Xia, Y | 1 |
| Wang, ZH | 1 |
| Ling, JY | 1 |
| Bo, LJ | 1 |
| Liang, AB | 1 |
| Liu, B | 1 |
| Chen, YH | 1 |
| Wang, F | 1 |
| Jin, XP | 1 |
| Al-Faris, N | 1 |
| Al Harbi, T | 1 |
| Goia, C | 1 |
| Pappo, A | 2 |
| Doyle, J | 1 |
| Gassas, A | 1 |
| Khoury-Collado, F | 1 |
| Bowes, RJ | 1 |
| Jhamb, N | 1 |
| Aghajanian, C | 1 |
| Moleti, ML | 1 |
| Testi, AM | 1 |
| Giona, F | 1 |
| Malandruccolo, L | 1 |
| Pescarmona, E | 1 |
| Martino, P | 1 |
| Paoloni, F | 1 |
| Barberi, W | 1 |
| Palumbo, G | 1 |
| Mandelli, F | 1 |
| Foa, R | 1 |
| Eckardt, JJ | 1 |
| Grobmyer, SR | 1 |
| Forscher, C | 3 |
| Magois, E | 1 |
| Guigay, J | 1 |
| Blancard, PS | 1 |
| Margery, J | 1 |
| Milleron, B | 1 |
| Lher, P | 1 |
| Jounieaux, V | 1 |
| Kako, S | 1 |
| Izutsu, K | 1 |
| Oshima, K | 1 |
| Kanda, Y | 1 |
| Motokura, T | 1 |
| Chiba, S | 1 |
| Kurokawa, M | 1 |
| Brady, MF | 1 |
| Rocereto, T | 1 |
| Mannel, RS | 1 |
| Lee, YC | 1 |
| Futoran, RJ | 1 |
| Cohn, DE | 1 |
| Ioffe, OB | 1 |
| Hamlin, PA | 1 |
| Gabrilove, J | 1 |
| Bertino, JR | 1 |
| Portlock, CS | 1 |
| Straus, DJ | 1 |
| Gencarelli, AN | 1 |
| Nimer, SD | 1 |
| Miyaji, M | 1 |
| Yagyu, S | 1 |
| Koizumi, M | 1 |
| Nishimura, T | 1 |
| Tokiwa, K | 1 |
| Iwai, N | 1 |
| Yanagisawa, A | 1 |
| Bauditz, J | 1 |
| Lochs, H | 1 |
| Ventz, M | 1 |
| Navid, F | 1 |
| Rao, BN | 1 |
| Mandal, S | 1 |
| Varma, K | 1 |
| Mahajan, A | 1 |
| Woo, SY | 1 |
| Kornguth, DG | 1 |
| Hughes, D | 1 |
| Huh, W | 1 |
| Chang, EL | 1 |
| Herzog, CE | 1 |
| Pelloski, CE | 1 |
| Anderson, P | 1 |
| Meyers, PA | 1 |
| Krailo, MD | 4 |
| Healey, JH | 1 |
| Bernstein, ML | 2 |
| Betcher, D | 1 |
| Ferguson, WS | 1 |
| Goorin, AM | 1 |
| Harris, M | 1 |
| Kleinerman, E | 1 |
| Link, MP | 1 |
| Nadel, H | 1 |
| Nieder, M | 1 |
| Siegal, GP | 1 |
| Weiner, MA | 1 |
| Wells, RJ | 1 |
| Park, BB | 1 |
| Im, YH | 1 |
| Hwang, IG | 1 |
| Lee, SC | 1 |
| Ahn, JS | 1 |
| Ahn, MJ | 1 |
| Park, K | 1 |
| Recchia, F | 2 |
| Candeloro, G | 1 |
| Di Staso, M | 1 |
| Necozione, S | 1 |
| Bisegna, R | 1 |
| Bratta, M | 1 |
| Tombolini, V | 1 |
| Rea, S | 2 |
| Thiele, OC | 1 |
| Freier, K | 1 |
| Bacon, C | 1 |
| Hofele, CM | 1 |
| Steinke, B | 2 |
| Heidemann, E | 1 |
| Ostendorf, P | 1 |
| Wilms, K | 1 |
| Waller, HD | 1 |
| Karrer, K | 1 |
| Denck, H | 1 |
| Pridun, N | 1 |
| Zwintz, E | 1 |
| Benner, SE | 2 |
| Lippman, SM | 7 |
| Huber, MH | 2 |
| Hong, WK | 7 |
| Dhote, R | 1 |
| Castagne, C | 1 |
| Zuber, M | 1 |
| Beuzeboc, P | 2 |
| Christoforov, B | 1 |
| Rousseau, P | 1 |
| Voute, PA | 3 |
| Singhal, RM | 1 |
| Jindel, R | 1 |
| Gupta, AK | 1 |
| Akimoto, S | 1 |
| Ohki, T | 1 |
| Akakura, K | 1 |
| Masai, M | 1 |
| Shimazaki, J | 2 |
| Le Cesne, A | 1 |
| Antoine, E | 1 |
| Spielmann, M | 1 |
| Le Chevalier, T | 2 |
| Brain, E | 2 |
| Toussaint, C | 1 |
| Janin, N | 1 |
| Kayitalire, L | 1 |
| Fontaine, F | 1 |
| Genin, J | 1 |
| Klumper, E | 1 |
| Pieters, R | 1 |
| Veerman, AJ | 1 |
| Huismans, DR | 1 |
| Loonen, AH | 1 |
| Hählen, K | 1 |
| Kaspers, GJ | 1 |
| van Wering, ER | 1 |
| Hartmann, R | 1 |
| Henze, G | 1 |
| Wainer, IW | 1 |
| Ducharme, J | 1 |
| Batist, G | 1 |
| Perkins, JB | 1 |
| Fields, KK | 1 |
| Elfenbein, GJ | 1 |
| Hirabayashi, K | 2 |
| Okada, E | 2 |
| Eghbali, H | 1 |
| Catry-Thomas, I | 1 |
| Soubeyran, P | 1 |
| Bonnel, C | 1 |
| Hoerni, B | 1 |
| Faylona, EA | 1 |
| Loehrer, PJ | 3 |
| Ansari, R | 1 |
| Sandler, AB | 1 |
| Gonin, R | 1 |
| Kattan, J | 1 |
| Segal, LS | 1 |
| Palumbo, RC | 1 |
| Robertson, WW | 1 |
| Bajorin, DF | 1 |
| Nichols, CR | 2 |
| Kantoff, PW | 1 |
| Demetri, GD | 1 |
| Sørensen, P | 1 |
| Pfeiffer, P | 1 |
| Bertelsen, K | 1 |
| Fanning, J | 1 |
| Ladd, C | 1 |
| Hilgers, RD | 1 |
| Hayot, M | 1 |
| Rouanet, P | 1 |
| Michel, FB | 1 |
| Stornes, I | 1 |
| Mejlholm, I | 1 |
| Marina, NM | 2 |
| Wilimas, JA | 1 |
| Meyer, WH | 2 |
| Jones, DP | 1 |
| Douglass, EC | 2 |
| Pratt, CB | 2 |
| Kalifa, C | 1 |
| Rodary, C | 2 |
| Raquin, M | 1 |
| Valteau-Couanet, D | 1 |
| Lemerle, J | 1 |
| Reichel, C | 1 |
| Fehske, W | 1 |
| Fischer, HP | 1 |
| Hartlapp, JH | 1 |
| Patel, SR | 1 |
| Burgess, MA | 1 |
| Plager, C | 1 |
| Papadopoulos, NE | 1 |
| Linke, KA | 1 |
| Benjamin, RS | 1 |
| Shema, SJ | 1 |
| Bowman, LC | 1 |
| Rodman, J | 1 |
| Furman, WL | 1 |
| Santana, VM | 1 |
| Hudson, M | 1 |
| Cabanillas, F | 1 |
| Thigpen, JT | 1 |
| Vance, RB | 1 |
| Khansur, T | 1 |
| Sutton, GP | 2 |
| Blessing, JA | 3 |
| Homesley, HD | 1 |
| McGuire, WP | 1 |
| Adcock, L | 1 |
| Lowenbraun, S | 1 |
| Eilber, F | 1 |
| Holmes, C | 1 |
| Fu, YS | 1 |
| Beddoe, AM | 1 |
| Dottino, PR | 1 |
| Cohen, CJ | 1 |
| Devalck, C | 1 |
| Tempels, D | 1 |
| Ferster, A | 1 |
| De Laet, MH | 1 |
| Bujan, W | 1 |
| Heiman, P | 1 |
| Sariban, E | 1 |
| Whitehead, VM | 1 |
| Devine, S | 1 |
| Grier, H | 1 |
| Kung, F | 1 |
| Krischer, J | 1 |
| Dreyer, Z | 1 |
| Bell, B | 1 |
| Land, V | 1 |
| Buchanan, GR | 1 |
| Filtenborg, TA | 1 |
| Hansen, HH | 1 |
| Aage Engelholm, S | 1 |
| Rørth, M | 1 |
| Bosse, D | 1 |
| Starck, M | 1 |
| Schildberg, FW | 1 |
| Wilmanns, W | 1 |
| Martín, M | 1 |
| Diaz-Rubio, E | 1 |
| González Larriba, JL | 1 |
| Casado, A | 1 |
| Sastre, J | 1 |
| López-Vega, JM | 1 |
| Almenarez, J | 1 |
| Dominguez, S | 1 |
| Kung, FH | 2 |
| Vega, RA | 1 |
| Jaffe, N | 1 |
| Strother, D | 1 |
| Schwenn, M | 1 |
| Nitschke, R | 1 |
| Homans, AC | 1 |
| Holbrook, CT | 1 |
| Golembe, B | 1 |
| Azzarelli, A | 2 |
| Casali, P | 1 |
| Fissi, S | 1 |
| Montalto, F | 1 |
| Baker, TR | 1 |
| Piver, MS | 2 |
| Hempling, RE | 2 |
| Fruchart, C | 1 |
| Bastit, D | 1 |
| Boulet, D | 1 |
| Moncondult, M | 1 |
| Piguet, H | 1 |
| Tilly, H | 1 |
| Bhardwaj, A | 1 |
| Badesha, PS | 1 |
| Park, R | 1 |
| DiSaia, PJ | 1 |
| Rosenshein, N | 1 |
| Pohlman, B | 1 |
| Shirinian, M | 1 |
| Dimery, IW | 1 |
| Dunnington, JS | 1 |
| Stein, ME | 1 |
| Ruff, P | 1 |
| Weaving, A | 1 |
| Fried, J | 1 |
| Bezwoda, WR | 1 |
| Dorval, T | 1 |
| Soussain, C | 1 |
| Garcia-Giralt, E | 1 |
| Jouve, M | 1 |
| Livartowski, A | 1 |
| Palangié, T | 1 |
| Scholl, S | 1 |
| Sastre, X | 1 |
| Pouillart, P | 1 |
| Behbakht, K | 1 |
| Massad, LS | 1 |
| Yordan, EL | 1 |
| Lincoln, SH | 1 |
| Eriksson, JA | 1 |
| Winkelman, L | 1 |
| DeGeest, K | 1 |
| Kirschner, C | 1 |
| Wilbanks, GD | 1 |
| DeMars, LR | 1 |
| Moore, D | 1 |
| Burke, TW | 1 |
| Grendys, EC | 1 |
| Balat, O | 1 |
| Kudelka, AP | 1 |
| Edwards, CL | 1 |
| Verschraegen, C | 1 |
| Kavanagh, JJ | 1 |
| Sanson, M | 1 |
| Ameri, A | 1 |
| Monjour, A | 1 |
| Sahmoud, T | 1 |
| Ronchin, P | 1 |
| Poisson, M | 1 |
| Delattre, JY | 1 |
| Broun, ER | 1 |
| Gize, G | 1 |
| Cornetta, K | 1 |
| Hromas, RA | 1 |
| Schacht, B | 1 |
| Oliver, RT | 3 |
| Eltabbakh, GH | 1 |
| Recio, FO | 1 |
| O'Neill, CP | 1 |
| Celik, I | 1 |
| Başçil, N | 1 |
| Güllü, IH | 1 |
| Kars, A | 1 |
| Barişta, I | 1 |
| Tekuzman, G | 1 |
| Hirota, Y | 1 |
| Miyamura, K | 1 |
| Hayata, T | 1 |
| Miyakawa, I | 1 |
| Rosito, P | 2 |
| Barbieri, E | 2 |
| Iantorno, D | 1 |
| Brach Del Prever, A | 3 |
| Sottili, S | 1 |
| Gasbarrini, A | 2 |
| Cesari, M | 4 |
| Campanacci, M | 3 |
| Flentje, M | 1 |
| Weirich, A | 1 |
| Pötter, R | 1 |
| Zimmerman, H | 1 |
| Ludwig, R | 1 |
| Shin, DM | 6 |
| Glisson, BS | 5 |
| Khuri, FR | 5 |
| Ginsberg, L | 3 |
| Lawhorn, K | 2 |
| Hirota, T | 1 |
| Takeuchi, M | 1 |
| Iwata, A | 1 |
| Kitagawa, S | 1 |
| Sato, T | 1 |
| Konno, K | 1 |
| Sawada, K | 1 |
| Kobayashi, S | 1 |
| Hamaguchi, N | 1 |
| Agata, H | 1 |
| Katano, N | 1 |
| Fujimoto, T | 1 |
| Fabbri, N | 2 |
| Sandler, A | 1 |
| Saxman, S | 2 |
| Bandealy, M | 1 |
| Heilman, D | 1 |
| Monaco, F | 1 |
| McClean, J | 1 |
| Arquette, M | 1 |
| Papadimitrakopoulou, V | 1 |
| Lee, JJ | 2 |
| Gillenwater, AM | 1 |
| Ang, KK | 2 |
| Clayman, GL | 1 |
| Callender, DL | 1 |
| Friedlaender, MM | 1 |
| Haviv, YS | 1 |
| Rosenmann, E | 1 |
| Peylan-Ramu, N | 1 |
| Fujita, A | 1 |
| Takabatake, H | 1 |
| Tagaki, S | 2 |
| Sekine, K | 1 |
| Vansteenkiste, JF | 1 |
| De Leyn, PR | 1 |
| Deneffe, GJ | 1 |
| Lievens, YN | 1 |
| Nackaerts, KL | 1 |
| Van Raemdonck, DE | 1 |
| van der Schueren, E | 1 |
| Lerut, TE | 1 |
| Demedts, MG | 1 |
| Cairo, MS | 3 |
| Weinthal, JA | 1 |
| Secola, R | 2 |
| Bergeron, S | 2 |
| van de Ven, C | 2 |
| Blazar, BR | 2 |
| Garrison, L | 1 |
| Reaman, GH | 3 |
| Praquin, MT | 1 |
| Sommelet, D | 1 |
| Theobald, S | 1 |
| Brunat-Mentigny, M | 3 |
| Otten, J | 1 |
| Barrett, A | 1 |
| Muraki, O | 1 |
| Itoh, M | 1 |
| Haga, N | 1 |
| Tsuruya, Y | 1 |
| Honda, K | 1 |
| Yamaguchi, O | 1 |
| Ohto, H | 1 |
| van den Bent, MJ | 1 |
| Schellens, JH | 1 |
| Vecht, CJ | 1 |
| Sillevis Smit, PA | 1 |
| Loosveld, OJ | 1 |
| Ma, J | 1 |
| Tijssen, CC | 1 |
| Jansen, RL | 1 |
| Kros, JM | 1 |
| Lehrich, RW | 1 |
| Moll, S | 1 |
| Luft, FC | 1 |
| Kumar, L | 2 |
| Pokharel, YH | 1 |
| Kumar, S | 1 |
| Singh, R | 1 |
| Rath, GK | 1 |
| Kochupillai, V | 1 |
| Harris, MB | 1 |
| Krischer, JP | 1 |
| Zolezzi, C | 1 |
| Fasano, MC | 1 |
| Lamanna, G | 1 |
| Palumbo, R | 1 |
| Neumaier, C | 1 |
| Cosso, M | 1 |
| Bertero, G | 1 |
| Raffo, P | 1 |
| Spadini, N | 1 |
| Valente, S | 1 |
| Villani, G | 1 |
| Pastorino, M | 1 |
| Toma, S | 1 |
| Czyzewski, EA | 1 |
| Goldman, S | 1 |
| Mundt, AJ | 1 |
| Nachman, J | 1 |
| Rubin, C | 1 |
| Hallahan, DE | 1 |
| La Rocca, RV | 1 |
| Morgan, KW | 1 |
| Paris, K | 1 |
| Baeker, TR | 1 |
| Pichler, R | 1 |
| Hatzl-Griesenhofer, M | 1 |
| Huber, H | 1 |
| Wimmer, G | 1 |
| Wahl, G | 1 |
| Maschek, W | 1 |
| Shamash, J | 2 |
| Ong, J | 1 |
| Edmonds, P | 1 |
| Gallagher, CJ | 3 |
| Ostrowski, MJ | 1 |
| LeVay, J | 1 |
| Williams, M | 1 |
| Victoria, L | 1 |
| McCulloch, TM | 1 |
| Callaghan, EJ | 1 |
| Bauman, NM | 1 |
| Hara, I | 1 |
| Yamada, Y | 1 |
| Miyake, H | 1 |
| Nomi, M | 1 |
| Hara, S | 2 |
| Yamanaka, K | 1 |
| Takechi, Y | 1 |
| Oka, Y | 1 |
| Nakamura, I | 1 |
| Gotoh, A | 1 |
| Gohji, K | 1 |
| Arakawa, S | 1 |
| Kamidono, S | 1 |
| Zanetta, G | 2 |
| Fei, F | 2 |
| Parma, G | 1 |
| Balestrino, M | 1 |
| Lissoni, A | 1 |
| Gabriele, A | 1 |
| Soulié, P | 1 |
| Garrino, C | 1 |
| Bensmaïne, MA | 1 |
| Bekradda, M | 1 |
| Di Palma, M | 1 |
| Goupil, A | 1 |
| Misset, JL | 1 |
| Cvitkovic, E | 1 |
| Campisi, C | 1 |
| Fabi, A | 1 |
| Papaldo, P | 1 |
| Tomao, S | 1 |
| Massidda, B | 1 |
| Zappala, A | 1 |
| Ionta, MT | 1 |
| Rimondini, S | 2 |
| Shankar, AG | 1 |
| Pinkerton, CR | 2 |
| Atra, A | 1 |
| Ashley, S | 1 |
| Lewis, I | 1 |
| Cannon, S | 1 |
| Grimer, R | 1 |
| Cotterill, SJ | 1 |
| Craft, AW | 1 |
| King, K | 1 |
| Chua, DT | 1 |
| Kwong, DL | 1 |
| Sham, JS | 1 |
| Au, GK | 1 |
| Choy, D | 1 |
| Elomaa, I | 1 |
| Blomqvist, CP | 1 |
| Akerman, M | 1 |
| Stenwig, E | 1 |
| Björk, O | 1 |
| Roganovich, J | 1 |
| Sotti, G | 1 |
| Ninfo, V | 1 |
| di Montezemolo, LC | 1 |
| Mascarin, M | 1 |
| Mazumdar, M | 1 |
| Bains, M | 1 |
| Mariani, T | 1 |
| de Bono, JS | 1 |
| Paul, J | 2 |
| Simpson, A | 1 |
| Anthoney, A | 1 |
| Kirk, D | 1 |
| Underwood, M | 1 |
| Graham, J | 1 |
| Kaye, SB | 1 |
| Takasu, S | 1 |
| Wakabayashi, T | 1 |
| Kajita, Y | 1 |
| Hatano, N | 1 |
| Hatano, H | 1 |
| Usui, T | 1 |
| Kinoshita, T | 1 |
| Yoshida, J | 1 |
| Lejeune, FJ | 1 |
| Pujol, N | 1 |
| Liénard, D | 1 |
| Mosimann, F | 1 |
| Raffoul, W | 1 |
| Genton, A | 1 |
| Landry, M | 1 |
| Chassot, PG | 1 |
| Chiolero, R | 1 |
| Bischof-Delaloye, A | 1 |
| Mirimanoff, RO | 1 |
| Bejkos, D | 1 |
| Leyvraz, PF | 1 |
| Iacconi, P | 1 |
| Cosio, S | 1 |
| Fanucchi, A | 1 |
| Cristofani, R | 1 |
| Riccardo Genazzani, A | 1 |
| Casadei, R | 1 |
| Versari, M | 1 |
| Takita, H | 1 |
| Pitoniak, RF | 1 |
| O'Doherty, CA | 1 |
| Kelsey, S | 1 |
| Gupta, RK | 1 |
| Newland, AC | 1 |
| Lister, TA | 1 |
| Veronesi, G | 1 |
| Spaggiari, L | 1 |
| Mazzarol, G | 1 |
| De Pas, M | 1 |
| Leo, F | 1 |
| Solli, P | 1 |
| Pastorino, U | 1 |
| Ruiz Hernández, G | 1 |
| Pallardó-Calatayud, J | 1 |
| Ferrer Albiach, C | 1 |
| Balaguer-Martínez, JV | 1 |
| Romero-de-Avila, C | 1 |
| Castillo-Pallarés, FJ | 1 |
| Bracho, F | 1 |
| Shen, V | 1 |
| Davenport, V | 2 |
| Liu-Mares, W | 1 |
| Panoskaltsis-Mortari, A | 1 |
| Ames, MM | 1 |
| Reid, JM | 1 |
| Fiorentini, G | 1 |
| De Giorgi, U | 1 |
| Papadimitrakopoulou, VM | 1 |
| Clayman, G | 1 |
| Feyerabend, T | 1 |
| Wiedemann, GJ | 1 |
| Jäger, B | 1 |
| Vesely, H | 1 |
| Mahlmann, B | 1 |
| Richter, E | 1 |
| Thurnher, D | 1 |
| Kornfehl, J | 1 |
| Burian, M | 1 |
| Gedlicka, C | 1 |
| Selzer, E | 1 |
| Quint, C | 1 |
| Neuchrist, C | 1 |
| Kornek, GV | 1 |
| Panopoulos, C | 1 |
| Vadiaka, M | 1 |
| Stavroyianni, N | 1 |
| Kourelis, T | 1 |
| Antonopoulos, M | 1 |
| Kalofonos, HP | 1 |
| Siegert, W | 2 |
| Gortzak, E | 1 |
| Buesa, J | 1 |
| Bramwell, VH | 1 |
| van Coevorden, F | 1 |
| van Geel, AN | 1 |
| Oosterhuis, JW | 1 |
| van Glabbeke, M | 1 |
| Kirkpatrick, A | 1 |
| Wendtner, C | 2 |
| Falk, MH | 2 |
| Kurze, V | 1 |
| Sauer, H | 2 |
| Aydemir, U | 1 |
| Baumert, J | 1 |
| Krych, M | 1 |
| Santl, M | 1 |
| Lalli, A | 1 |
| Lombardo, M | 1 |
| De Filippis, S | 1 |
| Saggio, G | 1 |
| Fabbri, F | 1 |
| Rosselli, M | 1 |
| Capomolla, E | 1 |
| Delahunt, B | 1 |
| Lewis, ME | 1 |
| Pringle, KC | 1 |
| Wiltshire, EJ | 1 |
| Crooke, MJ | 1 |
| Köstler, WJ | 1 |
| Brodowicz, T | 1 |
| Attems, Y | 1 |
| Hejna, M | 1 |
| Tomek, S | 1 |
| Amann, G | 1 |
| Fiebiger, WC | 1 |
| Wiltschke, CH | 1 |
| Krainer, M | 1 |
| Zielinski, CC | 1 |
| De Raeve, H | 1 |
| Jeuris, W | 1 |
| Wyndaele, JJ | 1 |
| Van Marck, E | 1 |
| Bertè, R | 1 |
| Vallisa, D | 1 |
| Civardi, G | 1 |
| Moroni, CF | 1 |
| Lazzaro, A | 1 |
| Cavanna, L | 1 |
| Timmermann, B | 1 |
| Kühl, J | 2 |
| Meisner, C | 1 |
| Dieckmann, K | 1 |
| Bamberg, M | 1 |
| Raney, RB | 1 |
| Anderson, JR | 1 |
| Barr, FG | 1 |
| Pappo, AS | 1 |
| Qualman, SJ | 1 |
| Wiener, ES | 1 |
| Maurer, HM | 1 |
| Crist, WM | 1 |
| MacRae, R | 1 |
| Grimard, L | 1 |
| Hsu, E | 1 |
| Nizalik, E | 1 |
| Halton, JM | 1 |
| Abu-Ghosh, AM | 1 |
| Goldman, SC | 1 |
| Slack, RS | 1 |
| Morris, E | 1 |
| Laver, JH | 1 |
| Sarris, K | 1 |
| Aravantinos, G | 1 |
| Kalofonos, C | 1 |
| Gourgoulis, GM | 1 |
| Efstathiou, E | 1 |
| Skarlos, D | 1 |
| Bafaloukos, D | 1 |
| Teufel, G | 1 |
| Pfleiderer, A | 1 |
| Tay, SK | 1 |
| Lai, FM | 1 |
| Soh, LT | 1 |
| Ho, TH | 1 |
| Ang, PT | 1 |
| Au, E | 1 |
| Relf, M | 1 |
| Boal, DK | 1 |
| Kudo, R | 1 |
| Sagae, S | 1 |
| Nakazuma, Y | 1 |
| Akamatsu, Y | 1 |
| Sezaki, H | 1 |
| Ohta, M | 1 |
| Nakanishi, Y | 1 |
| Ramm, K | 1 |
| Vergote, IB | 1 |
| Kaern, J | 1 |
| Tropé, CG | 1 |
| Coene, IJ | 1 |
| Schouwenburg, PF | 1 |
| Marion, J | 1 |
| Burgers, V | 1 |
| Hilgers, FJ | 1 |
| Wood, DP | 1 |
| Herr, HW | 1 |
| Reuter, V | 1 |
| Sogani, PC | 1 |
| Morse, MJ | 1 |
| Buxton, EJ | 5 |
| Zülfikar, B | 1 |
| Gedikoğlu, G | 1 |
| Van Gool, S | 1 |
| Brock, P | 1 |
| Wijndaele, G | 1 |
| Van de Casseye, W | 1 |
| Kruger, M | 1 |
| Proesmans, W | 1 |
| Casteels-Van Daele, M | 1 |
| Prendiville, J | 1 |
| Radford, J | 1 |
| Thatcher, N | 1 |
| Steward, W | 1 |
| Ranson, M | 1 |
| Burt, P | 1 |
| Stout, R | 1 |
| Cantwell, BM | 1 |
| Hennessy, C | 1 |
| Millward, MJ | 1 |
| Lennard, TW | 1 |
| Saunders, N | 1 |
| Blackledge, GR | 1 |
| Kelly, K | 1 |
| Redman, CW | 2 |
| Monaghan, J | 2 |
| Paterson, ME | 1 |
| Luesley, DM | 2 |
| Bhargava, VL | 1 |
| Lewis, CR | 1 |
| Fossà, SD | 1 |
| ten Bokkel Huinink, W | 1 |
| Harding, MJ | 1 |
| Mill, L | 1 |
| Jones, WG | 1 |
| Rodenburg, CJ | 1 |
| Cantwell, B | 1 |
| Manetta, A | 1 |
| Hannigan, EV | 1 |
| Dinh, TV | 1 |
| Doherty, MG | 1 |
| Kredentser, DC | 1 |
| Ishida, S | 1 |
| Akiba, Y | 1 |
| Ohosaki, Y | 1 |
| Onodera, S | 1 |
| Fujita, Y | 1 |
| Shimizu, T | 1 |
| Sakai, E | 1 |
| Ikushima, Y | 1 |
| Saotome, K | 1 |
| Elliott, TE | 1 |
| Buckner, JC | 1 |
| Cascino, TL | 1 |
| Levitt, R | 1 |
| O'Fallon, JR | 1 |
| Scheithauer, BW | 1 |
| Buesa, JM | 1 |
| Fernández, R | 1 |
| Esteban, E | 1 |
| Estrada, E | 1 |
| Barón, FJ | 1 |
| Palacio, I | 1 |
| Gracia, M | 1 |
| Lacave, AJ | 1 |
| Chastagner, P | 1 |
| Sommelet-Olive, D | 1 |
| Fornasiero, A | 2 |
| Daniele, O | 1 |
| Ghiotto, C | 2 |
| Piazza, M | 1 |
| Fiore-Donati, L | 1 |
| Calabró, F | 1 |
| Rea, F | 1 |
| Fiorentino, MV | 1 |
| Willemse, PH | 1 |
| vd Burg, ME | 1 |
| vd Gaast, A | 1 |
| Neijt, JP | 1 |
| ten Bokkel Huinink, WW | 1 |
| Aalders, JG | 1 |
| de Vries, EG | 1 |
| Halligan, AW | 1 |
| McGuinness, EP | 1 |
| Paccagnella, A | 1 |
| Favaretto, A | 1 |
| Brandes, A | 1 |
| Volpi, A | 1 |
| Pappagallo, G | 1 |
| Festi, G | 1 |
| Cipriani, A | 1 |
| Vinante, O | 1 |
| Freund, M | 1 |
| De Boben, M | 1 |
| Diedrich, H | 1 |
| Ganser, A | 1 |
| Heil, G | 1 |
| Heyll, A | 1 |
| Henke, M | 1 |
| Knauf, U | 1 |
| Koch, P | 1 |
| Zeymer, U | 1 |
| Neuhaus, KL | 1 |
| Kohler, R | 1 |
| Blondet, R | 1 |
| Bérard, J | 1 |
| Chauvot, P | 1 |
| Carret, JP | 1 |
| Jonas, P | 1 |
| Patricot, LM | 2 |
| Coleman, RE | 2 |
| Clarke, JM | 1 |
| Slevin, ML | 1 |
| Sweetenham, J | 1 |
| Williams, CJ | 1 |
| Blake, P | 1 |
| Calman, F | 1 |
| Wiltshaw, E | 2 |
| Harper, PG | 2 |
| Fuse, H | 1 |
| Zama, S | 1 |
| Kreuser, ED | 1 |
| Jaeger, N | 1 |
| Altwein, JE | 1 |
| Egghart, G | 1 |
| Hartlapp, J | 1 |
| Gaus, W | 1 |
| Schreml, W | 1 |
| Kazama, T | 1 |
| Katayama, T | 1 |
| Umeda, K | 1 |
| Akiya, T | 1 |
| Nakada, T | 1 |
| Krüger, HU | 1 |
| Kraft, H | 1 |
| Heim, ME | 1 |
| Günther, E | 1 |
| Arnold, H | 1 |
| Busch, FW | 1 |
| Meanwell, CA | 4 |
| Mould, JJ | 4 |
| Latief, T | 2 |
| Chetiyawardana, AD | 2 |
| Tobias, JS | 1 |
| Sokal, M | 1 |
| Alcock, C | 2 |
| Hilton, C | 2 |
| Chetiyawardana, A | 1 |
| Paterson, M | 2 |
| Blackledge, G | 2 |
| Tobias, J | 1 |
| Nishida, T | 1 |
| Nagasue, N | 1 |
| Arimatsu, T | 1 |
| Nagano, H | 1 |
| Izumi, S | 1 |
| Okura, N | 1 |
| Yakushiji, M | 1 |
| Clemm, C | 1 |
| Hartenstein, R | 1 |
| Nourissat, C | 1 |
| Tachon, G | 1 |
| Manoukian, A | 1 |
| Schwartzman, E | 1 |
| Scopinaro, M | 1 |
| Angueyra, N | 1 |
| Jürgens, H | 1 |
| Exner, U | 1 |
| Ritter, J | 1 |
| Treuner, J | 1 |
| Weinel, P | 1 |
| Winkler, K | 1 |
| Williams, SD | 1 |
| Tournade, MF | 1 |
| Watkin, SW | 1 |
| Errington, RD | 1 |
| Green, JA | 1 |
| Warenius, HM | 1 |
| Meier, W | 1 |
| Eiermann, W | 1 |
| Stieber, P | 1 |
| Fateh-Moghadam, A | 1 |
| Hepp, H | 1 |
| Pritchard, J | 1 |
| Sangster, G | 1 |
| Patton, WN | 1 |
| Harris, RI | 1 |
| Grieve, RJ | 1 |
| Leyland, MJ | 1 |
| Höfeler, H | 1 |
| Höffken, K | 1 |
| Niederle, N | 1 |
| Schoetensack, B | 1 |
| Wandl, U | 1 |
| Kath, R | 1 |
| Müller, M | 1 |
| Schmidt, CG | 1 |
| Lawton, FG | 1 |
| Stuart, NS | 1 |
| Kavanagh, J | 1 |
| Latief, TN | 1 |
| Kinsella, TJ | 1 |
| Triche, TJ | 1 |
| Tsokos, M | 1 |
| Jarosinski, P | 1 |
| Forquer, R | 1 |
| Wesley, R | 1 |
| Magrath, I | 2 |
| Sandlund, J | 1 |
| Raynor, A | 1 |
| Rosenberg, S | 1 |
| Arasi, V | 1 |
| Miser, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation[NCT02686346] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Dose Intensification Phase II Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis. TICE Protocol : Paclitaxel and Ifosfamide Followed by Carboplatine and Etoposide Intensification With Individual Carboplatine Dose Adjustment.[NCT00864318] | Phase 2 | 101 participants (Actual) | Interventional | 2009-03-13 | Completed | ||
| Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults[NCT00003052] | Phase 3 | 340 participants (Anticipated) | Interventional | 1997-07-31 | Completed | ||
| Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age[NCT00346164] | Phase 3 | 588 participants (Actual) | Interventional | 2007-02-05 | Completed | ||
| A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicted Favorable Prognosis[NCT00127049] | Phase 2 | 37 participants | Interventional | 2004-12-31 | Recruiting | ||
| Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy.[NCT03500133] | Phase 4 | 500 participants (Anticipated) | Interventional | 2017-10-06 | Recruiting | ||
| A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy With and Without SGN-40 (Anti-CD40 Humanized Monoclonal Antibody) for Second-line Treatment of Patients With Diffuse Large B-Cell Lymphoma (DLBCL)[NCT00529503] | Phase 2 | 151 participants (Actual) | Interventional | 2007-09-30 | Terminated | ||
| A Phase II Study of Bortezomib (Velcade, PS-341) in Combination With Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults With Refractory/Recurrent Hodgkin Disease[NCT00381940] | Phase 2 | 26 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Multicenter Study on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy With Cisplatin and Docetaxel Combined With Radiotherapy for Local Advanced Cervical Cancer[NCT02703961] | Phase 3 | 598 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | ||
| High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors[NCT00936936] | Phase 2 | 64 participants (Actual) | Interventional | 2009-06-02 | Active, not recruiting | ||
| Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy[NCT01710176] | Phase 3 | 550 participants (Actual) | Interventional | 2011-06-01 | Active, not recruiting | ||
| A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone)[NCT01501149] | Phase 4 | 80 participants (Anticipated) | Interventional | 2011-01-31 | Recruiting | ||
| High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841] | Phase 3 | 250 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)[NCT02993705] | Phase 2 | 45 participants (Actual) | Interventional | 2017-02-22 | Completed | ||
| ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING)[NCT03840772] | Phase 2 | 16 participants (Anticipated) | Interventional | 2019-07-17 | Recruiting | ||
| A Phase II Study Evaluating Neo-/Adjuvant EIA Chemotherapy, Surgical Resection and Radiotherapy in High-risk Soft Tissue Sarcoma[NCT01382030] | Phase 2 | 50 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Efficacy and Safety of Brentuximab Vedotin in Combination With Tislelizumab for the Treatment of CD30-positive Relapsed/Refractory NK/T-cell Lymphoma[NCT05316246] | Phase 2 | 40 participants (Anticipated) | Interventional | 2022-06-01 | Not yet recruiting | ||
| Multicenter Observational Study on the Treatment of Patients With Localized Osteosarcoma[NCT04890067] | 120 participants (Anticipated) | Observational | 2021-07-30 | Recruiting | |||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| The Use of Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Treatment of High-grade Extremity Soft Tissue and Non-metastatic Sarcomas[NCT02812654] | Phase 2 | 70 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| Sequential High-Dose Chemotherapy Combining Two Mobilization and Cyto-Reductive Treatments Followed by Three High-Dose Chemotherapy Regimens Supported by Autologous Stem Cell Transplantation[NCT00231582] | Phase 2 | 50 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus[NCT00002546] | Phase 3 | 216 participants (Anticipated) | Interventional | 1993-12-31 | Completed | ||
| MISTOSUS: Iscador® P (Mistletoe) Immunotherapy To Improve Event Free Survival In Patients With Relapsed Osteosarcoma After Resection Of Pulmonary Metastases[NCT05726383] | Phase 2 | 32 participants (Anticipated) | Interventional | 2023-12-15 | Not yet recruiting | ||
| Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma[NCT00978471] | Phase 2 | 44 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Endometrial Stromal Tumors: an Observational Study[NCT02829437] | 100 participants (Anticipated) | Observational | 2016-10-31 | Recruiting | |||
| A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy[NCT02711007] | Phase 2/Phase 3 | 37 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Late Effects of Treatment in Survivors of Pediatric Sarcomas[NCT00006515] | 39 participants (Actual) | Observational | 2000-11-16 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Tumor response by imaging. Complete Response (CR): Complete disappearance of the tumor. Partial Response (PR): At least 64% decrease in volume compared to the measurement obtained at study enrollment. Overall Response (OR)=CR+PR. (NCT00346164)
Timeframe: 13 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| Arm D | 33.1 |
Probability of no relapse, secondary malignancy or death after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years
| Intervention | Probability (Number) |
|---|---|
| Non-metastatic | 0.7758 |
| Metastatic | 0.1960 |
Probability of no relapse, secondary malignancy or death after 5 years since enrollment (NCT00346164)
Timeframe: 5 years
| Intervention | Probability (Number) |
|---|---|
| Histologic Grade 1 | 0.9636 |
| Histologic Grade 2 | 0.8505 |
| Histologic Grade 3 | 0.6136 |
Percent of patients who had distant metastasis. (NCT00346164)
Timeframe: Up to 10 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Non-metastatic | 10.59 |
| Metastatic | 60.87 |
| Histologic Grade 1 | 0.00 |
| Histologic Grade 2 | 5.06 |
| Histologic Grade 3 | 23.38 |
Probability of survival after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years
| Intervention | Probability (Number) |
|---|---|
| Non-metastatic | 0.8752 |
| Metastatic | 0.3153 |
Probability of survival after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years
| Intervention | Probability (Number) |
|---|---|
| Less Than Total Resection | 0.5975 |
| Negative Margins | 0.9353 |
| Positive Margins | 0.7764 |
Percent tumor necrosis by pathology review. (NCT00346164)
Timeframe: 13 weeks
| Intervention | percentage of tumor necrosis (Mean) |
|---|---|
| Arm D | 59.4 |
Probability of no relapse, secondary malignancy or death after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years
| Intervention | Probability of EFS at 5 years (Number) |
|---|---|
| Arm A: No Adjuvant Treatment | 0.8984 |
| Arm B: Low Risk; Adjuvant Radiotherapy | 0.7647 |
| Arm C: Intermediate & High Risk; Adjuvant Chemoradiotherapy | 0.6079 |
| Arm D: Intermediate & High Risk; Neoadjuvant Chemoradiotherapy | 0.4873 |
Percentage of Arm D patients experiencing grade 4+ adverse events. (NCT00346164)
Timeframe: 13 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Arm D | 3.06 |
POG and FNCLCC grades were determined by pathologists based on published standards. A higher grade is associated with a more severe disease. (NCT00346164)
Timeframe: At diagnosis
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Histologic grade 1 by POG | Histologic grade 2 by POG | Histologic grade 3 by POG | |
| Histologic Grade 1 by FNCLCC | 46 | 24 | 9 |
| Histologic Grade 2 by FNCLCC | 8 | 69 | 145 |
| Histologic Grade 3 by FNCLCC | 1 | 0 | 240 |
Histologic grades were determined by the central pathology reviewers and institutional pathologists based on published standards. A higher grade is associated with a more severe disease. (NCT00346164)
Timeframe: At Diagnosis
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Histologic grade 1 by central pathology reviewers | Histologic grade 2 by central pathology reviewers | Histologic grade 3 by central pathology reviewers | |
| Histologic Grade 1 by Enrolling Institution | 38 | 4 | 3 |
| Histologic Grade 2 by Enrolling Institution | 5 | 56 | 10 |
| Histologic Grade 3 by Enrolling Institution | 1 | 9 | 268 |
Grade 3 and 4 non-hematologic toxicity during protocol therapy. The number of patients that experience CTC Version 4 grade 3 or higher non-hematologic at any time during protocol therapy (NCT00381940)
Timeframe: 4 weeks following completion of therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Ifosfamide, Vinorelbine, Bortezomib) | 9 |
Success is defined as the ability to harvest 2x10^6 CD34+ cells/kg within 5 collection days. (NCT00381940)
Timeframe: After 2 cycles
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Ifosfamide, Vinorelbine, Bortezomib) | 19 |
CR is defined as at least 80% reduction in the sum of the products of the perpendicular diameters of each of the nodal masses or return to normal size, along with negative nuclear medicine imaging. (NCT00381940)
Timeframe: After 2 cycles of treatment
| Intervention | participants (Number) | |
|---|---|---|
| With CR | Without CR | |
| Treatment (Ifosfamide, Vinorelbine, Bortezomib) | 2 | 21 |
Induction success is defined as achieving CR or PR without a targeted primary toxicity. Primary toxicity includes toxic death (which is any death predominantly attributable to treatment-related toxicities or complications, occurring during or within one month of the completion of therapy), Non-hematologic grades 3 or 4 toxicities attributable to drug (with the specific exclusion of 1) Grade 3 or 4 nausea or vomiting, 2) grade 3 transaminases (AST/ALT) elevations which return to < grade 1 prior to the time of the next treatment course, 3) grade 3 or 4 fever or infection, and 4) Grade 3 mucositis.) and Hematologic toxicity (Delay of >2 weeks in the start of re-induction cycle 2 or in hematologic recovery after cycle 2 secondary to severe myelosuppression, infection, or sepsis.) (NCT00381940)
Timeframe: After 2 cycles and 4 cycles
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Induction Success Rate (After 2 cycles) | Induction Success Rate (After 4 cycles) | |
| Treatment (Ifosfamide, Vinorelbine, Bortezomib) | 19 | 12 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR (NCT00381940)
Timeframe: After 2 cycles and 4 cycles
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Overall Response Rate (After 2 cycles) | Overall Response Rate (After 4 cycles) | |
| Treatment (Ifosfamide, Vinorelbine, Bortezomib) | 19 | 12 |
39 reviews available for ifosfamide and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Lym | 2022 |
Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem | 2021 |
Current medical management of patients with poor-risk metastatic germ-cell tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Humans; Ifosfamide; | 2018 |
Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2018 |
[Multimodal treatment of sarcomas: standards and new aspects in pharmacological and radio-oncological treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; H | 2019 |
Laryngeal Synovial Sarcoma: A Systematic Review of the Last 40 Years of Reported Cases.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Diagnosis, Differential; Female; Humans; Ifos | 2021 |
Recurrent primary cardiac osteosarcoma: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Fatal Outcome; Heart | 2014 |
[CNS primitive neuroectodermal tumor suspected as a secondary recurrence after radiation therapy for medulloblastoma:a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cisplatin | 2014 |
The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Deoxycytidine; Doc | 2014 |
[Primary breast diffuse large B-cell lymphoma-report of 21 cases from China with literatures review].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2015 |
High-dose chemotherapy as salvage treatment in germ-cell cancer: when, in whom and how.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Dose-Response Relati | 2017 |
Salvage chemotherapy after failure of first-line chemotherapy in patients with metastatic testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dose-Response R | 2008 |
[Clinical characteristics and treatment of desmoplastic small round cell tumor].
Topics: Abdominal Neoplasms; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2010 |
Extraskeletal Ewing's sarcoma of the thoracic epidural space: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epidural Neopl | 2011 |
Treatment of relapsed/refractory germ cell tumours: an equipoise between conventional and high dose therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Ifosfamide; Male; Neop | 2012 |
Malignant primary cardiac tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardiac Surgical Procedures; | 2012 |
Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin | 2002 |
Role of ifosfamide in cervical cancer: an overview.
Topics: Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Humans; Ifosfamide; Neoadjuvant T | 2003 |
Palliative treatment for advanced or metastatic osteosarcoma.
Topics: Amputation, Surgical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic A | 2004 |
Emerging treatments for soft tissue sarcoma of adults.
Topics: Adult; Antineoplastic Agents; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Ther | 2004 |
Pregnancy following recurrent angiosarcoma of the ovary--a case report and review of literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Femal | 2005 |
[Orbital rhabdomyosarcoma: difficulties with European treatment protocol].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Child; Child, P | 2005 |
Myxoid liposarcoma metastatic to the thyroid gland: a case report and literature review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Da | 2006 |
Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Humans; Ifosfamide; Lymphoma; N | 2006 |
Second-line chemotherapy for recurrent carcinoma of the ovary.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance; Female; Hum | 1993 |
Ifosfamide in the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Ste | 1996 |
Remission of recurrent mixed germ cell tumor of the ovary after treatment with vincristine, carboplatin, fluorouracil, and ifosfamide: a case report and review of the literature.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 1996 |
Future trials in germ cell malignancy (GCM) of the testis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineopl | 1997 |
Malignant triton tumor of the head and neck: A case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Child; Cisplatin; Combined Modality | 1999 |
Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials a | 2000 |
Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2000 |
Paclitaxel (Taxol)/ifosfamide-based chemotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cl | 2000 |
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Head and Nec | 2000 |
Salvage chemotherapy in relapsed germ cell tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Germinoma; Humans; Ifosfamide; | 2001 |
Cystosarcoma phyllodes of the prostate with rhabdomyoblastic differentiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Fatal | 2001 |
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Clin | 2001 |
Brain metastases in Wilms' tumor: case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Combined Modality Ther | 2002 |
Epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; D | 2002 |
Salvage therapy in recurrent testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cisplatin; Cyclophosphamide; | 1992 |
153 trials available for ifosfamide and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carboplatin; Etoposide; Hodgkin | 2022 |
Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dactin | 2023 |
Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; L | 2023 |
Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; Etoposide; Humans; Hydra | 2021 |
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
Topics: Adolescent; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Central Nervous | 2021 |
Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response | 2021 |
Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc | 2017 |
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Drug Administ | 2018 |
A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting.
Topics: Aged; Amylases; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; E | 2018 |
Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2018 |
Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Surviv | 2018 |
Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2019 |
Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati | 2013 |
Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplati | 2013 |
[ATP-tumor chemosensitivity assay directed chemotherapy in patients with cervical cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisp | 2013 |
Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration | 2014 |
Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 2015 |
Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2015 |
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placeb
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carb | 2015 |
A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Pres | 2015 |
Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2015 |
Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Fiv
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2015 |
DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; China; Cisplatin; D | 2016 |
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 2016 |
Ongoing Clinical Trials in Testicular Cancer: The TIGER Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Su | 2016 |
Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2008 |
Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free S | 2008 |
[Efficacy and tolerability of the combination of oxaliplatin, ifosfamide, and epirubicin in treatment of recurrent or platinum-resistant ovarian epithelial cancer patients].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; | 2008 |
[DNCE regimen for treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2008 |
Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2010 |
Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality | 2009 |
Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; | 2009 |
Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dexa | 2009 |
Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Fem | 2010 |
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2010 |
[Treatment of relapsed osteosarcoma. Role of chemotherapy using ifosamide and carboplatin].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chem | 2010 |
Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2011 |
[Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistanc | 2010 |
Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemoradiotherapy, Adjuvant; D | 2012 |
Did salvage ICE chemotherapy improve the outcome in primary resistant/relapsing stage III/IV neuroblastoma?
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Pres | 2011 |
A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 2011 |
Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemothe | 2013 |
Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors.
Topics: Adult; alpha-Fetoproteins; Biomarkers, Tumor; Carboplatin; Chorionic Gonadotropin; Cisplatin; Cyclop | 2013 |
First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease | 2003 |
Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Child; Child | 2003 |
Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2003 |
Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carboplatin; Child; Child, Presc | 2004 |
[Effect of neoadjuvant chemotherapy in the treatment of patients with stage IIIB cervical cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemothe | 2003 |
Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: a Hoosier Oncology Group (HOG) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etoposide; F | 2004 |
First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Ca | 2004 |
Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2004 |
A phase I study of ifosfamide, paclitaxel, and carboplatin in advanced and recurrent cervical cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Resp | 2004 |
Two- vs three-drug combination chemotherapy in advanced or recurrent head and neck cancer: a single institution experience of 361 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Head and | 2004 |
Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Ifosfamide; | 2005 |
Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Surviva | 2005 |
Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chem | 2005 |
Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Da | 2005 |
Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphami | 2005 |
Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Confidence Intervals; Dose-Respons | 2005 |
Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cyclophosphamide | 2006 |
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2005 |
Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Germinoma; Humans; Ifosfamide; Mal | 2005 |
Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug | 2006 |
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combi | 2006 |
Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Respons | 2006 |
Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Child | 2006 |
The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Fe | 2007 |
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 2006 |
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap | 2007 |
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap | 2007 |
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap | 2007 |
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap | 2007 |
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose | 2007 |
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2008 |
Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CD4-CD8 Ratio | 2008 |
[Chemotherapy of nonseminomatous testicular tumors. The results of a pilot study with reduced cis-platin dosage].
Topics: Bleomycin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Humans; | 1983 |
Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1995 |
Primary chemotherapy in rhabdomyosarcomas and other malignant mesenchymal tumors of the orbit: results of the International Society of Pediatric Oncology MMT 84 Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dactinomycin; H | 1994 |
Chemotherapy for endocrine-therapy-refractory prostate cancer.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 1994 |
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Dacarbazine; Doxorubici | 1995 |
Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbo | 1995 |
Combination chemotherapy with 254-S, ifosfamide, and peplomycin for advanced or recurrent cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 1993 |
Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.
Topics: Administration, Oral; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1995 |
Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms | 1995 |
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Germinoma; | 1995 |
A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Infusions, | 1995 |
Hoosier Oncology Group studies in extensive and recurrent small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etopo | 1995 |
Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1995 |
Long-term results of neoadjuvant ifosfamide, cisplatin, and etoposide combination in locally advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 1994 |
A phase II trial of ifosfamide, 5-fluorouracil, and leucovorin in recurrent uterine cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combination; Female; Fluo | 1994 |
Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Combined Modality Therapy; Endometrial Neoplasms; Female; H | 1994 |
Synovial sarcoma. Uniform response of metastases to high dose ifosfamide.
Topics: Adolescent; Adult; Female; Humans; Ifosfamide; Infusions, Parenteral; Lung Neoplasms; Male; Mesna; N | 1994 |
Phase II trial of etoposide, carboplatin, and ifosfamide as salvage therapy in advanced ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Etoposide; Female; Humans; I | 1993 |
Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantat | 1993 |
A phase II study of ifosfamide, carboplatin and cisplatin in advanced and recurrent squamous cell carcinoma of the uterine cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1993 |
Ifosfamide in advanced epidermoid head and neck cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Hea | 1993 |
Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Etoposid | 1993 |
Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Ch | 1993 |
The addition of etoposide and ifosfamide to cisplatin as second line therapy in ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide | 1993 |
Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diseas | 1996 |
Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Drug Administration Schedule; Endometrial Neoplasms; Female; Huma | 1996 |
A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Female; H | 1996 |
A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1996 |
Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer.
Topics: Adult; Aged; Alopecia; Ambulatory Care; Antineoplastic Agents, Alkylating; Female; Hematologic Disea | 1996 |
A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Endometrial Neoplasms; Fe | 1996 |
Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Etopo | 1996 |
The addition of bleomycin and dose-escalated ifosfamide to the combination of cisplatin plus ifosfamide does not improve survival in advanced or recurrent cervical carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Antineoplastic Combined C | 1997 |
Paclitaxel in salvage therapy for germ cell tumors.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 1997 |
Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1997 |
Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 1998 |
Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chem | 1998 |
Ifosfamide in the treatment of advanced or recurrent squamous cell carcinoma of the head and neck: a phase II Hoosier Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carcinoma, Squamous Cell; Female; | 1998 |
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc | 1998 |
Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 1998 |
Vindesine-ifosfamide-platinum (VIP) induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective study. Leuven Lung Cancer Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoth | 1998 |
A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer G
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Car | 1998 |
Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dactinomycin; F | 1998 |
Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Female; Glioma; H | 1998 |
Single agent versus combination chemotherapy in recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cispl | 1998 |
Ifosfamide/carboplatin/etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: a Pediatric Oncology Group phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati | 1999 |
Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1999 |
Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubici | 1999 |
Clinical outcome of high-dose chemotherapy combined with peripheral blood stem cell transplantation for male germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Combined Modal | 1999 |
Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1999 |
Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
Topics: Adolescent; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ch | 1999 |
Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 1999 |
A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Follow-Up Studies; Huma | 2000 |
Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Chil | 2000 |
Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Germ | 2000 |
[Effectiveness of DeVIC chemotherapy for recurrent primary central nervous system lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplati | 2000 |
Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, C | 2000 |
Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2000 |
Should high-dose chemotherapy be used to consolidate second or third line treatment in relapsing germ cell tumours?
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplat | 2000 |
A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a h
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 2001 |
A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2001 |
Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2001 |
Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 2001 |
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2001 |
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com | 2001 |
Combined results from three phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2001 |
Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; | 2001 |
Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; | 2001 |
Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 2001 |
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Pro | 2001 |
Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Comb | 2002 |
Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child, Preschool; Etoposide | 2002 |
Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Ad | 2002 |
Experience with bleomycin, ifosfamide, and cisplatin in primary and recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamo | 1992 |
BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Brain Neoplasms; Chorioni | 1991 |
Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Evaluation; Head and Ne | 1991 |
Chemotherapy for invasive thymoma. A 13-year experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1991 |
Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 1990 |
Treatment of relapsed acute lymphocytic leukemia in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transpl | 1990 |
The role of ifosfamide in cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1989 |
272 other studies available for ifosfamide and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Atypical involvement of central nervous system in classic Hodgkin lymphoma: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Hodgkin Disease; Huma | 2021 |
High-dose Chemotherapy Response in Adults with Relapsed/Refractory Small Round Cell Tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Hematopoietic Stem Cell Transplan | 2022 |
Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only - the SIOP 93-01 and 2001 protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Dactinomycin; Disease-Free Survi | 2022 |
Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carboplatin; Central Nervous System; D | 2022 |
Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carboplatin; Depsipeptides; Eto | 2022 |
Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2022 |
Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Huma | 2022 |
Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cause of Death; Cisplati | 2022 |
Outcomes of relapsed/refractory extracranial germ cell tumors treated on conventional salvage chemotherapy without stem cell rescue: Experience from a tertiary cancer center.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Eto | 2023 |
Strategies for the Treatment of Infantile Soft Tissue Sarcomas With BCOR Alterations.
Topics: Biomarkers, Tumor; Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant | 2023 |
PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Lymphoma | 2023 |
Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 2020 |
High Dose Chemotherapy with Autologous Stem Cell Transplantation in Hepatoblastoma does not Improve Outcome. Results of the GPOH Study HB99.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; D | 2019 |
Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Ci | 2020 |
Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Female; Follow-Up Studies; H | 2020 |
Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin | 2020 |
Double recurrence of double cancers: Rhabdomyosarcoma and secondary AML.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Fatal Outco | 2020 |
Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cerebellar Neoplasms; | 2020 |
Clinical factors affecting prognosis of limb osteosarcoma in China: a multicenter retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Chin | 2020 |
Epithelioid Hyalinizing Sarcoma With MGA-NUTM1 Fusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Cyclop | 2020 |
[A Case of Primary Ewing Sarcoma of the Kidney Treated with Multidisciplinary Approach].
Topics: Female; Homeobox Protein Nkx-2.2; Homeodomain Proteins; Humans; Ifosfamide; In Situ Hybridization, F | 2020 |
Immunotherapy for osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Humans; Ifosfamide; Immunotherapy; | 2021 |
Locally advanced malignant solitary fibrous tumour successfully treated with conversion chemotherapy, operation and postoperative radiotherapy: a case report.
Topics: Adolescent; Disease-Free Survival; Humans; Ifosfamide; In Situ Hybridization, Fluorescence; Male; Ne | 2021 |
Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2017 |
Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Female; Follow-Up Studies; Humans | 2017 |
Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasm | 2017 |
Establishment of a spontaneously transformed cell line (JU-PI) from a myxoinflammatory fibroblastic sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Transformed; Cell Proliferation; D | 2018 |
Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Cyclophosphamide; Disease Progression; F | 2018 |
Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2018 |
R-ICE Chemotherapy with or without Autologous Transplantation for Elderly Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Resistance, Neoplasm; Etopos | 2018 |
Primary hepatic carcinosarcoma with multimodal treatment.
Topics: Aged; Antibiotics, Antineoplastic; Carcinosarcoma; Combined Modality Therapy; Doxorubicin; Humans; I | 2018 |
[RETROPERITONEAL LIPOSARCOMA WITH MULTIPLE RECURRENCE OF LUNG METASTASES TREATED BY MULTIMODAL THERAPY CENTERING ON THE OPERATION: A CASE REPORT].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Etopo | 2018 |
Success of chemotherapy and a liver transplant in a pediatric patient with hepatic angiosarcoma: A case report.
Topics: Antineoplastic Agents; Biopsy; Child, Preschool; Docetaxel; Doxorubicin; Female; Hemangiosarcoma; Hu | 2019 |
MAID chemotherapy regimen as a treatment strategy for metastatic malignant ameloblastoma: A case report.
Topics: Adult; Ameloblastoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; | 2019 |
Sustained Remission After Maintenance Irinotecan in Patient With Multiply Relapsed Hepatoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chemotherapy, Adjuvant; D | 2020 |
SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for pat
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Che | 2013 |
Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carmustin | 2015 |
Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla | 2013 |
Successful treatment of recurrent pediatric inflammatory myofibroblastic tumor in a single patient with a novel chemotherapeutic regimen containing celecoxib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Humans; Ifosfamide; Lung Neoplasms | 2013 |
Patterns of local recurrence and dose fractionation of adjuvant radiation therapy in 462 patients with soft tissue sarcoma of extremity and trunk wall.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemothera | 2013 |
Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central | 2013 |
Salvage therapy for refractory or recurrent pediatric germ cell tumors: the French SFCE experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cisplatin; Drug | 2014 |
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carb | 2013 |
Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Dexamethasone; Etoposide; Human | 2014 |
[Efficacy of postoperative simple chemotherapy and concurrent chemoradiotherapy in FIGO stage IB2-IIB cervical cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamou | 2013 |
Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp | 2013 |
Successful treatment of metastatic βHCG-secreting germ cell tumor occurring 3 years after total resection of a pineal mature teratoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin, beta Subunit, Hu | 2014 |
Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumo
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cisplatin; Cyclams; Granulocyte | 2014 |
Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cetuximab; | 2015 |
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemothera | 2014 |
A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Deoxycytidine; Dexamethasone; Etoposid | 2014 |
Myxofibrosarcoma of the thyroid gland.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fibrosarcoma; Humans; Ifo | 2014 |
Is it important to maintain high-dose intensity chemotherapy in the treatment of adults with osteosarcoma?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Dose-R | 2014 |
The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2016 |
Favorable control of rapidly progressive retroperitoneal pleomorphic leiomyosarcoma with multimodality therapy: a case report.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Doxorubicin; Female; Ga | 2014 |
Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Consolidation Chemotherapy; Drug R | 2015 |
Response to chemotherapy is not related to chromosome instability in synovial sarcoma.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chromosomal Instability; Female; Genome, Human; Hu | 2014 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherap | 2014 |
Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin | 2015 |
Marginal resection for osteosarcoma with effective neoadjuvant chemotherapy: long-term outcomes.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2014 |
Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; | 2015 |
Testicular germ cell tumors in adolescents - results of the protocol MAHO 98 and the identification of good risk patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Child | 2014 |
[Primary mediastinal germs cells tumors: a twenty years experience in a comprehensive cancer center].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cancer Care Facilities; Cisplatin; | 2014 |
Ifosfamide-containing regimens for treating patients with osteosarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Epirubicin; F | 2014 |
A case of clonally distinct relapse of Burkitt lymphoma 9 years after complete remission.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Burkitt Lymphoma; Cycloph | 2015 |
Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2014 |
Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; China; Dox | 2015 |
Adjuvant Chemotherapy in Locally Advanced Cervical Cancer After Treatment with Concomitant Chemoradiotherapy--Room for Improvement?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemoradiotherapy; Chemo | 2015 |
Clinical interpretation of residual uptake in 11C-methionine positron emission tomography after treatment of basal ganglia germ cell tumors: report of 3 cases.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Basal Ganglia; Carbon Radioisotopes; Chi | 2015 |
Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2015 |
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; C | 2015 |
Primary Pleural Synovial Sarcoma Treated with Pazopanib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Doxorubicin; Dyspnea; Fatal Outco | 2015 |
Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposi | 2015 |
Combination of Cisplatin, Ifosfamide, and Adriamycin as Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcoma: A Report of Twenty-Eight Patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin | 2016 |
A single-centre analysis of 30 patients with relapsed germ cell tumours treated with the TI-CE regimen.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplati | 2016 |
Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Genital Neo | 2016 |
High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female | 2016 |
[Synovial sarcoma. Case report].
Topics: Abdominal Wall; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2016 |
Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.
Topics: Antigens, CD34; Antineoplastic Agents; Epirubicin; Etoposide; Hematopoietic Stem Cell Mobilization; | 2016 |
Angiomatoid fibrous histiocytoma: A case of local recurrence and metastases to loco-regional lymph nodes that responded to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Doxorubicin; Histiocytoma, Maligna | 2017 |
Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2017 |
[Frontal relapse of medulloblastoma. Causes and consequences (a case report)].
Topics: Brain Neoplasms; Cerebellar Neoplasms; Child; Combined Modality Therapy; Humans; Ifosfamide; Male; M | 2008 |
Recurrent melanotic neuroectodermal tumor of infancy: a proposal for treatment protocol with surgery and adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Chromosomes, Hu | 2008 |
Retrospective analysis of surgical resection after induction chemotherapy for patients with T4b squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2008 |
Rebound thymic hyperplasia after pneumonectomy and chemotherapy for primary synovial sarcoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; I | 2008 |
A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Diseas | 2008 |
Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy.
Topics: Acetabulum; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neoplasms; Brain; B | 2008 |
Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Cyclophosphamide; | 2008 |
Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality | 2009 |
Temporary remission of a multirecurrent cystosarcoma phyllodes of the breast by using continuous chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Ifos | 2009 |
Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Etoposide; Fe | 2009 |
Local and systemic control of Ewing's bone sarcoma family tumors of the ribs.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bone Plates; Chil | 2009 |
Metastatic phyllodes tumor causing small-bowel obstruction.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Breast Neoplasms; Combined Modality | 2009 |
Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfamide; | 2009 |
Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod | 2009 |
[Mullerian adenosarcoma of the uterus: A clinicopathologic analysis of 9 cases].
Topics: Adenosarcoma; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2010 |
Ifosfamide-induced encephalopathy in patients with uterine sarcoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Methylene Blue; Middle Aged; Ne | 2010 |
Moyamoya in a child treated with interferon for recurrent osteosarcoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Carotid Artery Diseases; Cerebral Arterial Diseases; Cerebral | 2010 |
Pulmonary blastoma in adult: dramatic but transient response to doxorubicin plus ifosfamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Drug Administration Sch | 2011 |
Pattern of relapse and outcome of non-metastatic germinoma patients treated with chemotherapy and limited field radiation: the SFOP experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Case-Control Studies; | 2010 |
Chest wall Ewing sarcoma family of tumors: long-term outcomes.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla | 2011 |
Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modal | 2010 |
Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 2011 |
Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Ex | 2011 |
Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for uterine leiomyosarcoma: a report of two cases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubic | 2011 |
Treatment outcome of Korean patients with localized Ewing sarcoma family of tumors: a single institution experience.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleom | 2011 |
Type II radical hysterectomy and adjuvant therapy for pelvic lymph node metastasis with stage IB-IIB cervical carcinoma: a retrospective study of 288 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carcinoma, Sq | 2011 |
Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2011 |
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclo | 2011 |
Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant | 2013 |
Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Epirubicin; Female; Humans; I | 2012 |
Paclitaxel-ifosfamide-carboplatin combination chemotherapy regimen in advanced uterine and adnexal malignant mixed Mullerian tumours.
Topics: Adnexal Diseases; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplat | 2011 |
Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free | 2011 |
A case of intimal sarcoma of the pulmonary artery successfully treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Doxorubicin; Female; Humans; | 2012 |
Application of high-dose rate (60)Co remote after-loading system for local recurrent neuroblastoma.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Busulfan; Carbop | 2011 |
Successful treatment of ICE-rituximab chemotherapy and subsequent bone marrow transplantation in a patient with early-relapse Burkitt leukemia and inverted duplication of 1q.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 2012 |
Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2012 |
Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2012 |
Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squ | 2012 |
Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma.
Topics: Adolescent; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemo | 2012 |
Ifosfamide and doxorubicin combination chemotherapy for recurrent nasopharyngeal carcinoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamo | 2012 |
SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Clinic | 2012 |
Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Epi | 2013 |
Early relapses in patients with primary CNS lymphoma treated with methotrexate-based chemotherapy without consolidating whole brain irradiation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2013 |
[Treatment and prognosis of stage IV alveolar soft part sarcoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Dacarbazine; | 2012 |
Salvage chemotherapy for advanced sarcoma patients: a single-institution experience survey.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; D | 2002 |
Impact of maintenance chemotherapy on disease-free survival in patients with stage Ic and II epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Antineoplastic Combin | 2002 |
[Pediatric rhabdomyosarcoma of the infratemporal fossa].
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co | 2002 |
Neo-adjuvant chemotherapy in early stages of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 2002 |
Regression of refractory rhabdomyosarcoma after allogeneic stem-cell transplantation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cispl | 2003 |
Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arm; ATP Binding Cassette T | 2003 |
High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality.
Topics: Amputation, Surgical; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Do | 2003 |
High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality.
Topics: Amputation, Surgical; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Do | 2003 |
High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality.
Topics: Amputation, Surgical; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Do | 2003 |
High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality.
Topics: Amputation, Surgical; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Do | 2003 |
Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2003 |
[Primary pulmonary synovial sarcoma: a report and diagnosis of 2 cases].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2003 |
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2003 |
Pericardial synovial sarcoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Heart Neoplasms; H | 2003 |
[Leiomyosarcoma of the heart--interdisciplinary therapeutic approach of systemic chemotherapy and subsequent heart transplantation].
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Heart Atria; He | 2003 |
Management of hepatic epithelioid haemangio-endothelioma in children: what option?
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Child | 2004 |
[Paclitaxel, ifosfamide, nedaplatin (TIN) for patients with metastatic urothelial cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; | 2004 |
Cytoreductive surgery plus intraperitoneal hyperthermic perfusion is an effective treatment for metastasized malignant mixed mesodermal tumours (MMMT)--report of six cases.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2004 |
Primary omental synovial sarcoma: a case with cytogenetic confirmation.
Topics: Adult; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; D | 2004 |
Pericardial synovial sarcoma: 14-year survival with multimodality therapy.
Topics: Adult; Chemotherapy, Adjuvant; Dimethoate; Disease Progression; Doxorubicin; Drug Administration Sch | 2004 |
The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Anti | 2004 |
Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with Cisplatin-based chemotherapy.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chil | 2004 |
Spinal cord compression and lung metastasis of Wilms' tumor in a pregnant adolescent.
Topics: Abdominal Pain; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carbopla | 2004 |
Tumor excision and reconstruction of the upper cervical spine: a multidisciplinary approach.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axis, Cervical Vertebra; Bone Transplantation | 2004 |
VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug R | 2004 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant mixed mesodermal tumours with peritoneal dissemination.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2005 |
Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic A | 2005 |
[Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Dexametha | 2005 |
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Remodeling; Caspases; Cell Line, Tumor | 2005 |
Medulloblastoma in two successive pregnancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherapy, Adjuvant; | 2005 |
Definitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors: local outcome and prognostic factors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modalit | 2005 |
Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Mesn | 2005 |
[Upper cervical chondrosarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axis, Cervical Vertebra; Brachytherapy; Cervical Ver | 2005 |
Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: role of rituximab, high-dose therapy, and allogeneic stem cell transplantation.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2005 |
Stereotactic radiation therapy with chemotherapy in the management of recurrent medulloblastomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemotherap | 2006 |
Another example of the highly variable clinical course of recurrent/resistant/persistent ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Drug Resistan | 2006 |
[A case of liposarcoma of the sigmoid colon mesenterium successfully treated with chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colon, Sigmoid; Drug Administration Sched | 2006 |
Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2006 |
Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplati | 2006 |
Metachronous intracranial germinoma in a patient with a previous primary mediastinal seminoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Cisplatin; Combin | 2006 |
Pancreatoblastoma in a teenage patient.
Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2006 |
Recurrent superior mediastinal primary hemangiopericytoma 23 years after the complete initial excision: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Epirubicin; Fatal Outcome | 2006 |
[Efficacy of chemotherapy regimen using ifosphamide and carboplatin on recurrent or refractory neuroblastoma].
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carbo | 2006 |
[Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2006 |
Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Combined | 2007 |
Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease- | 2007 |
CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, P | 2007 |
Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Arm; Diseas | 2007 |
Multimodal treatment of thymic carcinoma: Report of nine cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; E | 2008 |
Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Crypt | 2007 |
Continuous remission in an infant with chest wall malignant rhabdoid tumor after relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphami | 2007 |
[Long-term follow-up of patients with suprasellar germinomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin | 2007 |
Prognostic factors for local and distant control in Ewing sarcoma family of tumors.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Child, Pres | 2008 |
Multiple cutaneous relapses in an adolescent in anaplastic large cell lymphoma diagnosed by FNAC.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Fine-Needle; | 2008 |
Multimodality treatment of osteosarcoma: radiation in a high-risk cohort.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2008 |
Interdisciplinary combined treatment of craniofacial osteosarcoma with neoadjuvant and adjuvant chemotherapy and excision of the tumour: a retrospective study.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2008 |
[Prevention of recurrence of small-cell lung cancer by adjuvant polychemotherapy (author's transl)].
Topics: Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Human | 1982 |
[Paraneoplastic peripheral neuropathy in the course of leiomyosarcoma].
Topics: Aged; Combined Modality Therapy; Humans; Ifosfamide; Leiomyosarcoma; Male; Neoplasm Recurrence, Loca | 1995 |
Bleomycin, cisplatinum and ifosfamide infusion chemotherapy in advanced/recurrent cancer of cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1993 |
In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 1995 |
"Ifosfamide: should the honeymoon be over?": a two-dimensional question for a three-dimensional problem.
Topics: Female; Humans; Ifosfamide; Neoplasm Recurrence, Local; Nervous System; Pelvic Neoplasms; Stereoisom | 1995 |
[Combination of etoposide, cisplatin and ifosfamide (VPH) in the salvage chemotherapy of relapsing or refractory aggressive malignant lymphoma. Study of 51 patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Femal | 1994 |
The development of rickets as a complication of chemotherapy for the treatment of Wilms' tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bicarbonates; Calcitriol; Child; Child, Preschool; F | 1995 |
Refining therapeutic strategies for patients with resistant Wilm's tumor.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Ci | 1994 |
Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1994 |
Undifferentiated (embryonal) sarcoma of the liver in an adult patient with metastasis of the heart and brain.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; E | 1994 |
Myxoid liposarcoma. Experience with chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1994 |
Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Et | 1994 |
MINE-ESHAP salvage therapy for recurrent and refractory lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Humans; Ifosfamide | 1994 |
Long-term disease-free survival in a child with refractory metastatic malignant germ cell tumor treated by high-dose chemotherapy with autologous bone marrow rescues.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Cisplat | 1994 |
[Soft tissue tumors: indications and results of hyperthermia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 1993 |
Ifosfamide-induced nonconvulsive status epilepticus.
Topics: Aged; Antineoplastic Agents, Alkylating; Carcinosarcoma; Female; Genital Neoplasms, Female; Humans; | 1995 |
A bleomycin/ifosfamide/cisplatin regimen exhibits poor activity against persistent or recurrent squamous gynecologic cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Combined Modali | 1996 |
Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant | 1997 |
Ifosfamide-based chemotherapy for recurrent or metastatic hemangiopericytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Fema | 1997 |
Treatment of metastatic uterine leiomyosarcoma with cisplatin, pirarubicin, and ifosfamide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Humans; Ifosf | 1997 |
[The type of local treatment conditions the prognosis in patients with nonmetastatic Ewing's sarcoma of the extremities treated with adjuvant chemotherapy].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Chemotherapy, Adjuv | 1997 |
Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen.
Topics: Adolescent; Adult; Amputation, Surgical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplasti | 1997 |
Abdominal irradiation in unilateral nephroblastoma and its impact on local control and survival.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined | 1998 |
[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; | 1998 |
End-stage renal interstitial fibrosis in an adult ten years after ifosfamide therapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Fibrosis; Humans; Ifosfamide; Kidney; Kidney Failure, Chro | 1998 |
[Pilot study of cisplatin, ifosfamide and irinotecan (CPT-11) with granulocyte colony-stimulating factor support (CIC-regimen) in relapsed small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Ci | 1998 |
Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherap | 1998 |
[A case of neutropenic enterocolitis in high dose chemotherapy with peripheral blood stem cell transplantation for relapsed testicular tumor].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Enter | 1998 |
Evaluating a critically ill patient with metabolic acidosis: the ifosfamide paradigm.
Topics: Acidosis; Acidosis, Renal Tubular; Antineoplastic Combined Chemotherapy Protocols; Carbon Dioxide; C | 1999 |
Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 1999 |
Recurrent chondrosarcoma of the cranial base: a durable response to ifosfamide-doxorubicin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chondrosarcoma; Doxorubicin; Female; Humans; Ifosfam | 1999 |
[Primary lymphoma of the thyroid with contralateral recurrence--case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Citrates; Cyclophosphamide; Dexamethasone; Epirubici | 1999 |
Sixty percent salvage rate for germ-cell tumours using sequential m-BOP, surgery and ifosfamide-based chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Disease Pro | 1999 |
Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2000 |
Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. United Kingdom Children's Cancer Study Group (UKCCSG).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1999 |
Desmoplastic small round cell tumour in children and adolescents.
Topics: Abdominal Neoplasms; Adolescent; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Ant | 2000 |
Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT).
Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chorionic Gona | 2000 |
Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modali | 2000 |
Induction chemotherapy for locoregional lung cancer using paclitaxel combination. A preliminary report.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2000 |
Huge malignant localized fibrous tumor of the pleura.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Fibroma; Hum | 2000 |
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combi | 2001 |
Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2001 |
Serum creatine kinase levels parallel the clinical course for rhabdomyomatous Wilms tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Creatine Kinase; Dactinomycin; Di | 2001 |
Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2001 |
Chemotherapy in patients with metastatic or relapsed germ-cell tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Etop | 2001 |
[Ifosfamide in comparison with cyclophosphamide in advanced ovarian carcinomas (author's transl)].
Topics: Cyclophosphamide; Female; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Remissi | 1976 |
Combined chemotherapy using cisplatin, ifosfamide and bleomycin (PIB) in the treatment of advanced and recurrent cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S | 1992 |
Rickets--a complication of ifosfamide chemotherapy for Wilms tumor.
Topics: Child, Preschool; Humans; Ifosfamide; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Rickets; W | 1992 |
[Treatment of recurrent ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Drug | 1992 |
[Combination chemotherapy with 254-S, ifosfamide and peplomycin for advanced or recurrent cervical cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; | 1992 |
Bleomycin-ifosfamide-cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: a second look.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug Administration Schedule; | 1992 |
Rhabdomyosarcoma of the head and neck in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; | 1992 |
Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers.
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, | 1992 |
Ewing's sarcoma: experience with 12 cases.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1992 |
Reversible hypophosphatemic rickets following ifosfamide treatment.
Topics: Abdominal Neoplasms; Child; Fanconi Syndrome; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; | 1992 |
Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cis | 1991 |
Epidermal growth factor receptors and doxorubicin plus ifosfamide/mesna in recurrent breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; ErbB Receptors | 1991 |
The potential for adjuvant therapy in early-stage cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; B | 1990 |
Chemotherapy in recurrent and advanced cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplati | 1991 |
Bleomycin, ifosfamide, and cisplatin (BIP) in patients with recurrent and advanced cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Humans; Ifosfamide; Ne | 1991 |
Ifosfamide with mesna in squamous carcinoma of the cervix: phase II results in patients with advanced or recurrent disease.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Drug Therapy, Combination; Female; Hematolog | 1991 |
Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female | 1991 |
[Two cases of Ewing's sarcoma originating from the adult rib].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality | 1991 |
Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Blood Cell Count; Brain Neoplasms; Drug Evaluation; Humans; If | 1991 |
Cyclophosphamide versus ifosfamide in paediatric oncology.
Topics: Brain Neoplasms; Child; Cyclophosphamide; Drug Administration Schedule; Humans; Ifosfamide; Neoplasm | 1990 |
Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Infusions, Intravenous; | 1990 |
Malignant fibrous histiocytoma of the fallopian tube.
Topics: Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fallopian Tube Neoplasms; Female; Histio | 1990 |
[Acute coronary thrombosis and myocardial ischemia following chemotherapy of Hodgkin's disease].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Coronary Disease; | 1990 |
[Developments in the treatment of osteosarcoma since 1979. Report of the statistics at the Centre Léon-Bérard].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 1990 |
A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
[Reactivation of prostatic cancer and chemotherapy in reactivated prostatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Humans; Ifosfamid | 1985 |
Bulky germinal tumors: comparison of different induction regimens and significance of residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorubicin; Humans; Ifosfamid | 1985 |
[Combination chemotherapy of vincristine, ifosfamide and peplomycin in patients with reactivated prostatic cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Hu | 1986 |
Response-oriented therapy with CHOP and VIM-Bleo in high-grade malignant non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Evalu | 1988 |
Phase II studies of bleomycin, ifosfamide and cis-platinum in advanced and recurrent cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug Evaluation; | 1988 |
Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug Evaluation; | 1989 |
Ifosfamide, adriamycin and cisplatin (IAP) plus bleomycin (B) combination chemotherapy in patients with recurrent cancer of the uterine cervix.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S | 1989 |
[Treatment of stage I-IIB nonseminomatous testicular tumors].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Mo | 1989 |
[Desmoid fibroma of the scapula. Recurrence with pulmonary metastasis].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dactinomycin; Female; Fibroma | 1989 |
Phase II study of ifosfamide as a single drug for relapsed paediatric patients.
Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Ifo | 1989 |
High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasm | 1989 |
Ifosfamide in testicular cancer: the Indiana University experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Etoposide; Humans; Ifo | 1989 |
A phase II study of ifosfamide in the treatment of relapses in Wilms' tumor.
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Evaluation; Drug Therapy, Combination; Humans; Ifos | 1989 |
Sequential combination chemotherapy and radiotherapy in locally advanced non-small cell carcinoma of the bronchus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Small C | 1989 |
A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administrat | 1989 |
[The course of squamous cell carcinoma antigen and CEA as prognostic criteria for response to chemotherapy in cervix cancer].
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 1989 |
A phase II study of ifosfamide in paediatric solid tumours.
Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Drug Tolerance; Female; Humans; Ifosfamide; In | 1989 |
Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Evaluation; Etoposide | 1989 |
[Therapy of primary resistant or recurrent small cell bronchial carcinoma with vindesine and ifosfamide].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Drug Administration Schedule; | 1986 |
Phase II study of ifosfamide in cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Central Nervo | 1986 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb | 1987 |
A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Drug Evaluation; Femal | 1986 |